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ABSTRACT 
Duchenne muscular dystrophy (DMD) is a fatal muscle wasting disease caused by 
the absence of functional dystrophin protein. Dystrophin-deficiency results in numerous 
cellular dysfunctions and increased muscle injury leading to progressive muscle 
weakness and ultimately death due to cardiomyopathy or respiratory insufficiency. 
Overexpression of the transcriptional coactivator, PGC-1a, has been shown to provide 
therapeutic benefits for dystrophic muscle. In a preliminary experiment, quercetin, a 
nutraceutical that can drive PGC-1a through SIRT1, protected dystrophin-deficient 
skeletal muscle following 6 months of treatment. Therapies for DMD must demonstrate 
long-term efficacy, therefore in the first research chapter we evaluated the effect of 12 
months of quercetin treatment on dystrophin-deficient skeletal muscle. To improve the 
lasting efficacy of quercetin, in the second and third research chapters we fed dystrophic 
mice quercetin in combination with several agents intended to potentiate or augment the 
effects of quercetin. We found that these quercetin-based cocktails failed to protect 
muscle from injury or preserve respiratory or muscle function. Collectively, these studies 
suggest that quercetin and these quercetin-based cocktails do not attenuate disease 
pathology long-term.  
Stemming from our biochemical experiments from the first research chapter, we 
began to investigate the role of autophagy in dystrophic muscle.  During autophagy a 
membrane is formed around protein aggregates or dysfunctional organelles, which then 
fuses with a lysosome for degradation.  To better understand autophagy in the context of 
DMD and identify new therapeutic targets, in the fourth research chapter we evaluated 
autophagy at 7 weeks and 17 months of age in healthy and dystrophic mice. We 
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discovered that autophagy was impaired in dystrophic muscle. Additionally, we 
discovered that lysosome abundance was decreased with advanced disease and 
Transcription Factor EB (TFEB), a transcription factor that drives lysosome biogenesis, 
was partially excluded from dystrophic myonuclei.  In the fifth research chapter we used 
an adeno-associated virus (AAV) vector to drive PGC-1a expression, which is known to 
increase TFEB protein abundance in healthy tissue. The data suggest that PGC-1a 
overexpression increased TFEB nuclear localization and subsequently lysosome 
abundance and autophagosome degradation.  
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CHAPTER 1: DISSERTATION ORGANIZATION 
This dissertation begins with an introduction and a review of the literature 
addressing key knowledge helpful in appreciating the impact of the following research 
chapters.  The review of the literature includes three sections.  The first provides an 
overview of DMD.  The second section discusses the use of exercise as a therapy for 
DMD and was recently published in Medicine & Science in Sports & Exercise.  The third 
section provides an overview of autophagy signaling, autophagy within the context of 
DMD, and the relationship between autophagy and transcriptional coactivator, PGC-1a. 
The review of literature is followed by five research chapters. The first research chapter 
explores the effect of long-term quercetin treatment on dystrophic limb muscles, which 
led to the second and third research chapters evaluating the use of quercetin in 
combination with nutraceuticals and pharmaceuticals that have shown promise in 
attenuating disease pathology. The second research chapter specifically assesses limb 
muscle function and injury while the third research chapter evaluates respiratory and 
diaphragm function and muscle injury. During the course of my work we began to 
suspect that dysfunctional autophagy played a role in diseased pathology. In the fourth 
research chapter we investigated the effect of disease progression on autophagy in 
dystrophin deficient skeletal muscle. This led to a fifth research chapter evaluating the 
effect of PGC-1a overexpression on transcription factor EB nuclear localization, 
lysosome abundance and autophagic degradation in dystrophic skeletal muscle. The final 
research chapter is followed by a general discussion of these data as a whole and 
comments about future directions of this work. 
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CHAPTER 2: GENERAL INTRODUCTION 
Duchenne Muscular Dystrophy 
Duchenne muscular dystrophy (DMD) is an X-linked, progressive muscle wasting 
disease affecting 1:3500-5000 boys (124).  DMD is characterized by the absence of 
functional dystrophin protein due to mutations in the dystrophin gene.  It is estimated that 
about 20% of disease-causing mutations are small mutations (smaller than 1 exon) 
resulting in small deletions, insertions, missense mutations, and nonsense mutations, and 
the remaining 80% are large mutations (1 exon or larger), of which 86% are deletions and 
14% are duplications (23). Ultimately, these mutations disrupt the reading frame and 
prevent translation of full-length dystrophin protein. Dystrophin is a vital structural 
protein and the anchor of the dystroglycoprotein (DGC) complex, which connects the 
cytoskeleton to the extracellular matrix through the sarcolemma (65, 153).  The DGC is 
composed of a variety of extracellular, cytoplasmic and transmembrane proteins 
including dystrophin, sarcoglycans, dystroglycans, sacrospan, dystrobrevin, laminin (79). 
Together these proteins function to tether dystrophin to the sarcolemma, provide structure 
to the sarcolemma, participate in force transmission, and act as a platform for signaling.  
Dystrophin is a 427 kDa protein composed of four distinct domains including an 
actin-binding domain (ABD1), a central rod-like domain, a cysteine-rich domain, and a 
carboxyl terminal domain (77, 112). The ABD1 has 2 calponin homolog domains, which 
facilitate the binding of dystrophin directly to F-actin (208). ABD1 also interacts with 
cytokeratin 19, an abundant intermediate filament protein, to attach dystrophin to the 
costamere and ultimately the contractile apparatus of muscle, the sarcomere (194). The 
central rod-like domain also has an actin-binding motif (ABD2), which allows for lateral 
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association of dystrophin with actin filaments (77, 168).  As the name describes, the 
central rod-like domain is made up of 24 spectrin-like repeats, which fold together as a 
triple a-helix into a rod shape (30, 112). This region provides structure along with 
increased actin binding, microtubule binding, and microtubule organization (18, 156). 
Within the central rod-like domain there are four “hinges” which are proline-rich spacers 
that provide elasticity to the dystrophin protein (1, 111). Additionally, a-syntrophin 
interacts with dystrophin at spectrin-like repeat 16/17 to facilitate nNOS signaling (1).  
The cysteine-rich domain and first portion of the C-terminal domain of dystrophin 
binds b-dystrogylcan (64, 77). b-dystrogylcan is a single-pass transmembrane protein that 
is glycosylated and binds a-dystroglycan to anchor a-dystroglycan to the exterior of the 
sarcolemma. Glycosylation of a-dystroglycan is required for this binding of laminin to a-
dystroglycan (64), and other extracellular matrix ligands, such as perlecan and agrin. 
Additionally, b-dystrogylcan interacts with the sarcoglycan complex, which is made up 
of four subunits: a, b, g and d.  The sarcoglycan complex facilitates stabilization of b-
dystrogylcan at the sarcolemma (96, 134). Interestingly, the mutation of even one of these 
four sarcoglycan subunits prevents the proper formation and localization of the 
sarcoglycan proteins to the (126) membrane, which is known to cause limb girdle 
muscular dystrophy (96). The sarcoglycans are glycosylated transmembrane proteins that 
bind sarcospan, a transmembrane protein that interacts with multiple sarcoglycan 
subunits (48), generating a subcomplex. Sarcospan interacts with not only b-
dystrogylcan, but also binds integrins to further stabilize the sarcolemma (126).  
On the cytosolic face of the dystroglycoprotein complex, dystrophin binds 
directly to syntrophin and a-dystrobrevin (171).  To assist in muscle stability, a-
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dystrobrevin binds to intermediate filaments and works together with syntrophin and 
dystrophin to localize nNOS at the DGC (141). Syntrophin further acts a signaling 
platform for proteins involved in signaling transduction, ion transport and calcium 
homeostasis (46, 141).   
Boys are typically diagnosed with DMD between 2-5 years of age due to delayed 
time to walking, waddling gait, struggling to stand (Gower’s movement), and other 
missed movement milestones (62, 196). Typically, boys are treated with glucocorticoids, 
prednisone and more recently, deflazacort (182), to preserve muscle function, prolong 
ambulation, and decrease inflammation (17). As muscle weakness progresses, boys will 
first rely on assisted walking and eventually lose ambulation resulting in part-time and 
then full-time wheelchair assistance. Ultimately their respiratory muscles will weaken 
and require respiratory support. Due to the progress in respiratory care, the natural history 
of the disease has evolved to include more frequent mortality due to cardiomyopathy 
making therapies to protect the heart important for consideration (61). Commonly, once 
left ventricle ejection fraction falls to less than 55% patients are started on angiotensin 
converting enzyme inhibitors (ACEi), such as Lisinopril, to delay cardiomyopathy (155). 
As a multifaceted disease, DMD disease pathology does not only affect muscle 
function and injury, but a variety of physiological systems and can have psychological 
impacts. As muscle wasting progresses, muscle injury accumulates resulting in 
degradation of muscle fibers and subsequent infiltration of adipose tissue and fibrotic 
tissue (164). Increased fibrosis and adipose combined with reduced mobility can lead to 
an increased risk of obesity, hyperinsulinemia and insulin resistance (165, 175). As 
muscle continues to deteriorate, joint contractures resulting in further reduced mobility 
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and decreased ability to perform daily tasks (187). Similarly, patients also experience 
anxiety and depression due, at least in part, to stress from social and physical hardship 
endured throughout disease progression (170). Lastly, muscle wasting, chronic 
inflammation and immobility further contribute to reduced bone density in patients with 
DMD leading to bone fractures and immobility (32). 
 
Mouse Models 
 Duchenne muscular dystrophy is most often modeled by the mdx mouse.  The 
mdx mouse has been used for decades to investigate fundamental dysfunctions of 
dystrophic muscle and evaluate potential therapies for DMD (183). The mdx mouse is on 
the C57BL/10 (B10) mouse background and has an exon 23 point mutation (C-T) within 
the dystrophin gene resulting in a nonsense mutation (186, 93). The mdx mouse was 
discovered in the 1984 due to increased creatine kinase, a marker of muscle damage, and 
histological lesions similar to those found in muscular dystrophies (33).  
At 2-weeks of age mdx mice are indistinguishable from their healthy controls, but 
by 3-8 weeks mdx muscle undergoes an intense bout of necrosis followed by remarkable 
regeneration (132). The only muscle to escape this pathology is the diaphragm, which 
displays progressive muscle injury and weakness similar to DMD patients (193).  These 
mdx mice also experience limb muscle weakness. By 28 weeks of age, forelimb grip 
strength is reduced 25% (45). At 12-14 months of age, solus, extensor digitorum longus, 
and diaphragm in vitro specific force decreased by 18-40% and EDL fatigue resistance 
fell to less than 50% of healthy control (122, 190). At this same time point, respiratory 
function measured by whole body plethysmography was also largely decreased (180).  
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 Though mdx mice have been an invaluable model to investigate DMD, many 
argue that the phenotype of mdx limb muscles and the heart are too mild.  For example, 
cardiac dysfunction and the onset of scoliosis are delayed relative to human disease and 
mice live a nearly normal lifespan compared to the profound reduction in human disease 
(41, 116). To increase disease severity in a mouse model, the mdx mutation was bred 
onto a variety of genetic backgrounds.  Ultimately, it was discovered that when 
introgressed into the DBA/2J background, the exon 23 mutation caused an earlier onset 
of disease and a more severe phenotype compared to the C57 line (45).  Fibrosis and 
inflammation are increased in D2-mdx (D2.B10-Dmdmdx/J) compared to DBA controls 
and increased compared to traditional mdx mice due to a 12-amino acid deletion in the 
latent TGF-b-binding protein gene 4 (Ltbp4) (45, 74). DMD patients also have increased 
fibrosis and a relationship is emerging between mutations in the Ltbp4 gene and time to 
loss of ambulation such that the Ltbp4 gene mutation accelerates loss of ambulation (69). 
Additionally, when dystrophic DBA mice were compared to mdx, Evan’s blue dye 
uptake, a marker of membrane instability, was further increased 30% at 8 weeks of age 
suggestive of increased muscle fiber damage in the D2-mdx model (45). When ejection 
fraction was directly compared between D2-mdx and age-matched mdx mice, ejection 
fraction was decreased 10% and shortening fraction was reduced by 7% as early as 28 
weeks of age suggestive of an early onset of cardiac dysfunction (45). Further, signs of 
cardiomyopathy were already present at 7 weeks in D2-mdx hearts compared to mdx and 
DBA demonstrated by histopathological changes (45).  
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Exercise as a therapy for DMD 
 Exercise may be able to counter some DMD-associated effects, such as muscle 
weakness, kyphosis, obesity, and depression (24, 50). In healthy muscle, exercise 
elevated a transcriptional coactivator, peroxisome proliferator-activated receptor-gamma 
coactivator (PGC-1α), able to promote mitochondrial biogenesis and utrophin abundance,   
a protein able to compensate for the absence of dystrophin (145, 172). Indeed, increased 
PGC-1α, mitochondrial biogenesis, and utrophin have all been shown to decrease 
dystrophin pathology (89, 94, 181, 202, 203). DMD patients also develop kyphosis and 
endure vertebral and leg fractures (131). In non-DMD patients, exercise increased bone 
density (24), which may prevent fractures that coincide with premature loss of 
ambulation in DMD patients (131). The following review was undertaken to compile the 
current literature evaluating exercise as a treatment for DMD and assess the effect of 
exercise intensity, modality and duration on functional outcome in dystrophic muscle. 
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Is Exercise the Right Medicine for Dystrophic Muscle? 
Hannah R. Spaulding and Joshua T. Selsby 
Department of Animal Science, Iowa State University, Ames, IA 50011 
 
Modified from a review published in  
Medicine & Science in Sports & Exercise, September 2018 Volume 50, Issue 9, pages 
1723-1732. 
 
Abstract 
Introduction: Duchenne muscular dystrophy (DMD) is a neuromuscular disease caused 
by a dystrophin protein deficiency.  Dystrophin functions to stabilize and protect the 
muscle fiber during muscle contraction, thus the absence of functional dystrophin protein 
leads to muscle injury. DMD patients experience progressive muscle necrosis, loss of 
function, and ultimately succumb to respiratory failure or cardiomyopathy.  Exercise is 
known to improve muscle health and strength in healthy individuals as well as positively 
impact other systems.  Because of this, exercise has been investigated as a potential 
therapeutic approach for DMD.  Methods: This review aims to provide a concise 
presentation of the exercise literature with a focus on dystrophin deficient muscle.  Our 
intent was to identify trends and gaps in knowledge with an appreciation of exercise 
modality.  Results: After compiling data from mouse and human studies it became 
apparent that endurance exercises such as a swimming and voluntary wheel running have 
therapeutic potential in limb muscles of mice and respiratory training was beneficial in 
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humans.  However, in the comparatively few long-term investigations the effect of low 
intensity training on cardiac and respiratory muscles was contradictory.  In addition, the 
effect of exercise on other systems is largely unknown.  Conclusion: In order to safely 
prescribe exercise as a therapy to DMD patients, multi-systemic investigations are needed 
including the evaluation of respiratory and cardiac muscle.   
 
Key words: mdx, DMD, dystrophin, running, swimming  
Introduction 
Duchenne muscular dystrophy (DMD) affects one in every 5,000 boys (124) and 
is caused by a deficiency of the protein, dystrophin.  It is a muscle wasting disease that 
leads to impaired mobility, wheel chair confinement, and ultimately patients succumb to 
respiratory or cardiac failure.  Diagnoses of DMD typically occur around 4-5 years of 
age, driven largely by parental concerns about missed or delayed achievement of 
developmental milestones, frequent falls, and in some instances a distinct gait.  
Dystrophin is a 2.3 Mb gene with 79 exons that is translated into a 427 kDa protein (2).  
Mutations to the dystrophin gene resulting in a frame shift or nonsense mutation cause a 
deficiency of functional dystrophin protein.  Dystrophin acts as the anchor for the 
dystrophin-glycoprotein complex, functions in related signaling, and serves a critical role 
in membrane stability during muscle contraction and eccentric contractions, in particular. 
In the absence of dystrophin, muscle cells are sensitive to eccentric injury resulting in 
physical disruption of the sarcolemma, loss of Ca2+ homeostasis, increased proteolysis, 
free radical injury, and widespread cellular dysfunction, among other maladies (3, 82, 
138, 177). DMD is most commonly modeled by the mdx mouse which has a nonsense 
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mutation in exon 23.  On the whole, the disease phenotype is relatively mild with only 
slight reductions in longevity (41) and impaired cardiac function only apparent after 
approximately 8 months (158, 218) likely due to increased utrophin protein abundance 
(128), increased capacity for repair (26), and differences in locomotion (99).  Limb 
muscles experience an acute necrotic bout from approximately 3-8 weeks of age followed 
by relative stability before declining again following 12 months of age (166).  The 
diaphragm undergoes a progressive disease and most accurately recapitulates many 
aspects of disease progression including impaired function, fibrosis, and necrosis, among 
others (193).    
The absence of functional dystrophin not only affects skeletal and cardiac muscle 
cells, but also the skeletal, endocrine, and central nervous systems (36).  Kyphosis, due in 
part to osteoporosis, is prevalent in DMD patients.  Indeed, vertebral and leg fractures are 
common in DMD patients and resultant immobilization from leg fractures can lead to 
permanent loss of ambulation (131).   The use of glucocorticoids, which is the standard of 
care for DMD patients, may exacerbate bone loss and contribute to fractures directly and 
indirectly, and it prolongs ambulation, which increases the opportunity for fractures due 
to falls (107).  DMD patients tend to be obese with excess weight gain beginning early in 
disease progression due to decreased mobility and weight gain is further driven by 
increased appetite with steroid treatments (50).  Obesity and increased weight gain result 
in increased rate of hyperinsulinemia and insulin resistance leading to increased 
occurrence of type 2 diabetes and cardiovascular disease for DMD patients (165).  In 
addition, and perhaps due, at least in part, to these physical effects, DMD patients suffer 
increased risk of depression and anxiety (189).  Importantly, in healthy populations 
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exercise has been widely shown to counter many of these DMD-associated effects.  At 
the very core of endurance training is increased cardiorespiratory function while overload 
training increases hypertrophy serving to combat two significant problems encountered 
by DMD patients.  In addition, exercise has been shown to decrease the severity of 
depression, maintain bone density, and increase overall muscle health, among other 
benefits (24).  Thus, exercise would appear to be a well-suited intervention for DMD 
patients.  Indeed, exercise serves as the basis of physical therapy and utilizes multiple 
exercise modalities to maintain muscle flexibility and health in DMD patients.   
As a premise of this review it is assumed that patients are receiving appropriate 
nutritional support and effective physical therapy.  This review will focus on exercise 
beyond that what is generally performed during physical therapy. The role of exercise on 
DMD has been previously reviewed, i.e. Gianola et al. (80), Grange et al. (85) and 
Markert et al. (125), though in many of these previous studies exercise was broadly 
considered.  Here, we will independently explore exercise modality and consider 
independent muscle groups, with a particular focus on functional and histological 
outcomes, with the intention that this more refined approach will allow us to better 
identify emerging patterns of exercise benefits for dystrophic muscle.  
Endurance Exercise 
Researchers have investigated the effects of a variety of exercise modalities in 
mouse and human studies.  The breadth of exercise regimens, measures, durations, and 
disease states makes comparisons between these investigations difficult.  To better 
elucidate the effects of low intensity exercise in dystrophic muscle, data were collected 
from studies using swimming, voluntary wheel running, and treadmill running 
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interventions (Figure 1).  To visualize these data we plotted exercise modality, age of 
intervention initiation, duration of treatment, and effect of exercise on a single set of 
axes.  The effect of exercise on a dependent variable was estimated from published 
investigations in order to calculate a percent change caused by exercise compared to 
sedentary dystrophic controls.  In this manner, values less than 100% indicate a 
detrimental effect of exercise while values larger than 100% indicate a dependent 
variable was improved with exercise.  To appropriately report and plot measurements 
such as fibrosis, necrosis and creatine kinase (CK) activity, in which an increase indicates 
a negative effect, an inverse calculation was used to appropriately place these data on the 
figures. Hind limb muscles were divided into two categories defined as anterior [i.e.. 
tibialis anterior (TA) and extensor digitorum longus (EDL)] and posterior compartments 
[i.e.. gastrocnemius (GAST), soleus, and plantaris].  In total, the literature provides 
contradictory information regarding the impact of exercise on disease severity (Figure 1).  
Duration, intensity and modality of exercise complicate interpretation of data supporting 
the use of or contraindication of exercise as an intervention for DMD patients. To better 
identify the effect of exercise modality on disease severity the effects of voluntary wheel 
running, swimming and treadmill/rota-rod exercises were considered in more depth.   
Voluntary wheel running.   In the investigations considered, voluntary wheel 
running maintained or positively affected all measures of relative tension and fatigue 
resistance in muscles of the forelimb and in anterior and posterior compartments of the 
hind limb in dystrophic mice regardless of age and duration of wheel running (Figure 2).  
Forelimb strength increased by over 25% after four weeks of exercise starting at 12 
weeks of age (37).  Fatigue resistance of the EDL in vitro and TA in situ was improved 
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by 45% and 48% after sixteen and eighteen weeks of exercise, respectively, starting at 4 
weeks of age (92, 98).  In addition, relative tension in the EDL improved while other 
measures of EDL function were preserved (38) and maximum torque in the plantarflexor 
muscles were increased with voluntary wheel running (13).  Similarly, EDL fatigability 
decreased by 65% following forty-eight weeks of exercise started at 24-week-old mice 
(211).  Following nine weeks of exercise 12-week old mice maintained soleus function 
and fatigue resistance was significantly increased (59).  Relative tension and specific 
eccentric force of the soleus in 16-week-old mice also increased 25% following twelve 
weeks of exercise and tetanic force was increased 45% after sixteen weeks of exercise, 
while other measures of soleus and EDL function were maintained (37, 92).  Following 
one year of voluntary wheel running EDL relative tension and soleus function, such as 
relative tension, fatigue resistance and half relaxation time were maintained compared to 
unexercised controls (59, 60, 178).  While these data seem to provide compelling 
evidence supporting the use of exercise to maintain limb muscle health conflicting results 
were reported in the diaphragm (Figure 2).  In three independent studies 3 to 4-week-old 
mice ran on a wheel for one year.  In one investigation diaphragm relative tension was 
impaired by nearly 3-fold (178), however, a 30% increase in active tension, a 14% 
increase in fatigue resistance, and preservation of a variety of respiratory function and 
fatigue measures were reported in the other investigations (59, 60).  In a shorter 
experiment, mice exercised for nine weeks starting at 3 weeks of age had increased 
diaphragm contraction time, while maintaining other measures of diaphragm function 
(59).  The effect of voluntary wheel running on cardiac function is also unclear (Figure 
2).   After just four weeks of exercise, 11-week-old mice had over 25% thinning of the 
  
14 
left ventricle wall thickness and increased left ventricle dilation similar to dystrophin-
related cardiomyopathy (47).  In one investigation left ventricle ejection fraction 
decreased by 30% after fourteen weeks of exercise (98), but in another, after one year of 
exercise left ventricle ejection fraction was similar between sedentary and exercised mice 
while cardiac output was increased 2-fold and stroke volume increased by 80% with 
exercise training (178).    
Integrity of the skeletal system is also compromised in DMD patients both as a 
function of dystrophin deficiency and common use of glucocorticoids.  Kyphosis is a 
spinal deformity that is a hallmark of dystrophin deficiency and a negatively impacts 
respiratory function (114).  Brereton et al. (29) indicated that after one month of 
voluntary wheel running kyphosis increased by 25% in 4-month-old mice.  In addition to 
increased kyphosis, and perhaps contributing to it, fibrosis of the erector spinae increased 
by 40% (29).  Kyphosis and injury to the erector spinae is not routinely reported in the 
dystrophic literature making comparisons difficult.  Notably, these findings are in 
contrast to the bulk of data that show younger mice after a similar duration of exercise 
and 4-month-old mice following a longer duration of exercise have improved limb 
muscle function (13, 37, 38)  However, given its function, the erector spinae may 
experience increased, damaging stress during exercise.   
Swimming.  Swimming interventions were beneficial for most skeletal muscles in 
mdx mice (Figure 3).  Forelimb strength increased by 30% at 8 weeks of age following 
four weeks of exercise training (100).  Similarly, EDL half relaxation time decreased in 
20-week-old mice after fifteen weeks of swimming, indicating improved Ca2+ 
sequestration, fatigability decreased by over 20% in EDL, and EDL relative tension was 
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sustained (90). In addition, soleus half relaxation time was maintained and relative 
tension increased by 60% following fifteen weeks of swimming (90).  In older animals, 
eight weeks of exercise begun at 44 weeks of age increased relative tension in the soleus 
and EDL and sustained half relaxation time suggesting improved limb muscle health with 
exercise in aged animals (91).  Importantly, however, cardiac and respiratory muscle had 
increased fibrosis in exercised mdx mice compared to sedentary mdx mice after ten 
weeks of swimming in 19-week-old mice (Figure 3).  In addition, inflammation was 
increased 2-fold as was the heart wall to lumen ratio (16).   
The intensity of exercise in these studies and how this may affect interpretation of 
findings above make the impact of swimming unclear.  Playing in a swimming pool is a 
low intensity exercise recommended by physical therapists for a variety of muscle 
dysfunctions including DMD.  It is likely that the intensity of exercise, as a percent 
VO2max, in mice from these studies greatly exceeded that of DMD patients playing in a 
pool.   
Forced running.  Unlike voluntary wheel running, treadmill and rota-rod running 
are forced exercises that generally led to increased muscle damage and impaired function 
(Figure 4).  Following four weeks of training 8-week-old mice had a 20-50% reduction in 
forelimb strength (34, 35, 39, 53, 54), increased plasma CK activity, increased fibrosis in 
the quadriceps and heart, and increased oxidative stress in the quadriceps and abdominal 
muscles (35, 88, 176).  In the TA the abundance of necrotic muscle cells and 
inflammatory cells increased 2-fold, further supporting increased damage and decreased 
muscle function with treadmill training (54).  Interestingly, damage and muscle 
regeneration were similar in TA, gastrocnemius and diaphragm muscles following four 
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weeks of treadmill running compared to unexercised controls. Also, diaphragm relative 
tension was maintained (35).  Animals that began training at 8 weeks of age also had 
reduced forelimb strength after four weeks of training (159) and decreased force 
production in the gastrocnemius after twenty-four weeks (137). Twelve weeks of training 
starting at 12 weeks of age decreased tetanic force and increased fibrosis 2-fold in the 
gastrocnemius (152). Similarly, following six weeks of rota-rod training, forelimbs 
fatigue was similar between exercised and sedentary age-matched controls, but the 
gastrocnemius and quadriceps of 14-week-old mdx mice had over 2-fold more necrosis 
than sedentary age-matched controls (72), further supporting increased muscle damage 
and decreased muscle function caused by forced training. In some contrast, training for 
ten weeks starting at 10 weeks of age decreased soleus and gastrocnemius necrosis by 
over 40%, but, consistent with previous findings, dramatically increased plantaris 
necrosis (216).  The authors suggest (216) the degree of fiber loss may be related to the 
increased contractile activity, though it seems likely the increased relative activity of the 
plantaris in combination with the fast fiber type is accountable for increased plantaris 
necrosis while the soleus and gastrocnemius are protected.  Finally, following four weeks 
of treadmill training, oxidative stress was increased in quadriceps and abdominal 
muscles, but not the heart (176). In the same animals, fibrosis was increased in the heart 
and quadriceps, but the abdominal muscles were protected. 
In most studies mice were forced to run for 30 min at 12 m/min (360 m/day) 2-3 
times/wk, and in one investigation mice ran at 9 m/min for 60 min, 5 times/wk.  By 
comparison, with volitional wheel running young mdx mice ran an estimated peak of 14 
km/day (100 km/wk), 28-week-old mice ran nearly 3 km/day (20 km/wk), and 52-week-
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old mice ran approximately 2 km/day (14 km/wk) (178).  The role of distance (daily or 
weekly) is unclear, though data suggest that these shorter, forced bouts with treadmill 
running are not as efficacious as larger daily running volumes seen during wheel running.  
This interpretation is complicated, however, by the intermittent nature of mouse wheel 
running, which has typical bouts of 1-10 minutes in mdx mice (188). 
Downhill running.  Downhill running has been used as a method for deliberate 
induction of contraction-induced injury in dystrophic muscle (31, 127).  Our analysis of 
these investigations strongly supports this conclusion (Figure 5).  For example, after only 
three days of downhill running, there was a 40% increase in damage to the biceps brachii, 
triceps brachii, soleus, gastrocnemius and diaphragm in 2-month-old mice (31).  
Interestingly, damage was not increased in the TA or EDL (31).  Following seven weeks 
of training, fibrosis increased 3-fold in the TA of 31-week-old mice.  In addition, plasma 
CK activity and fibrosis of the biceps increased over 2-fold, further supporting increased 
damage (200).  Forelimb strength also decreased by 15% in these same animals (200).   
Fibrosis of the diaphragm and heart following two weeks of downhill running were 
similar to sedentary controls (200), but after ten weeks of downhill running dystrophic 
lesions increased in the heart by 3-fold with a 17% increase in heart mass (142).    The 
only improvement was the soleus in which twitch tension increased 50% after three 
weeks of downhill running, though half relaxation time increased (70). 
Human studies 
Conservative exercise protocols have been investigated in the context of both 
ambulatory and non-ambulatory DMD patients.  Despite the advent of mechanical 
respiratory support, respiratory failure remains a significant cause of death in DMD 
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patients.  Given this, inspiratory and expiratory muscle training as well as resistive 
training protocols have been utilized in ambulatory patients.  Generally, these 
interventions increased respiratory endurance by 46% with training after six weeks (204) 
and increased respiratory pressure and markers of respiratory strength after twenty-four, 
thirty-six, forty and ninety-six weeks of training (84, 113, 163, 212) (Figure 6).  In non-
ambulatory patients, six and a half weeks of respiratory exercise increased vital capacity 
and airway pressure over 70% making clear that non-ambulatory patients can respond 
favorably to a therapeutic intervention (4).   
In addition to respiratory function, range of motion and ability to complete tasks 
of daily living are important to the quality of life of DMD patients.  To identify exercise 
protocols to prolong independence, non-ambulatory patients were provided jaw stretching 
and strengthening interventions (104, 146).  Collectively, Nozaki et al (146) and 
Kawazoe et al. (104) discovered that masticatory performance and occlusal force and the 
degree of mouth opening were improved following twenty-four weeks of jaw exercises.  
In ambulatory patients, training by an assisted cycle or arm ergometer resulted in 
increased or maintained endurance and range of motion in targeted muscles (5, 102). 
These data suggest that stretching and exercise increased range of motion and maintain 
strength of skeletal muscles.  However, given the concerning respiratory and cardiac data 
presented above more information regarding the interplay between limb muscle exercise 
and impact on respiratory and cardiac function is necessary.   
Acute Exercise 
Performance of activities of daily living in DMD patients requires consideration 
of acute bouts of exercise.  This seems particularly urgent considering few patients are 
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part of regular exercise training regimens and regular play, not to mention occasional, 
high intensity activities, such as the violent forces experienced on inflatable playground 
equipment (i.e. a bouncy castle or the like), could certainly be considered an acute 
exercise bout.  Indeed, activities like this can lead to agonizing decisions as competing 
parental roles are in conflict.  Despite its importance, the literature does not provide 
fertile ground or necessary nuance for a rich discussion of acute exercise and we 
recognize this as an important gap in the literature.  Nevertheless, summation of limited 
available evidence points to increased susceptibility to acute injury in dystrophic muscle.    
In mdx mice, less than 30 min of swimming appeared damaging, despite being a 
non-weight bearing activity, as the number of damaged fibers in the TA were increased 
by up to 5-fold (28).  Further, Evan’s blue dye penetration into dystrophic muscle was 
dramatically elevated compared to healthy following a single 20 min swimming bout 
(206).  Of interest, in this investigation fibers expressing a microdystrophin construct 
were also resistant to swimming-induced injury, while fibers from within the same 
section lacking microdystrophin expression had robust penetration of Evan’s blue dye 
(206).  These sections are particularly important as they clearly demonstrate increased 
damage in dystrophin-deficient muscle compared to dystrophin-expressing muscle when 
subjected to the same acute exercise bout.   In addition, a single bout of treadmill running 
increased serum CK activity 7-fold (201) while in healthy mice only a 2 to 3-fold change 
might be expected following either treadmill running or even eccentric exercises (15, 
110).  In the quadriceps, necrosis was increased over 2-fold following 30 min of treadmill 
running (201), and in the EDL force was decreased 2.5-fold and membrane permeability 
was increased following 45 minutes of downhill running in mdx mice (209).  While 
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direct comparison to injury in healthy muscle is rare, our expectation, based on the 
sensitivity of dystrophic muscle to contraction-induced injury, demonstrated elevations in 
serum CK activity, and increased Evan’s blue dye penetration, is that this degree of 
damage in dystrophic muscle surpasses that anticipated in healthy muscle following 
performance of the same activity.  To that point, and while not a single acute running 
bout, 3-days of downhill running increased membrane permeability in dystrophic limb 
muscle by 10% while in healthy muscle no permeability was noted (31).  Lastly, when 
mdx mice ran voluntarily for twenty-four hours, damaged fibers in the gastrocnemius 
were increased 18% and 6-fold in the TA and quadriceps (8). This later study is of note as 
long-term volitional wheel running generally improved outcomes while shorter treadmill 
bouts exacerbated markers of injury.  Collectively, these data suggest that dystrophic 
skeletal muscle is capable of exercise-mediated adaptations despite increased damage 
early in a training regimen (i.e. acute exercise) though the degree to which it may be 
trained and how closely the training response of dystrophic muscle follows that of 
healthy muscle is unclear.   
Importantly, and consistent with the animal literature, acute or single bouts of 
exercise result in increased serum CK activity in DMD patients (154). While certainly 
increased serum CK activity can occur as a result of exercise in healthy patients the 
effect, and thus presumptive underlying muscle injury, is greater in DMD patients 
following similar activities.  For example, eight hours after a 15 minute bout of physical 
therapy in the water, serum CK activity increased nearly 1,000 U/l from baseline in DMD 
patients compared to an increase of less than 10 U/l in healthy subjects (154).  Supporting 
this notion of increased susceptibility to acute injury, circulating myoglobin increased 
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1,114.8 ng/ml from baseline in DMD patients but only 46.2 ng/ml in healthy controls 
eight hours post-exercise (154).  
While dystrophic muscle appears capable of exercise-mediated adaptations under 
the right training conditions (13, 37, 38, 59, 91, 92, 211), it is associated with increased 
injury following acute exercise, which may suppress exercise-mediated adaptations 
compared to healthy.   Further, despite these data seeming to make clear an acute bout of 
exercise is more damaging to dystrophic muscle compared to healthy muscle we cannot 
rule out the possibility that because DMD patients ostensibly have a lower VO2max than 
healthy controls, DMD patients or dystrophic muscle was operating at a higher relative 
workload and therefore, may be expected to have a greater degree of muscle injury.  
Moreover, as injury following acute exercise may be necessary for adaptation in healthy 
muscle, we cannot rule out the possibility that increased damage following acute exercise 
is necessary for a training adaptation in dystrophic muscle, though the degree to which 
disease and disease-related injury may alter this process, either directly or indirectly, is 
unknown.   
Exercise mimetics 
Exercise has the potential to provide a robust therapeutic effect to dystrophic 
muscle, however, the forces produced during exercise and its multi-systemic involvement 
make its use tenuous.  To harness the effects of exercise without associated complications 
several groups have used pharmaceutical and nutraceutical approaches to mimic the 
effects of exercise.  For example, myostatin inhibition has repeatedly resulted in 
increased muscle mass and function in a dystrophic muscle (25, 87), which ostensibly 
would translate into improved tasks of daily living.  Indeed, several clinical trials are 
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currently making use of myostatin inhibition as a therapy for muscular dystrophy 
(NCT02310763, NCT02515669, NCT02907619), however the impact on cardiac 
function will need to be carefully monitored.  In addition, induction of oxidative 
metabolism and the oxidative muscle phenotype has been successfully accomplished 
using the AMPK-activator, AICAR (121, 151), and activation of mitochondrial 
biogenesis pathways has been attempted via PGC-1α over-expression and gene transfer 
(82, 89, 181) and supplementation with resveratrol and quercetin (12, 95, 119, 179, 190).  
While generally further testing is needed, including long-term investigations and clinical 
trials, these approaches have the promise to afford DMD patients with some benefits of 
exercise while minimizing risk.   
Conclusion 
When considering exercise as a therapy for DMD patients it is essential to 
consider the totality of effects on patients and particularly to vital muscles.  Duchenne 
muscular dystrophy patients typically succumb to respiratory or cardiac failure, thus 
exercises that protect or improve limb muscle function while impairing respiratory or 
cardiac function provide little benefit to the patient.  In mouse studies, swimming 
generally improved limb muscle function, but caused histopathological damage in cardiac 
and respiratory muscles, suggesting that caution should be used when considering 
swimming as an exercise for DMD patients until the role of exercise intensity is made 
clearer.  Similarly, voluntary wheel running provided contradictory information regarding 
the impact on cardiac and respiratory function, though was consistently beneficial to limb 
muscles.  The multi-systemic nature of DMD and the impacts of exercise on these 
systems are also of interest for DMD patients.  Increased kyphosis (29) paired with 
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conflicting diaphragm (59, 178) and heart function data in mice (47, 98, 178) brings to 
light the need to further investigate and balance the benefits of exercise while minimizing 
detrimental side effects. Concurrent investigation of respiratory and cardiac function as 
well as other systems are necessary to effectively prescribe exercise as a therapy for 
DMD. 
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Figures 
 
 
Figure 1. Effect of low intensity exercise on health outcomes in dystrophic mice.  
Low intensity exercise provides both beneficial and detrimental health outcomes. The 
breadth of initiation age, duration, and modality complicate an appreciation for the effects 
of exercise on disease severity. Data were obtained from the literature and the effect of 
exercise normalized to sedentary mdx mice.  Additional statistical analyses were not 
performed.  For any given variable age of initiation is shown at 100% (Y-axis) and the 
deviation from 100% and the duration of the intervention can be determined.  The figure 
is constructed such that beneficial changes are above 100% and detrimental changes are 
below 100%, including those where an elevation would indicate increased pathology.  
Nonsignificant data were omitted from the figure but can be found in the supplementary 
file.  Data point shapes represent activities as indicated.  Colors represent muscles as 
follows:  black = whole body, gray = forelimb, purple = anterior hind limb, blue = 
posterior hind limb, red = heart, and green = diaphragm  
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Figure 2. Effect of voluntary wheel running on health outcomes in mdx mice. All 
measures of hind limb muscle function were maintained or improved by voluntary wheel 
running.  Conflicting results emerged concerning the effect of voluntary wheel running 
on cardiac and respiratory function.  Values above 100% are measures positively affected 
by exercise.  Nonsignificant data were omitted from the figure.  Data point shapes/colors 
represent measures as indicated.   
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Figure 3. Effect of swimming on health outcomes in mdx mice. Exercise improved 
forelimb function and hindlimb muscle function but was detrimental to cardiac muscle 
function. Values above 100% are measures positively affected by exercise. 
Nonsignificant data were omitted from the figure.  Data point shapes/colors represent 
measures as indicated.   
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Figure 4. Effect of treadmill running/rota-rod on health outcomes in mdx mice. 
Forced running caused a variety of responses in dependent variables. Values above 100% 
are measures positively affected by exercise.  Nonsignificant data were omitted from the 
figure.  Data point shapes/colors represent measures as indicated.   
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Figure 5. Effect of downhill running on health outcomes in mdx mice. Downhill 
running was largely detrimental hind limb (anterior and posterior compartments), 
forelimb, and cardiac muscles.  Values above 100% are measures positively affected by 
exercise. Nonsignificant data were omitted from the figure.  Data point shapes/colors 
represent measures as indicated.   
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Figure 6. Effect of exercise on DMD patients. Exercises designed to improve range of 
motion and respiratory endurance improved health outcome measure in DMD patients.  
Starting ages were not provided in this figure as the range of starting ages within a study 
varied as did ambulatory status. Values above 100% are measures positively affected by 
exercise. Nonsignificant data were omitted from the figure. Data point shapes/colors 
represent exercises as indicated.        
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Exercise Mimetics, Current Therapeutics and Autophagy 
Relevant Therapies  
Quercetin 
 Quercetin is a natural flavonoid with antioxidant and anti-inflammatory properties 
and GRAS (Generally Regarded as Safe) status (7, 27, 56). In an obesity mouse model 
quercetin reduced pro-inflammatory cytokines, decreased macrophage abundance and 
reduced muscle fiber atrophy (115). Quercetin may stimulate SIRT1 (57), a NAD+-
dependent deacetylase, which interacts with metabolic regulator, PGC-1a (144). In healthy 
muscle, quercetin increased gene expression of Sirtuin 1 (SIRT1) and PGC-1a, and 
increased mitochondrial DNA content suggestive of increased mitochondrial biogenesis 
(51). Further, quercetin increased cytochrome c protein abundance suggestive of increased 
mitochondrial biogenesis (51). PGC-1a is a transcriptional coactivator that is elevated 
following exercise and can increase mitochondrial biogenesis and utrophin protein 
abundance, both of which are beneficial to dystrophic muscle (42, 118, 181). Indeed, PGC-
1a overexpression has been shown to prevent/delay disease onset and rescue muscle from 
active decline. Hence, quercetin may decrease disease severity by decreasing oxidative 
stress, reducing inflammation and increasing abundance of the dystrophin-like protein, 
utrophin. While quercetin does appear to increase mitochondrial biogenesis the role of 
increased mitochondria in disease mitigation is unclear. 
In support of this hypothesis, quercetin provided histological benefits to dystrophic 
skeletal muscle following 6 months of treatment (95). Additionally, quercetin improved 
respiratory function for the first 6 months of supplementation, but by 12 months respiratory 
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function was not preserved and markers of histological damage were similar between 
treated and untreated mdx mice (180).   
In dystrophic hearts following 6 months of quercetin treatment, histological 
damage was decreased and utrophin abundance was increased (12). Additionally, 
cytochrome c and SOD2 content increased, which the authors suggest may be indicative of 
increased mitochondrial abundance (12). Following 8 months of quercetin, indices of 
cardiac function were improved, animal activity increased as well as increased 
colocalization of utrophin and DGC components by immunofluorescence (11). 
Additionally, markers of damage were reduced and indices of mitochondrial abundance, 
such as PGC-1a and electron transport complex I-V, were increased (11). Similarly, 
following 12 months of quercetin, mitochondrial biogenesis was elevated and indices of 
inflammation decreased, though quercetin did not improve cardiac function (10). These 
data suggest that quercetin is cardioprotective and transiently protects skeletal muscle 
necessitating further investigation to establish the viability of quercetin as a long-term 
treatment for DMD. 
 
Nicotinamide riboside 
 In dystrophic muscle, NAD+ is depleted along with nicotinamide phosphor-
ribosyltransferase (NAMPT), an essential enzyme in the NAD+ salvage pathway (40). 
Supplementation with nicotinamide riboside (NR) may increase the NAD+ pool and can 
protect against mitochondrial and metabolic dysfunction (71). In mdx mice, 10 weeks of 
NR supplementation increased stem cell function and abundance (217). After treating mdx 
mice with NR for 12 weeks, NAD+ bioavailability increased along with running capacity, 
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mitochondrial abundance, mitochondrial capacity, and dystroglycoprotein complex protein 
abundance (169).  Furthermore, cardiac and diaphragm fibrosis, necrosis, inflammation 
and overall damage decreased in the diaphragm (169). Similarly, NR supplementation in a 
zebrafish model of DMD improved muscle structure and mobility (83). Collectively, these 
data strongly suggest that NR supplementation may be an effective therapeutic for DMD. 
Moreover, NR may restore the depleted NAD+ supply in dystrophic muscle prolonging 
deacetylation activity of SIRT1 (57), a deacetylase in which NAD+ is required, increasing 
long-term efficacy of quercetin. 
 
Lisinopril 
 Lisinopril is an angiotensin converting enzyme (ACE) inhibitor that blocks the 
formation of angiotensin II from angiotensin I. Lisinopril was approved by the FDA to treat 
hypertension, but since gaining FDA approval has been used to reduce myocardial fibrosis 
and treat cardiomyopathy in DMD patients (155).  Further, Lisinopril has been shown to 
increase left ventricle function (6, 205) and has been recommended for DMD patients 
starting as young as 10 years of age (133), prior to left ventricle ejection fraction falling to 
less than 55%.  
 While Lisinopril appears to be cardioprotective the effect of Lisinopril on 
dystrophic pathology in skeletal muscle is relatively unknown. Recently, Lowe et al. 
(123) evaluated the effect of Lisinopril on dystrophic skeletal muscle and found that 
Lisinopril decreased muscle damage but did not improve muscle function. Lisinopril has 
also been used in combination with aldosterone antagonists, spironolactone and 
eplerenone, and with a common glucocorticoid taken by DMD patients, prednisolone. 
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Spironolactone and eplerenone function as aldosterone antagonists, which disrupt the 
binding of aldosterone to mineralocorticoid receptors (52). Mdx/Utrn+/- mice treated with 
Lisinopril and spironolactone for 4 weeks starting at 4 weeks of age increased skeletal 
muscle function and decreased histological damage (160). Given that Lisinopril is 
beneficial to cardiac muscle, the effect of Lisinopril on skeletal muscle alone and within 
the context of other therapies is vital to understanding the value of Lisinopril as a therapy 
for DMD patients.  
 
Glucocorticoids: Prednisone and Prednisolone 
 Glucocorticoids were first used to treat Duchenne muscular dystrophy in the early 
1970s and are currently the standard of care for DMD patients (21, 58). In the United 
States, most patients receive prednisone or prednisolone (the active form of prednisone) 
(14), which are typically administered daily (0.75 mg/kg/d) or intermittently (10 
mg/kg/weekend) (66, 81). In clinical studies prednisone and prednisolone preserved 
motor function and muscle strength, delayed loss of ambulation, reduced development of 
scoliosis and decreased rate of pulmonary function decline (81, 182).  A recent 
examination of long-term glucocorticoid use on natural history found that the use of 
glucocorticoids for longer than a year delayed loss of ambulation by 2.1-4.4 years and 
loss of upper limb mobility by 2.8-8 years (130). In one study, treatment with 
prednisolone resulted in no scoliosis over 1.5-5 years compared to untreated with 
scoliosis (214). Though the mechanism driving therapeutic effects on dystrophic tissue 
are unknown, it is well known that glucocorticoids increase myoblast proliferation, 
stimulate regeneration, and reduce inflammation via immunosuppression (214). Despite 
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these benefits, prednisone and prednisolone treatments result in several side-effects, such 
as behavioral changes, weight gain, cushingoid appearance and cataracts (17).  As a 
result, and despite the clear clinical benefit, dosing of steroids and age of application 
varies widely, and some patients remain steroid naive.   
Because of these significant side effects an alternative to prednisone and 
prednisolone was developed. While widely available in Europe and other places globally 
for some time, deflazacort was approved by the FDA for use in the United States in 2017.  
Deflazacort is a prednisolone derivative, which has been shown to provide similar 
benefits (182).  Deflazacort has been used routinely in Europe and has been shown to 
reduce growth which may delay loss of ambulation in addition to the benefits observed 
following prednisone and prednisolone treatment (86).  Similar to prednisone and 
prednisolone, deflazacort has been shown to have side-effects such as weight gain, 
behavioral changes, cushingoid appearance and cataracts (19, 86).  
 
Autophagy 
Function of Autophagy 
 Autophagy is a catabolic process by which cellular components are degraded into 
basic units to be recycled for energy, maintenance, and rebuilding of cellular 
components, ie. organelles, proteins etc. Autophagy can be stimulated by a variety of 
stressors, such as mitochondrially generated reactive oxygen species and the 
accumulation of dysfunctional proteins or organelles (44), but the majority of canonical 
autophagy is discussed within the context of nutrient depletion. Autophagy is separated 
into three major types: chaperone-mediated autophagy, microautophagy and 
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macroautophagy.  Briefly, chaperone-mediated autophagy (CMA) is a selective process 
by which proteins destined for degradation by CMA are identified and bound by 
chaperone complexes, such as heat shock-cognate protein of 70 kDa (Hsc70), or 
cochaperones to the KFERQ-like motif of the protein (162). Once bound, this protein is 
internalized by the lysosome through a translocation complex formed by lysosome-
associated membrane protein 2a (Lamp2A) multimerization (49). The second type, 
microautophagy, occurs when cargo is taken directly into the lysosome through a 
mechanism of lysosomal membrane invagination (162). The third type, and the type of 
autophagy we will further discuss, is macroautophagy, hereafter referred to as autophagy. 
Autophagy is the process by which cargo, both selectively and nonselectively, are 
engulfed along with a portion of the cytoplasm into a developing autophagosome.  The 
mature double-membraned autophagosome fuses with a lysosome forming an 
autophagolysosome (autolysosome).  Upon fusion the inner membrane of the 
autophagosome is degraded allowing for the lysosomal enzymes to degrade the cargo.  
Autophagy can be separated into four key states: initiation of phagophore 
formation, elongation of the phagophore, maturation of the autophagosome, and finally 
the fusion of the autophagosome with the lysosomes. Initiation or formation of the 
phagosome can be accomplished de novo or using previously existing membranes, such 
as the endoplasmic reticulum, mitochondria, lipid droplets, and golgi apparatus (9, 136). 
Prior to stimulation, for example in the presence of amino acids, mammalian target of 
rapamycin complex (mTORC1), a serine/threonine protein kinase that is known to 
regulate cell growth and metabolism, phosphorylates Unc-51 like autophagy activating 
kinase (ULK1) at Ser 757 and autophagy related protein 13 (ATG13) on Ser 258 
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inhibiting the kinase ability of ULK1 (105, 157). Phosphorylation of ULK and ATG13 
leads to an inhibition of autophagy and inhibits the ability of ATG13 to enhance ULK1 
activity and translocate the ULK1 complex to autophagy initiation sites (76, 97, 215).  
Upon stimulation of autophagy, typically through increased AMP-activated 
protein kinase (AMPK) and/or inhibition of mammalian target of rapamycin (mTOR), the 
ULK1 complex and the class III phosphatidylinositol 3-kinase (PI3KC3) complex are 
activated to initiate phagosome nucleation.  The ULK1 complex is composed of kinases, 
ULK1 or ULK2, and regulatory proteins, ATG13, focal adhesion kinase family-
interacting protein of 200 kDa (FIP200) and ATG101, an ATG13-binding protein (162). 
This complex is constitutively formed, but upon amino acid depletion, ULK1 is 
phosphorylated at Ser555 and dephosphorylated at Ser757 along with dephosphorylation 
of ATG13 (76, 157). Together this activates the ULK1 complex to promote 
autophagosome formation. The binding of ATG13 and FIP200 to ULK1 enhances ULK1 
activity and together this ULK1 complex promotes autophagosome formation and 
phosphorylation of Beclin-1 at Ser14 (76, 143, 167).  
PI3KC3 complex, composed of PI3KC3 (VPS34), p150, ATG14L and Beclin-1, 
is formed to facilitate membrane formation (136, 167). The binding of Beclin-1 to 
PI3KC3 enhances PI3KC3 activity (75) and the phosphorylation of ATG14L by ULK 
further increases PI3KC3 complex activity, which promotes the synthesis of 
phosphatidyl-inositol-3-phosphate (PI3P), lipids known to be essential for membrane 
dynamics (213). 
Given that role of Beclin-1 in the PI3KC3 complex and autophagosome 
nucleation, further research has been done to elucidate the regulation of Beclin-1.  
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Beclin-1 has two groups of binding proteins, some which promote and others that inhibit 
autophagy. Binding of autophagy Beclin-1 regulator (Ambra-1), UV radiation resistance-
associated gene (UVRAG), or bax-interfering factor 1 (bif-1) to Beclin-1 induces 
autophagosome formation (68, 197), while binding of BCL-2 or BCL-2 homology, BCL-
xL, inhibits autophagosome formation (150). Beclin-1 contains a conserved BH-3 domain 
allowing for it to interact with BCL-2 and BCL-xL (147). Interestingly, when nutrient-
deprivation autophagy factor-1 (NAF-1) interacts with BCL-2 at the endoplasmic 
reticulum the interaction of NAF-1 and BCL-2 stabilize the binding of BCL-2 and 
Beclin-1 inhibiting autophagy (43). Conversely, the liberating of Beclin-1 from BCL-2, 
through the binding of p62 to BCL-2, stimulates autophagosome formation (219).  
As the phagosome forms and matures, autophagy-related proteins are utilized to 
develop the phagophore into a mature autophagosome. Autophagosome expansion and 
maturation are controlled by two ubiquitin-like conjugation pathways, 
ATG5/ATG12/ATG16L complex and microtubule associated proteins (MAP1) light 
chain 3 (LC3) complex. To form the ATG12/ATG5/ATG16L complex the c-terminus of 
ATG12 is activated by ATG7, an E1-like enzyme (199), then transferred to ATG10, an 
E2-like enzyme (184). ATG12 is then conjugated to ATG5 forming ATG12/5 (135).  
Finally, ATG12/5 is conjugated to ATG16L completing the ATG12/ATG5/ATG16L 
complex, which is essential to the expansion and elongation of the autophagosome (185). 
Upon completion of the autophagosome, ATG12/ATG5/ATG16L complex is dissociated 
from the membrane (73).  
In the second ubiquitin-like conjugation pathway, LC3 is lipidated to become 
LC3II and is then integrated into autophagosome membrane.  LC3 is first cleaved at its 
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C-terminus by ATG4, a protease, to form LC3I, then conjugated to 
phosphatidylethanolamine (PE) by ATG7 and ATG3, E1 and E2-like enzymes, 
respectively. This lipidation converts LCI to LC3II, which is incorporated into the 
autophagosome membrane (101). Adaptor proteins, such as sequestosome 1 (p62), bridge 
LC3II to the selected cargo to be enclosed in the double-membraned autophagosome 
(149). Interestingly, the lipidation process has been shown to be reversible. LC3II can be 
liberated from the autophagosome membrane prior to fusion with the lysosome by 
delipidation, ie. the removal the PE group from LC3II by ATG4 (106), though 
delipidation by ATG4 occurs at a slower rate than the priming of LC3 for lipidation 
(103). Finally, autophagosomes fuse with lysosomes to degrade the cargo collected in the 
autophagosome.  
Lysosomes are a single membrane vesicle in which v-ATPase complexes in the 
membrane function to maintain the highly acidic internal environment (pH 4.5-5). 
Lysosomes contain numerous enzymes, such as hydrolases, proteases, lipases and 
nucleases, to degrade cellular components, such as organelles, lipids and proteins. The 
resulting monomers can either diffuse or are actively transported out of lysosome to be 
reused (140). To prevent degradation of the lysosome membrane by resident lysosomal 
enzymes, membrane proteins are glycosylated such that the inner membrane is covered in 
glycocalyx to protect the membrane. Two proteins of interest are lysosomal associated 
membrane protein (LAMP) 1 and 2, which are highly glycosylated proteins known to 
stabilize the lysosomal membrane and make up two-thirds of the lysosomal membrane 
providing the glycocalyx protection of the membrane (210). Additionally, hypotheses 
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have been advanced that posit that LAMP proteins may also play a role in positioning of 
lysosomes by acting as scaffolding for motor protein complexes (161). 
Lastly, interpretation of data to elucidate autophagic function must be approached 
delicately and have been under review and discussion within the research community. 
Recently, exhaustive guidelines for collecting and interpreting autophagy data have been 
established (108). Researchers use the ratio of lipidated LC3 (LC3II) to unlipidated LC3 
(LC3I) to indicate movement, or flux, through the autophagy pathway towards 
degradation. Similarly, p62 has been used as an inverse correlate to autophagosome 
degradation as p62 is degraded along with the cargo (22). For example, a decreased ratio 
of LC3II/I and increased p62 have previously been used as evidence of impaired 
autophagy in dystrophic muscle (20, 55, 148).  
To better elucidate the flux and function of the autophagy pathway, inhibitors of 
autophagosome-lysosome fusion and degradation have been utilized. Chloroquine is a 
commonly used inhibitor of autophagy, which inhibits fusion of the autophagosome 
(129). Bafilomycin A1, a v-ATPase inhibitor, reduces lysosome function, which may 
inhibit both degradation and fusion (109). By incorporating inhibitors of fusion into the 
experimental design, researchers can use a nuanced approach to discriminate increased 
autophagy resulting in increased autophagosome abundance from increased 
autophagosome abundance due to decreased degradation. Similarly, transgenic mice were 
generated to assess autophagic flux in vivo. Tandem fluorescent-tagged LC3 mice were 
generated that have an RFP-GFP-LC3 reporter in which initially both RFP and GFP are 
colocalized on LC3 and appear yellow, but once the autophagosome fuses with the 
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lysosome, the GFP is quenched and only RFP remains, thus the ratio of RFP to RFP-GFP 
indicates autophagic flux in vivo (139). 
 
Autophagy in Duchenne muscular dystrophy 
 Autophagy has become a pathway of interest in Duchenne muscular dystrophy as 
well as a variety of other myopathies in which autophagy is abnormally regulated, such 
as collagen-VI-related diseases, Emery–Dreyfuss muscular dystrophy (EDMD), Danon’s 
disease and Pompe disease (173). Impaired autophagy has also been established in 
Duchenne muscular dystrophy (55, 67, 148, 151, 191, 195). We and other have shown 
that autophagy is impaired prior to degradation of the autophagosome resulting in an 
accumulation of autophagosomes as indicated by increased p62 and decreased LC3II/I 
ratio (148, 191). Additionally, total AMPK and phosphorylated AMPK, an activator of 
autophagy, were decreased (120, 179) and phosphorylated mTOR/total mTOR ratio, an 
inhibitor of autophagy, were elevated (148) suggestive of decreased autophagic signaling 
in dystrophic muscle. Despite upstream signaling, autophagosome maturation and 
formation are increased as indicated by increased Beclin-1 and ATG12/5 in dystrophic 
muscle (191). Using inhibitors, Fiacco (67) further established that in aged mdx skeletal 
muscle autophagosome degradation was blocked as demonstrated by similar LC3II 
abundance when autophagosome degradation was inhibited with chloroquine. Further 
supporting impaired autophagy, colocalization of p62/LC3 as well as p62/LAMP1 were 
decreased in flexor digitorum brevis muscles isolated from mdx mice (148). Similarly, 
LC3II and p62 were elevated in muscle of 3- and 6-month-old golden retriever model of 
DMD with no change in LC3 gene expression supportive of impaired autophagy (195).  
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Autophagosome degradation could be impaired by several mechanistic 
dysfunctions. For example, impaired autophagy could be caused by an inability to fuse 
the autophagosome to the lysosome, decreased lysosome function and/or reduced 
lysosome abundance. We and other have demonstrated that LAMP1 and LAMP2 protein 
abundance are decreased in mdx skeletal muscle and as previously mentioned 
LC3/LAMP1 colocalization was decreased supporting that autophagic dysfunction could 
be due to insufficient lysosome abundance or impaired fusion (148, 191).  
Emerging evidence also suggest that autophagy in DMD patients is impaired. 
Biopsies from DMD patients demonstrate decreased LC3II/I ratio and increased p62 
suggestive of impaired autophagy (55). Interestingly, pAKT protein abundance, which 
should inhibit autophagy, was elevated despite an accumulation of p62 (55).  In 
immortalized myoblasts from DMD patients, initiators of autophagosomes formation, 
PI3KC3 and ATG3, were elevated and autophagosome abundance marker, LC3II, was 
increased in dystrophic myoblasts (207). Upon inhibition of lysosome acidification with 
E64D and pepstatin, LC3II protein abundance was elevated indicating successful 
degradation of autophagosomes in DMD myoblasts, but LC3II accumulation was further 
increased in healthy controls suggesting that fusion may be slightly inhibited (207). 
Similarly, LC3 abundance was increased in biopsies from 2- and 8-year-old DMD 
patients compared to healthy controls (67). These data suggest that autophagy is activated 
in DMD patients but is impaired prior to autophagosome degradation. Treatments to 
stimulate autophagy, such as low protein diets, AICAR, an AMPK activator, and 
rapamycin, an mTOR inhibitor, have successfully improved autophagic signaling and 
reduced histological injury, suggesting that therapies to repair autophagy may be 
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beneficial to DMD patients (20, 55, 151).  Despite success of these stimulators of 
autophagy, the benefits of directly improving impaired autophagosome degradation may 
further protect dystrophic muscle. 
 
PGC-1α and autophagy 
Peroxisome proliferator-activated receptor-gamma coactivator (PGC-1α) is a 
transcriptional coactivator known to drive genes involved in mitochondrial biogenesis, 
oxidative metabolism and maintenance of glucose, lipid and energy homeostasis, among 
other functions (173, 174). To regulate mitochondrial biogenesis, PGC-1α recruits 
histone acetyl transferases (HATs) to remodel chromatin and interacts with a variety of 
transcription factors to promote transcription of mitochondrial genes, such as nuclear 
respiratory factor 1 (NRF-1), nuclear respiratory factor 2 (NRF-2) and estrogen related 
receptor alpha (ERRα).  Together these transcription factors upregulate expression of 
nuclear encoded mitochondrial proteins (NEMP) and mitochondrial transcription factor A 
(TFAM) resulting in mitochondrial DNA replication and transcription of mitochondrially 
encoded genes.  
Specifically, in healthy skeletal muscle, PGC-1a overexpression increased the 
ratio of slow oxidative fibers to fast glycolytic fibers (118), helped maintain muscle mass 
and fiber volume following denervation (174), increased mitochondrial biogenesis (78, 
117, 118), and increased protection against reactive oxygen specifies (ROS) (192).  
Similarly, when PGC-1α was overexpressed in dystrophic muscle, there was a shift 
toward an increased ratio of slow oxidative fibers compared to fast glycolytic fibers 
(181), decreased histological markers of damage (89), and increased mitochondrial 
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markers suggesting increased mitochondrial abundance (181). PGC-1α overexpression 
has also been shown to increase muscle force and fatigue resistance (94, 181).  Further, 
PGC-1α has been shown to drive utrophin transcript and protein abundance (42, 181), a 
dystrophin-like protein typically localized to the neuromuscular junction that 
compensates for the absence of dystrophin in dystrophin-deficient skeletal muscle (202, 
203). Overexpression of PGC-1α increased utrophin abundance in dystrophic muscle, 
further, utrophin overexpression increased abundance of dystroglycoprotein complex 
proteins at the sarcolemma that are mislocalized with dystrophin deficiency (203). 
Importantly, PGC-1α has been shown to alter autophagy, through an elusive 
relationship with transcription factor EB (TFEB). TFEB is a master regulator of 
autophagy and lysosome biogenesis related genes. Interestingly, when TFEB was 
overexpressed, PGC-1a transcription abundance increased, also when PGC-1a was 
knocked out total TFEB protein abundance was decreased. (63). These data suggest that 
the relationship between TFEB and PGC-1a is unclear and it is more complex than 
expected. Nonetheless, these data suggest that TFEB can be manipulated through PGC-
1a. Further, in an aging model, PGC-1α overexpression increased markers of autophagy 
(78). Similarly, in a Pompe disease model transgenic overexpression of PGC-1α 
increased markers of autophagy, increased lysosome abundance, and decreased 
autophagosome accumulation suggesting increased efficiency of autophagy (198). 
Collectively, these data suggest that upregulation of PGC-1a is therapeutic for dystrophic 
muscle and can increase autophagy and lysosome biogenesis through a TFEB-mediated 
mechanism. 
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Abstract 
 Duchenne muscular dystrophy (DMD) results from a genetic lesion in the 
dystrophin gene and leads to progressive muscle damage.  PGC-1α pathway activation 
improves muscle function and decreases histopathological injury.  We hypothesized that 
mild disease found in the limb muscles of mdx mice may be responsive to quercetin-
mediated protection of dystrophic muscle via PGC-1α pathway activation.  To test this 
hypothesis muscle function was measured in the soleus and EDL from 14 month old C57, 
mdx, and mdx mice treated with quercetin (mdxQ; 0.2% dietary enrichment) for 12 
months.  Quercetin reversed 50% of disease-related losses in specific tension and partially 
preserved fatigue resistance in the soleus.  Specific tension and resistance to contraction-
induced injury in the EDL were not protected by quercetin.  Given some functional gain in 
the soleus it was probed with histological and biochemical approaches, however, in 
dystrophic muscle histopathological outcomes were not improved by quercetin and 
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suppressed PGC-1α pathway activation was not increased.    Similar to results in the 
diaphragm from these mice, these data suggest that the benefits conferred to dystrophic 
muscle following 12 months of quercetin enrichment were underwhelming.  Spontaneous 
activity at the end of the treatment period was greater in mdxQ compared to mdx indicating 
that quercetin fed mice were more active in addition to engaging in more vigorous activity.  
Hence, modest preservation of muscle function (specific tension) and elevated spontaneous 
physical activity largely in the absence of tissue damage in mdxQ suggests dietary 
quercetin may mediate protection.   
Key Words: mdx, Duchenne muscular dystrophy, PGC-1alpha 
Introduction 
Duchenne muscular dystrophy (DMD) is caused by the absence of the dystrophin 
protein, which acts to transmit force between cytoskeleton and extracellular matrix via the 
dystrophin glycoprotein complex (DGC) [1, 2].  The absence of dystrophin results in 
cellular dysfunction including decreased calcium homeostasis, increased necrosis, and 
disruption of DGC along with other secondary effects producing whole muscle 
dysfunction.  Utrophin, a dystrophin-like protein, participates in DGC formation, stability, 
and function in the absence of dystrophin [3, 4], hence utrophin upregulation remains an 
area of intense research interest [5-8]. Utrophin transcription can be driven by the exercise-
sensitive PGC-1α pathway [9], however, attempts to use various exercise modalities as 
interventions for DMD have been met with mixed results [10-13].  Direct activation of the 
PGC-1α pathway using transgenic and gene transfer approaches yields consistently 
positive results using both prevention and rescue paradigms [14-18].  Under these 
conditions PGC-1α pathway activation led to increased muscle function, decreased muscle 
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damage, increased utrophin abundance and a physiologic and metabolic type I shift in 
PGC-1α over-expressing dystrophic muscle compared to control muscle [14-18].    
Given the emerging success of PGC-1α pathway activation for treating dystrophic 
pathology we next searched for PGC-1α activators that already had FDA approval or were 
freely available to minimize time needed to impact patients.  Quercetin, a flavonoid with 
antioxidant and anti-inflammatory properties [19], drives the PGC-1α pathway through 
SIRT1 deacetylase [20, 21] or AMPK activity [22].  We found previously that six months 
of dietary quercetin enrichment decreased histopathology in diaphragms [23] and hearts 
[24] from dystrophic mice.  In a follow up experiment, we found that 12 months of 
quercetin dietary enrichment transiently protected dystrophic diaphragms and respiratory 
function though a developed quercetin insensitivity ultimately minimized therapeutic 
benefits [25].  Given that limb muscles from mdx mice suffer a more mild disease than 
diaphragms we reasoned that quercetin may continue to protect limb muscle from 
progressive disease and, therefore, that quercetin would have a role as a therapeutic 
intervention early in the disease process and would be most efficacious in the youngest 
DMD patients. We hypothesized that muscle function would be improved and histological 
injury would be decreased in dystrophic soleus and extensor digitorum longus (EDL) 
following 12 months of dietary quercetin enrichment compared to muscles taken from mice 
maintained on a control diet.   
Methods 
Ethical Approval and Animal Treatments   
The Institutional Animal Care and Use Committee at Auburn University reviewed 
and approved all procedures utilized in this work.  Previous work, including a detailed 
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study design, has been previously published [25].  Briefly, eight male C57 mice and 16 
male mdx mice (Jackson Laboratories) were acclimated for one week prior to the beginning 
of the experiments.  At 2 months of age a standard AIN93 diet (Bioserv, Flemington, NJ) 
was provided for C57 mice (n=8) and control mdx mice (n=8), while treated mdx mice 
received an AIN93 diet supplemented with 0.2% quercetin (n=8) for 12 months.  Both 
water and food were available ad libitum.  Throughout the study period animal food, water, 
bedding, general health, and environmental conditions were checked twice daily by a 
combination of research and vivarium staff.  Over the course of this longitudinal 
investigation one mouse from each group was identified as severely ill (monitored criteria 
included: physical appearance, weight loss, and behavior).  To minimize suffering animals 
were euthanized via CO2 inhalation followed by exsanguination consistent with our 
IACUC protocol. Changes in body weight throughout the study period have been 
previously reported as have average daily food consumption (3.9 g/day) and resultant daily 
quercetin exposure (204 mg/kg/day) [25]. At 14 months of age, activity was measured 
using an ethological approach.  Soleus and EDL in vitro muscle function were assessed at 
the Physiological Assessment Core of the Wellstone Muscular Dystrophy Cooperative 
Center at the University of Pennsylvania.  Prior to in vitro function all animals were 
assigned new numbers to establish blinded data collection and further preserve blinded 
conditions upon distribution of tissues for subsequent analyses.  Sample numbers and 
animal groups were revealed prior to biochemical analysis for properly controlled 
experiments.  Due to the length of this study several animals did not reach 14 months of 
age or tissues were unusable for some measures, thus number/group is identified for all 
measurements in the figure legends. 
  
70 
Animal Activity 
At 14 months of age, activity was recorded for 10 consecutive minutes in conscious 
mice and were averaged over two observation periods for occurrences of sitting, grooming, 
eating/drinking, socializing, standing, walking, wall pacing, running, and jumping.  This 
technique represents a species-specific ethogram (repertoire of discrete animal activities) 
using the “0-1 recording” method, which has been applied across many species.  When an 
observed mouse performed a particular activity (sitting, walking, etc.) it was recorded as 
1.  Activity counts were performed on two occasions by two investigators and activity 
recordings were performed every 15 seconds for 10 minutes and collectively equaled 40 
activity time periods.  Twenty total minutes of activity were recorded for the two sessions 
and final counts were averaged from scores generated by the two blinded observers. 
Activity counts were performed at a common time at the end of the photo light and photo 
dark cycles [26].  
Tissue Collection and Muscle Function   
After 12 months of treatment, mice were sedated to a surgical level of anesthesia 
using a ketamine/xylazine cocktail at the Physiological Assessment Core of the Wellstone 
Muscular Dystrophy Cooperative Center at the University of Pennsylvania (now housed at 
the University of Florida).  Upon sedation, soleus and EDL muscles were removed from 
each animal and used for measures of muscle function.  In vitro muscle function was 
measured using standard techniques as has been done previously [27-29].  Briefly, the 
tetanic force was determined in the EDL and soleus using stimulation of 120 Hz and 100 
Hz, respectively.   To determine fatigue resistance the soleus was stimulated for 10 minutes 
with one contraction/sec (100 Hz for 330 msec with 200 µsec pulse).   To determine 
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resistance to contraction-induced injury the EDL was given a series of five lengthening 
contractions (500 msec at 80 hz followed by 10% beyond Lo for 20 msec).  To determine 
fatigue resistance and resistance to contraction induced injury data are expressed relative 
to peak force produced during the first contraction. Specific tension and cross sectional 
area were calculated using standard equations [30].   As there were changes in soleus 
muscle function suggestive of a therapeutic effect tissues were examined with histological 
and biochemical approaches.  Following the fatigue test the soleus was frozen in melting 
isopentane and used for histological measures while the contralateral soleus was snap 
frozen upon removal and used for biochemical measures.   
Histological Analyses   
Muscle injury and fibrosis were measured as recently described [25].  Briefly, 10 
μm sections were cut and stained with either hematoxylin and eosin (H&E) or Masson’s 
Trichrome (KTMTR, American MasterTech, Lodi, CA).  H&E and trichrome stained slides 
were imaged with an inverted DMI3000 B microscope and QICAM MicroPublisher 5.0 
(MP5.0-RTV-CLR-10, QIMAGING) camera using QCapture software.  Trained, blinded 
technicians took 3-5 images at 10x magnification for each soleus section.  Overlapping 
images allowed for reconstruction of the entire muscle cross section using the Photoshop 
merge option (Adobe).  H&E sections were then analyzed by these technicians using Open 
Lab (Improvision) to quantify 1) total number of muscle cells, 2) central nucleation, 3) 
extracellular nuclei, 4) necrotic area, and 5) total contractile area (area of the section 
comprised of muscle fibers). Trichrome staining was used to quantify areas of fibrosis.  
Immunohistochemistry was utilized to confirm fibrosis findings and measure fiber 
area distribution.  To measure fibrosis and fiber area distribution anti-fibronectin (Sigma, 
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St. Louis, MO) and anti-laminin (1:100, Thermo Scientific, Waltham, MA) primary 
antibodies were applied to the samples at 4°C overnight, respectively.  At room 
temperature, sections were exposed to donkey anti-rabbit rhodamine secondary antibody 
(1:200, Millipore, Billerica, MA) for 1 hour.   3-5 non-overlapping images were taken with 
a QICAM 12-bit Mono Fast 1394 Cooled (QIC-F-M-12-C, QIMAGING) camera at 10x 
magnification attached to the Leica microscope under blinded conditions. 
qPCR 
Measurement of transcript abundance was performed in the soleus employing 
Fluidigm technology as we have done previously [25].  Our complete list of primer pairs 
has also been previously published.  Briefly, mRNA was isolated using TriZol 
(ThermoScientific) and reverse transcribed to cDNA using QuantiTect Reverse 
Transcriptase Kit (Qiagen) as described by the manufacture, but random hexamers (IDT 
PreMade Primers) were substituted for the RT Primer Mix (Qiagen).  cDNA was further 
prepared as suggested by Fluidigm then loaded onto a 96x96 Fluidigm chip.   
Western Blot   
Measurement of relative protein abundance was performed as previously described.  
Briefly, 200 μl of whole muscle buffer (10mM Sodium Phosphate buffer, pH 7.0, 2% SDS) 
was added to powdered soleus tissue and homogenized.  Once homogenized, samples were 
spun at 20,000 RCF for 15 minutes and supernatant containing the protein was collected 
for western blotting.  Protein concentration was measured using Pierce BCA Protein Assay 
Kit (ThermoScientific, 23225) and diluted with 2x Laemmli buffer.  Once diluted, samples 
were heated for 5 minutes at 95°C.  Thirty micrograms of protein were separate by mass 
using 4-20% gradient gels (Lonza).  Separation was run at 60 volts for 20 minutes followed 
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by 120 volts for 60 minutes, then transferred for 60 minutes at 100 volts onto a 
nitrocellulose membrane.  Membranes were probed for the following antibodies overnight 
at 4°C then incubated for 1 hour with anti-rabbit secondary: phosphorylated (p-) AMPKα 
(thr172) (P 1:500, S 1:2000, Cell Signaling), SIRT1 (P 1:500, S 1:2000, Millipore), Histone 
3 Lysine 9 Acetylation (H3K9ac) (P 1:1000, S 1:5000 in 0% milk, Cell Signaling), ERRα 
(P 1:1000, S 1:2000), TFAM (P 1:375 in 1% milk, S 1:1000 in 0% milk), Cytochrome C 
(P 1:1000, S 1:2000), SDHA (P 1:500, S 1:2000), VDAC (P 1:300, S 1:2000). 
Statistics 
All data were assessed using one-way ANOVA with a Newman-Keuls post-hoc test 
to assess significance of p<0.05.  Unless otherwise noted, data are shown as mean ± SEM.   
Results 
 To determine the extent to which quercetin decreased dystrophic injury mdx mice 
were treated with a 0.2% quercetin enriched diet or maintained on a control diet from 2-14 
months of age.  We have previously reported detailed food consumption and growth data 
[25].  In brief, animal growth was largely similar between groups though the mdxQ group 
was statistically smaller than the mdx group at the conclusion of the investigation (C57 – 
44.07 ± 2.13 g, mdx – 56.57 ± 2.30 g, mdxQ – 38.07 ± 2.35 g).  In the soleus, dystrophin-
deficiency caused a 40% increase in absolute muscle mass regardless of treatment (Table 
1).  Relative muscle mass was nearly doubled in mdx compared to C57 and mdxQ was 
11% greater (p<0.05) than mdx (Table 1).  In the EDL, absolute mass was 30 and 13% 
greater in mdx compared to C57 and mdxQ, respectively, and mdxQ was 20% greater than 
C57 (Table 1).  Relative EDL mass in dystrophic mice was increased by 60% compared to 
C57 (Table 1).    
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In vitro function 
Tetanic force was similar between groups in the soleus.  Specific tension, however, 
was decreased by 40% in mdx compared to C57.  Importantly, dietary quercetin enrichment 
attenuated approximately 50% of this loss (Fig 1).  Following a fatigue protocol, the 
percent of initial force produced by the mdx soleus was decreased by 50% compared to 
C57.  The addition of quercetin appeared to attenuate this loss but this numerical difference 
was not statistically significant from the other treatments (Fig 1C).       
Consistent with the soleus muscle, tetanic tension in the EDL was similar between 
groups (Table 1).  Specific tension was decreased by 36% in mdx and mdxQ groups 
compared to C57 (Figure 1B).   In addition, dietary quercetin failed to provide protection 
from eccentric injury in the EDL as the percent decline was similar in mdx and mdxQ and 
considerably less than C57 for each contraction (Fig 1E).   
Animal activity was assessed by counts of sedentary and active behaviors during 
15 second sampling windows averaged over two 10 minute observation periods.  For the 
sitting/standing metrics, mdx mice were 35% more stationary than C57 and mdxQ was less 
stationary than both C57 and mdx mice by 65% and 74%, respectively (Fig 2A).  Total 
activity followed a similar pattern such that mdx were 47% less active than C57 whereas 
mdxQ were 2-fold more active than C57 (Fig 2B). 
Histopathology  
Given that improved specific tension and fatigue resistance in the soleus provided 
some limited optimism for a successful intervention histological and biochemical studies 
were pursued.  The quantity of extracellular nuclei was increased by 4-fold and the percent 
of cells with a centralized nucleus was increased by 15-fold in dystrophic muscle compared 
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to healthy muscle and both measures were resistant to quercetin (Fig 3A-F).  Consistent 
with disease-related injury the total contractile area was decreased 20% in mdx and mdxQ 
mice compared to C57 due to an accumulation of non-contractile material in the whole 
muscle cross-section (Fig 3G).    Fibrotic tissue in the soleus of mdx mice measured via 
trichrome staining was 3.6-fold higher while mdxQ mice were 4-fold higher than C57.  In 
addition, trichrome staining revealed that fibrosis in mdxQ increased by 12.5% compared 
to mdx (Fig 4A-D).  To verify these changes we also assessed relative fibronectin 
abundance using an immunohistochemical approach.  We found that fibronectin was 9.0-
fold higher in both mdx and mdxQ compared to C57 and importantly, that mdx and mdxQ 
were similar between groups (Fig 5A-D). 
Lastly, we also measured fiber area distribution (Fig 6A-D).  We found that at 14 
months of age mean fiber area was similar between groups, however, the variance 
coefficient was 40% higher in dystrophic muscle compared to healthy muscle (Fig 6E-F).  
Further, we found that dystrophic muscle had a greater frequency of smaller diameter fibers 
and a smaller frequency of larger diameter fibers compared to healthy muscle (Fig 6G).  
While dystrophic muscle tended to have a greater frequency of very large fibers (>3000 
µm) this observation was not statistically significant from C57 (Fig 6D). 
Biochemistry   
We also assessed the impact of dystrophin deficiency on alterations in transcript 
expression and the degree to which these were corrected by dietary quercetin enrichment 
(Table 2).  Our findings largely suggest that following 12 months of quercetin treatment 
transcript expression was similar between mdx and mdxQ, however, numerous 
differences between dystrophic and healthy muscle were noted.  Specifically, metabolic 
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transcripts were significantly decreased in mdx mice compared to C57 as were transcripts 
related to mitochondrial biogenesis, redox balance, and cellular stability. 
Lastly, we evaluated the pathway driven by quercetin (Fig 7).  SIRT1 promotes 
PGC-1α pathway activity [31-33], thus protein abundance of SIRT1 was measured and was 
20% higher in dystrophic muscle regardless of treatment compared to healthy muscle. In 
contrast, SIRT1 activity was lower in dystrophic muscle as histone 3 lysine 9 acetylation 
(H3K9ac) was 80% higher in dystrophic muscle compared to control.  Due to the 
deacetylase activity of active SIRT1 increased H3K9ac is indicative of decreased SIRT1 
activity.  Downstream pathway components and end products of the PGC-1α pathway were 
similar between all groups.  Due to the potential function of quercetin as an AMPK 
activator [32, 34, 35], pAMPK T172 was measured to assess AMPK activity.  We found 
that AMPK activity was lower by more than 40% in dystrophic muscle compared to 
control, and independent of feeding treatment.  
Discussion 
Duchenne muscular dystrophy is a muscle wasting disease that leads to progressive 
deterioration of muscle function and muscle health.  Muscle atrophy and increased muscle 
injury negatively impact motor function and eventually lead to death from cardiac or 
respiratory failure.  Protection of muscle from secondary effects of dystrophin deficiency 
such as inflammation, metabolic dysfunction and free radical injury while simultaneously 
driving utrophin expression and mitochondrial biogenesis may slow disease progression 
and prolong muscle function.  Up regulation of PGC-1α in dystrophic muscle is well 
recognized to maintain muscle function, decrease histological damage and increase 
utrophin protein abundance and localization [14-18]. Currently needed is a pragmatic 
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strategy to translate this mechanistic understanding into clinical practice.  As such, 
quercetin is a promising therapeutic supplement that exhibits both antioxidant and anti-
inflammatory properties and also drives mitochondrial biogenesis and utrophin 
upregulation through PGC-1α activation.  Supporting a rationale for clinical applicability, 
quercetin is commonly sold as an over-the-counter supplement and is readily available to 
the DMD community.  Experimental evidence to support this postulate is derived from an 
initial investigation where we found that a 6 month dietary intervention with quercetin 
decreased histological injury in the dystrophic diaphragm [23] and heart [24].  In a 
subsequent 12-month study the beneficial effects following six months of treatment were 
recapitulated [25].  These effects appeared to be transient, however, in that control 
diaphragms from dystrophic mice were functionally, histologically, and biochemically 
indistinguishable from quercetin-treated diaphragms by the end of the study period.  We 
hypothesized that advanced disease progression in the diaphragm may limit the therapeutic 
potential of quercetin and that the milder phenotype found in dystrophic limb muscles 
would be a more amenable intracellular environment to support the therapeutic effects of 
quercetin.  
 Similar to our previous findings in diaphragms [25] from the same animals used 
herein, most outcomes examined at the end of the treatment period were not responsive to 
the quercetin intervention.  Of note, dietary quercetin consumption was associated with 
prevention of approximately 50% of the disease-related losses in specific tension and 
fatigue resistance in the soleus.  Improved specific tension in the soleus is surprising 
considering histological parameters were not improved by dietary quercetin enrichment.  
Hence, muscle function was improved in quercetin-treated mdx mice compared to control 
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mice despite similar degrees of muscle damage/unit cross sectional area.  We encourage 
future studies intended to improve clarity regarding the broad therapeutic effects of this 
strategy.   
While these functional benefits are cause for limited enthusiasm our biochemical 
and histological findings require caution.  On the whole, transcript expression was similar 
between treated and untreated mdx mice and cellular functions probed in this investigation 
were largely suppressed compared to C57.  Published studies indicate that quercetin drives 
the PGC-1α pathway through the deacetylase activity of SIRT1 [32, 36, 37] such that 
SIRT1 deacetylates PGC-1α and ultimately leads to mitochondrial biogenesis, increased 
utrophin abundance, a shift toward more oxidative fiber types, and decreased disease 
severity [14-18].  We previously noted quercetin insensitivity in diaphragm tissues marked 
by increased SIRT1 protein abundance coupled with impaired SIRT1 function [25].  In this 
investigation a similar mechanism is apparent despite continued quercetin 
supplementation.  We proposed previously that decreased ATP content found in dystrophic 
muscle may be part of that mechanism by limiting the potential of quercetin to increase 
SIRT1 activity via a blunted ATP/cAMP/pSIRT1 pathway.  Alternatively, we speculate 
that the lower abundance of NAD+ in dystrophic muscle [38], a cofactor of SIRT1 
activation [39], may also limit the capacity of quercetin to drive SIRT1 activity.  
Intriguingly, in a short-term investigation, supplementation with nicotinamide riboside to 
augment the muscle NAD+ pool was sufficient to increase regeneration following 
cardiotoxin injection in dystrophic muscle [40].  Hence, we propose that the combination 
of quercetin, to increase SIRT1 activity, and nicotinamide riboside, to increase muscle 
NAD+ content in order to sustain increased SIRT1 activity, may provide long term 
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therapeutic relief and greater impact than either approach applied independently and may 
overcome limitations in SIRT1 activation caused by age and/or disease severity.   
Given the largely unremarkable histological and biochemical findings in this 
investigation, one of the most notable findings in the current study was the quercetin-
mediated elevations in spontaneous activity in caged mice.  It is unclear if quercetin directly 
impacts behavior such that it serves to stimulate activity via mechanisms beyond the scope 
of this investigation [41] or below our detection threshold, or if quercetin supports 
improved function such that it permits increased spontaneous activity.  Nevertheless, that 
there was increased spontaneous physical activity provides an alternative interpretation of 
data contained herein.  Increased physical activity may hasten the decline of dystrophic 
muscle [42-44]; hence, improved specific tension in the face of increased activity supports 
the potential therapeutic role of quercetin.  This effect seems particularly profound in the 
diaphragm as increased spontaneous physical activity led to significantly impaired 
diaphragmatic function in animals of similar age [11].  Hence, that respiratory and 
diaphragmatic function and histopathology were not further impaired compared to 
untreated mdx mice in our previous investigation [25] may also be suggestive of a 
therapeutic success.  These histopathological results were largely recapitulated in limb 
muscle in this investigation, aside from the potential of increased fibrosis detected via 
trichrome staining but not fibronectin immunohistochemistry.  Given this integrated 
understanding from an established model of DMD, the current findings may be all the more 
important in the eventual translation of findings to clinical populations.  
 Comprehensive reports comparing dystrophic and healthy muscle from old 
animals, as performed currently, are rarely reported in the existing literature [45].  Absolute 
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and relative muscle mass was increased in dystrophic muscle compared to age-matched 
C57 mice suggestive of pseudohypertrophy.  Further, tetanic force was similar between 
groups but specific tension was greatly impaired in both the soleus and EDL at the end of 
the treatment periods indicating a compromised muscle quality in mdx mice.  Consistent 
with previous .reports, in dystrophic mice the soleus had compromised resistance to fatigue 
[43] and the EDL was more susceptible to contraction-induced injury compared to control 
[2].  Histologically, the dystrophic soleus had damage consistent with dystrophinopathy 
including increased centralized nuclei, necrotic area, immune cell infiltration, and fibrosis 
[46, 47].  Fiber area distribution was also consistent with dystrophin deficiency with a large 
proportion of small diameter fibers and much higher variability in fiber size resulting in 
similar mean fiber area compared to control [48]. Our biochemical evaluation found 
decreased transcript expression related to mitochondrial biogenesis, mitochondrial content, 
resistance to oxidative stress, and cellular stability.   
In total, the results of this investigation are in agreement with our previous report 
of age-dependent quercetin insensitivity leading to underwhelming therapeutic effects by 
the conclusion of the study period.  Specifically, quercetin insensitivity is made clear by a 
failure to increase SIRT1 activity and may be due to decreased ATP and/or NAD+ content 
in dystrophic muscle.  Future investigations should combine quercetin with an agent to 
increase the NAD+ pool in order to maximize therapeutic benefits.   Furthermore, this study 
underscores the importance of long-term investigations as therapeutics applied to the DMD 
community would be expected to be employed for years.  Only after 8 months of treatment 
was the transient therapeutic nature of quercetin apparent in respiratory function [25].  
Given the histological and biochemical data from the soleus improved function will likely 
  
81 
be lost with advancing age.  Data interpretation is complicated by our finding of increased 
spontaneous activity in quercetin-treated mice without widespread activity-induced tissue 
damage in the limb muscles.  This latter finding highlights a novel experimental facet of 
this investigation and may hold implications for clinical translation.  
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Figures and Tables 
Table 1.  Soleus and EDL muscle weights and function.  Rel – relative * indicates 
significantly different from C57; # indicates significantly different from mdx. C57 (n=6-7) 
mdx (n=6) mdxQ (n=5-6). 
 Soleus EDL 
 C57 mdx mdxQ C57 Mdx mdxQ 
Mass (mg)  11.39       
± 0.17 
17.61      
± 0.54* 
15.96      
± 1.08* 
12.73      
± 0.31 
18.65      
± 0.67* 
16.30      
± 0.76*# 
Rel Mass 
(mg/g) 
0.25         
± 0.01 
0.45        
± 0.01* 
0.49        
± 0.02*# 
0.28        
± 0.01 
0.47        
± 0.01* 
0.47        
± 0.03* 
Tetanic Force 
(mN) 
224.7      
± 8.1 
209.6      
± 21.5 
252.9      
± 8.8 
506.8      
± 13.7 
461.1      
± 33.4 
451.2      
± 13.0 
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Figure 1.  Soleus and EDL muscle function at 14 months of age.  A) Specific tension 
measured in the soleus and B) in the EDL.  C) The soleus was then subjected to a fatigue 
test where it was stimulated once per second for 10 minutes.  Force was normalized to force 
produced in the first contraction.  D) The relative force produced in the final contraction is 
shown.  Relative force produced in the final contraction was significantly less in mdx than 
C57.  E) The EDL was subjected to a series of five eccentric contractions and peak force 
normalized to peak force generated in the first contraction.  * indicates significantly 
different from C57; # indicates significantly different from mdx. C57 (n=7) mdx (n=6) 
mdxQ (n=6).    
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Figure 2.  Animal activity was increased by dietary quercetin enrichment.  At the 
conclusion of the investigation animal behavior was quantified using an ethological 
approach where a 10 minute observation period was divided into 15 second blocks.  A) 
The number of time blocks spent sitting or exhibiting sedentary behavior was quantified.  
B) We also quantified the number of active behaviors.  * indicates significantly different 
from C57; # indicates significantly different from mdx. C57 (n=7) mdx (n=7) mdxQ (n=6).  
 
  
88 
 
Figure 3.  Dystrophin deficiency causes histological injury that is not corrected by 
quercetin.  A-C) Representative images from H&E-stained, reconstructed soleus muscle 
cross sections.  D) Extra cellular nuclei, E) centralized nuclei, and F) total contractile area 
were calculated.  * indicates significantly different from C57.  Width of black bar 
represents 250 microns.  C57 (n=7) mdx (n=6) mdxQ (n=6). 
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Figure 4.  Dystrophin deficiency increased muscle fibrosis.  A-C) Representative 
images from trichrome-stained, reconstructed soleus cross sections.  D) Total fibrotic area 
was calculated by quantifying the blue staining material in the entire muscle cross section.  
* indicates significantly different from C57.  Width of black bar represents 250 microns.  
C57 (n=7) mdx (n=6) mdxQ (n=6). 
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Figure 5.  Dystrophin deficiency increased fibronectin in soleus muscles compared to 
healthy muscles.  A-C) Representative 10x immunohistochemical images for fibronectin 
(red) and DAPI (blue).  All images have been uniformly brightened to make the fibronectin 
signal easier to see.  D) The percent positive pixels were quantified.  * indicates 
significantly different from C57. Width of white bar represents 100 microns.  C57 (n=7) 
mdx (n=6) mdxQ (n=6).  
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Figure 6.  Fiber area distribution is altered by dystrophin deficiency in soleus muscle.  
A-C) Representative 10x images from an immunohistological experiment where laminin 
(red) was detected.  DAPI is shown in blue.  D) Fiber area distribution was measured and 
quantified in bins.  E) Mean fiber area and F) the variance coefficient were calculated.  G) 
We also determined the percent of fibers greater than the mean cross-sectional area as 
another indicator of fiber area variability.  * indicates significantly different from C57. 
Width of white bar represents 100 microns.  C57 (n=7) mdx (n=6) mdxQ (n=6).       
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Table 2.  Transcript expression in the soleus.  Data are shown as fold change relative 
to C57.  * indicates significantly different from C57; # indicates significantly different 
from mdx.  C57 (n=7) mdx (n=6) mdxQ (n=6). 
  
C57 Mdx mdxQ 
Average ± SEM Average ± SEM Average ± SEM 
Mitochondrial Biogenesis (PGC-1α Pathway Genes) 
Sirt1 1.00 ± 0.25   2.02 ± 0.45  1.94 ± 0.54 
Ppargc1a (Pgc-1α) 1.00 ± 0.11 -1.67 ± 0.09* -1.72 ± 0.09* 
Esrra (Errα) 1.00 ± 0.18 -3.47 ± 0.11* -2.65 ± 0.06* 
Nrf1 1.00 ± 0.23 -1.93. ± 0.11 -1.24 ± 0.28 
Nrip1 1.00 ± 0.18 -1.45 ± 0.20 -1.46 ± 0.21 
Tfam 1.00 ± 0.48 -1.34 ± 0.16 -2.07 ± 0.11 
Metabolic Genes 
Fnip1 1.00 ± 0.25 -1.84 ± 0.06 -2.08 ± 0.04 
Mtor 1.00 ± 0.27 -2.48 ± 0.12* -2.57 ± 0.10* 
Prkaa1 1.00 ± 0.16 -1.05 ± 0.14 -1.72 ± 0.12 
Gapdh 1.00 ± 0.20 -3.48 ± 0.04* -2.97 ± 0.04* 
Pfkm 1.00 ± 0.16 -2.38 ± 0.04* -2.38 ± 0.06* 
Pparg 1.00 ± 0.19 -1.32 ± 0.27 -1.18 ± 0.40 
Cs 1.00 ± 0.16 -3.64 ± 0.05* -3.60 ± 0.04* 
Mdh1 1.00 ± 0.15 -1.94 ± 0.07* -2.27 ± 0.08* 
Atp1a2 1.00 ± 0.07 -1.76 ± 0.10* -2.09 ± 0.06* 
Cybb 1.00 ± 0.30 -1.35 ± 0.03  2.77 ± 1.35 
Cycs 1.00 ± 0.27  1.11 ± 0.29 -2.45 ± 0.11 
Mb 1.00 ± 0.17 -4.35 ± 0.03* -4.61 ± 0.04* 
Mt-atp6 1.00 ± 0.07 -2.14 ± 0.05* -2.38 ± 0.06* 
Mt-co1 1.00 ± 0.17 -2.78 ± 0.04* -3.18 ± 0.05* 
Mt-co2 1.00 ± 0.14 -2.15 ± 0.07* -2.50 ± 0.06* 
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C57 Mdx mdxQ 
Average ± SEM Average ± SEM Average ± SEM 
Mt-cyb 1.00 ± 0.09 -2.35 ± 0.04* -2.59 ± 0.06* 
Mt-nd1 1.00 ± 0.06 -2.32 ± 0.04* -2.66 ± 0.06* 
Mt-nd4 1.00 ± 0.21 -2.32 ± 0.05* -2.85 ± 0.06* 
Uqcrc1 1.00 ± 0.17 -2.01 ± 0.09* -2.59 ± 0.05* 
Tfb1m 1.00 ± 0.66 -1.49 ± 0.26 -2.95 ± 0.06 
Tfb2m 1.00 ± 0.13 -2.50 ± 0.09* -1.70 ± 0.16 
Ucp3 1.00 ± 0.21 -3.50 ± 0.11* -4.50 ± 0.04* 
Ak1 1.00 ± 0.35 -2.68 ± 0.12 -2.18 ± 0.27 
Akt1 1.00 ± 0.56 -4.43 ± 0.07 -2.97 ± 0.11 
Ckm 1.00 ± 0.15 -1.87 ± 0.08 -1.92 ± 0.10 
Inflammation/antioxidant Genes 
Nfκb1 1.00 ± 0.24 -1.35 ± 0.31 -1.10 ± 0.40 
Il1b 1.00 ± 0.28 -1.23 ± 0.21 -2.55 ± 0.02 
Tlr4 1.00 ± 0.61 -2.18 ± 0.19 -3.56 ± 0.06 
Traf2 1.00 ± 0.16 -1.02 ± 0.40  1.23 ± 0.32 
Cat 1.00 ± 0.51 -5.53 ± 0.03* -4.96 ± 0.06* 
Gpx1 1.00 ± 0.47 -2.27 ± 0.17 -3.64 ± 0.07 
Gpx4 1.00 ± 0.31 -2.29 ± 0.09* -2.69 ± 0.05* 
Gsr 1.00 ± 0.29  2.02 ± 0.93 -1.25 ± 0.17 
Nfe2l2 1.00 ± 0.15 -1.98 ± 0.13* -2.11 ± 0.13* 
Prdx2 1.00 ± 0.25 -2.96 ± 0.06* -4.00 ± 0.04* 
Sod1 1.00 ± 0.40 -2.36 ± 0.10 -3.37 ± 0.05* 
Sod2 1.00 ± 0.25 -2.64 ± 0.05* -2.88 ± 0.06* 
Apoptosis Genes 
Apaf1 1.00 ± 0.27 -1.03 ± 0.07  1.68 ± 0.68 
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C57 Mdx mdxQ 
Average ± SEM Average ± SEM Average ± SEM 
Bax 1.00 ± 0.37  1.12 ± 0.22  1.16 ± 0.28 
Bcl2 1.00 ± 0.13 -1.59 ± 0.18 -1.63 ± 0.22 
Bnip2 1.00 ± 0.17 -2.45 ± 0.08* -1.29 ± 0.12*# 
Casp3 1.00 ± 0.44 -1.29 ± 0.33 -2.10 ± 0.18 
Trp53 1.00 ± 0.33 -2.97 ± 0.14 -1.19 ± 0.47 
Xiap 1.00 ± 0.27 -2.05 ± 0.12 -1.92 ± 0.12 
Muscle Repair and Protein Turnover Genes 
Fbl 1.00 ± 0.35 -1.48 ± 0.21 -1.15 ± 0.26 
Gata2 1.00 ± 0.60 -2.16 ± 0.19 -3.78 ± 0.12 
Hspa1a 1.00 ± 0.87 -1.88 ± 0.03 -2.47 ± 0.02 
Hspa5 1.00 ± 0.36 -2.60 ± 0.07* -1.97 ± 0.11 
Hspb1 1.00 ± 0.21 -1.33 ± 0.18 -1.99 ± 0.11* 
Mef2c 1.00 ± 0.17 -1.96 ± 0.09* -2.68 ± 0.03* 
Mstn 1.00 ± 0.26 -1.35 ± 0.19 -1.20 ± 0.21 
Myf5 1.00 ± 0.38 -3.32 ± 0.08 -1.39 ± 0.38 
Myocd 1.00 ± 0.26 -1.77 ± 0.33 -1.13 ± 0.71 
Myod1 1.00 ± 0.67 -1.33 ± 0.53 -2.48 ± 0.15 
Myof 1.00 ± 0.58 -2.06 ± 0.19 -2.39 ± 0.15 
Myog 1.00 ± 0.59 -2.24 ± 0.17 -4.87 ± 0.07 
Poldip2 1.00 ± 0.16 -1.24 ± 0.17 -2.11 ± 0.03* 
Tgfb1 1.00 ± 0.10  1.45 ± 0.47  2.10 ± 1.00 
Structural and Sarcomeric Genes 
Dag1 1.00 ± 0.10 -1.53 ± 0.13* -2.27 ± 0.07* 
Dtna 1.00 ± 0.16 -1.43 ± 0.08 -1.40 ± 0.12 
Dysf 1.00 ± 0.16 -1.40 ± 0.15 -1.58 ± 0.10 
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C57 Mdx mdxQ 
Average ± SEM Average ± SEM Average ± SEM 
Myh1 1.00 ± 0.39 -1.22 ± 0.15 -1.78 ± 0.05 
Myh2 1.00 ± 0.17 -3.24 ± 0.04* -3.29 ± 0.06* 
Myh7 1.00 ± 0.17 -2.56 ± 0.05* -2.92 ± 0.09* 
Sgca 1.00 ± 0.17 -2.74 ± 0.05* -3.49 ± 0.06* 
Utrn 3’ 1.00 ± 0.24 -1.15 ± 0.15 -1.32 ± 0.22 
Utrn 5’ 1.00 ± 0.15 -1.54 ± 0.14 -1.17 ± 0.32 
Fig 7.  Relative protein abundance was altered by dystrophin deficiency.  A) Protein 
abundance of PGC-1α pathway components was largely depressed by dystrophin 
deficiency independent of intervention compared to muscle from C57 mice.  B) 
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Representative blots were included and Ponceau S stain was included to demonstrate equal 
loading.  * indicates significantly different from C57. C57 (n=5) mdx (n=6) mdxQ (n=5).   
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Abstract 
Progressive muscle injury and weakness are hallmarks of Duchenne muscular 
dystrophy, which is caused by the absence of functional dystrophin protein. We showed 
previously that quercetin (Q) partially protected dystrophic limb muscles from disease-
related injury. As quercetin activates PGC-1α through Sirtuin 1, an NAD+-dependent 
deacetylase, the depleted NAD+ in dystrophic skeletal muscle may limit quercetin 
efficacy, hence, supplementation with the NAD+ donor, nicotinamide riboside (NR), may 
facilitate quercetin efficacy. Lisinopril (Lis) also protects skeletal muscle and improves 
cardiac function in dystrophin deficient mice, therefore it was included in this study to 
evaluate the effects of lisinopril with quercetin and NR.  Our purpose was to determine 
the extent to which Q, NR, and Lis alone and in combination decreased dystrophic injury. 
We hypothesized that Q, NR or Lis alone would improve muscle function and decrease 
histological injury and when used in combination would have additive or synergistic 
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effects. To address this hypothesis muscle function of 11-month-old DBA (healthy), D2-
mdx (dystrophin-deficient), and D2-mdx mice following treatment with Q, NR, or Lis 
independently or in combination for 7 months was assessed. To mimic typical 
pharmacology of DMD patients an additional group was treated with prednisolone (Pred) 
in combination with Q, NR and Lis. At 11 months of age, dystrophin deficiency 
decreased specific tension and tetanic force in both the soleus and extensor digitorum 
longus muscles and was not corrected by any treatment.  Dystrophic muscle was more 
sensitive to contraction induced injury, which was partially offset in the QNRLisPred 
group, while fatigue was similar between all groups. Histological damaged was increased 
in D2-mdx mice compared to DBA and not improved with treatments. These data suggest 
that treatment with Q, NR, Lis and Pred in combination failed to adequately maintain 
dystrophic limb muscle function or decrease histological damage. 
Keywords: DMD, prednisolone, glucocorticoid, ACE inhibitor, quercetin  
New and Noteworthy 
Despite a compelling rationale and previous evidence to the contrary in short-term 
investigations, quercetin, nicotinamide riboside, or Lisinopril, alone or in combination, 
failed to restore muscle function or decrease histological injury in dystrophic limb muscle 
from D2-mdx mice following long-term administration.  Importantly, we also found that 
in the D2-mdx model, an emerging and relatively understudied model of DMD, 
dystrophin deficiency caused profound muscle dysfunction and histopathology in skeletal 
muscle.   
  
99 
Introduction 
 Duchenne muscular dystrophy (DMD) is a progressive muscle wasting disease 
caused by a mutation in the dystrophin gene resulting in dystrophin protein deficiency. 
By the age of twelve children with DMD are usually wheelchair bound and will typically 
succumb to the disease in their 3rd decade of life due to respiratory or cardiac failure (12). 
In addition to muscle fragility, dystrophin deficiency results in a host of cellular 
dysfunctions including, but not limited to, impaired autophagy, calcium mishandling, 
oxidative stress, and mitochondrial dysfunction (4, 19, 28). Collectively, this structural 
injury and cellular dysfunction results in histopathologic changes including immune cell 
infiltration, fibrosis, increased necrotic area, increased fatty infiltration, and a reduction 
in contractile tissue (5, 16). 
Transgenic or vector-mediated overexpression of PGC-1a reduced histological 
damage and preserved muscle function in dystrophic skeletal muscle (8, 15, 16, 26). We 
have pursued the capacity of quercetin, a natural flavonoid with anti-oxidant and anti-
inflammatory properties (1, 6, 10), to attenuate disease severity as it drives PGC-1a 
activity through Sirtuin 1 (SIRT1), an NAD+-dependent deacetylase (11, 21).  We 
discovered previously that six months of oral quercetin delivery decreased 
histopathological injury in dystrophic diaphragms and hearts of mdx mice (3, 17), 
however, long-term administration of quercetin transiently maintained respiratory 
function and modestly protected limb muscles, while in corresponding hearts indices of 
inflammation were reduced and markers of mitochondrial biogenesis were increased (2, 
25, 27). 
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As quercetin relies on SIRT1 activity to drive signaling, we proposed that limited 
NAD+ in dystrophic muscle (7) may hinder the efficacy of quercetin (27) and that 
supplementation with nicotinamide riboside (NR), an NAD+ precursor, would maintain 
quercetin-mediated elevations in SIRT1 activity, PGC-1α activity, and muscle function.  
Indeed, it was recently demonstrated that muscle function was improved following 12 
weeks of NR supplementation (24). Independent of quercetin, early intervention with 
angiotensin-converting enzyme (ACE) inhibitor, Lisinopril (Lis), improved histological 
injury (20) and in combination with aldosterone receptor antagonist, spironolactone, 
improved function and reduced histological damage of dystrophic cardiac and skeletal 
muscle (18, 22). The goal of this investigation was to determine the extent to which NR 
and/or Lis would augment therapeutic effects of quercetin on disease severity in 
dystrophic limb muscles.  We hypothesized that the oral administration of quercetin in 
combination with NR and/or Lis would improve muscle function and decrease 
histological injury in dystrophic muscle compared to untreated dystrophic muscle.  We 
utilized an emerging model of DMD, the D2-mdx mouse (D2.B10-Dmdmdx/J), which was 
produced by crossing the traditional BL10-mdx mouse onto the DBA background such 
that dystrophin deficiency is caused by the identical nonsense mutation in exon 23 of the 
dystrophin gene. The DBA background has 12-amino acid deletion in the latent TGF-b-
binding protein gene 4 (Ltbp4), a gene which when mutated may accelerate loss of 
ambulation in DMD patients (9, 13). Additionally, the DBA background has a mutation 
to the Anxa6 gene leading to the truncation of annexin A6 protein, which is involved in 
satellite cell self-renewal and membrane repair (29). This DBA background provides a 
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more severe phenotype resulting in increased fibrosis, increased muscle damage, and 
decreased regenerative capacity in the D2-mdx mouse (9, 14, 23). 
Methods 
Animal Treatments. All animal procedures were approved by the Institutional 
Animal Care and Use Committees at University of Montana (047-16JQHHP-072616) and 
the University of Florida (201508822). Ten male DBA2/J (DBA; control) mice and 80 
male D2.B10-Dmdmdx/J (D2-mdx; dystrophin deficient) mice were obtained from 
Jackson Laboratory (Bar Harbor, ME).  Following an acclimation period of at least one 
week, 4 month old mice were assigned to nine groups (n=10/group): DBA, untreated D2-
mdx, and D2-mdx treated with quercetin (Q, 0.2% by diet, 275 mg/kg/d), nicotinamide 
riboside (NR, 0.04% by diet, 55 mg/kg/d ), Q and NR (QNR), Lisinopril (Lis, 33 mg/L in 
water, 9.15 ng/kg/d), Q and Lis (QLis), QNRLis, or  QNRLis + prednisolone 
(QNRLisPred, 10 mg/L by water, 2.77 mg/kg/d). The QNRLisPred group was included to 
test the most complete cocktail (QNRLis) in the context of common pharmacology used 
to treated DMD patients.  Treatments were initiated at 4 months of age to demonstrate the 
efficacy of these treatments using a rescue paradigm, which more closely replicates the 
onset of treatment for DMD patients. All animals were given access to food and water ad 
libitum regardless of treatment. Caregivers and technicians were blinded to animal 
treatment and treatment groups were assigned numbers to ensure blinded conditions 
throughout data collection. Following 7 months of treatment soleus and extensor 
digitorum longus (EDL) were collected.   
Muscle function.  In vitro muscle function was assessed in the soleus and EDL at 
the University of Florida Myology Institute Physiological Assessment Core as previously 
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described (27, 30). Briefly, soleus and EDL muscles were removed following surgical 
sedation with ketamine and xylazine and placed in a bath of oxygenated Ringers solution 
(120mM NaCl, 4.7mM KCl, 2.5mM CaCl2, 1.2mM KH2PO4, 1.2mM MgSO4, 25mM 
HEPES and 5.5mM Glucose). Isometric tetanic force was measured at 120 Hz and 100 
Hz for EDL and soleus, respectively. To determine fatigue resistance, the soleus was 
stimulated with 1 contraction/sec at 100Hz for 330 msec with 200 µsec pulses for 10 min. 
Fatigue resistance was reported as percentage of remaining initial force. Finally, to assess 
resistance to contraction-induced injury, five lengthening contractions of 500 msec 
duration at 80 Hz followed by a final 10% stretch beyond Lo for 200 msec were applied 
to EDL muscles.  Resistance to contraction-induce injury was reported as percent of 
initial force production.   
Histology.  Muscle damage and fibrotic area were assessed using hematoxylin & 
eosin (H&E) and Masson’s Trichrome (KTMTRPT, American MasterTech, Lodi, CA) 
staining as previously described (25, 27). Soleus and EDL muscles were coated in OCT 
and frozen for histology in liquid nitrogen-chilled isopentane. Briefly, 10 μm sections 
were stained with H&E or Masson’s Trichrome, and imaged at 10x and 40x 
magnification by a blinded, trained technician on an inverted Lecia DMI3000 B 
microscope and QICAM MicroPublisher 5.0 (MP5.0-RTV-CLR-10, QIMAGING) 
camera with QCapture software (Surrey, BC, Canada). Contractile area was quantified 
using the H&E images by alternatively density slicing for the hypercontracted cells and 
necrotic areas, then subtracting that sum from the total area using Open Lab Software 
(Improvision).  The density slice function uses prescribed pixel parameters to select the 
dark red hypercontracted cells and the light pink necrotic areas. Similarly, fibrotic area 
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was quantified by using the density slice function of the Open Lab Software to quantify 
the blue area of the trichrome images, which was divided by the total area to identify the 
percent of the total area that was fibrotic.  
Fiber area distribution was assessed using immunohistochemistry (IHC).  Sections 
were incubated with anti-laminin (anti-rabbit, ThermoScientific, RB-082-A) using our 
standard IHC protocol as previously described (28). Briefly, after washing (phosphate 
buffered saline (PBS)) and blocking (5% goat serum, 5% bovine serum albumin, 1% 
DMSO in 2X PBS) slides were incubated in primary antibody (laminin, 1:100 in blocking 
solution) overnight at 4°C, then washed and incubated in secondary antibody (anti-rabbit 
AlexaFluor 488, 1:500, Cell Signaling 4412S) for 1 h at room temperature. Slide covers 
were mounted with SlowFade™ Gold Antifade Mountant with DAPI (S36938, 
ThermoFisher) and sealed with nail polish.  Slides were imaged at 10x magnification on 
the same inverted microscope.  For each sample, two independent images were taken and 
quantified (100-400 fibers/image). Fiber areas were objectively measured using OpenLab 
Software. 
Statistics.  To determine significant sources of variation in single time point 
measures, such as muscle masses, tetanic force, specific force, fiber area distribution, 
contractile area, and fibrotic area, one-way ANOVAs were performed using GraphPad 
Prism with a Newman-Keuls post hoc test. Data from soleus fatigue experiments were 
analyzed utilizing a repeated measure model in which a spatial power variance structure 
was used. EDL contraction induced injury data were analyzed using a repeated measures 
model that implemented an autoregressive variance structure. A mixed model method 
was used to determine significant sources of variation (Proc Mixed, SAS V9.0, SAS Inst. 
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Inc., Cary, NC) that included fixed effects for treatment, time, and treatment×time 
interaction with pre-treatment value (20 min baseline measurement at 4 months of age) as 
a linear covariate. When fixed effects were significant sources of variation, the PDIFF 
statement of SAS was used at the fixed effect level of LS means to separate pairwise 
differences. 
Results 
  Animal characteristics. Mouse body mass was decreased by 13-38% in untreated 
and treated D2-mdx mice compared to healthy (DBA) mice (p<0.05).  In addition, the 
QNRLisPred group was decreased 38% and 28% compared to DBA and D2-mdx 
(p<0.05), respectively, and was significantly decreased compared to the remaining 
treatment groups except Q and QNRLis.  Additionally, body mass of Q-treated mice 
decreased 17% compared to D2-mdx untreated (p<0.05). Soleus, extensor digitorum 
longus (EDL), gastrocnemii and tibialis anterior (TA) muscles were weighed.  EDL, 
gastrocnemius and TA masses were decreased 29-47%, 58-71% and 42-56%, 
respectively, in untreated and treated D2-mdx mice compared to muscles from DBA mice 
(p<0.05). Interestingly, the soleus was similar between all groups with the exception of 
D2-mdx mice treated with QNRLisPred, which was decreased approximately 13% 
compared to all groups (p<0.05).  Similarly, the EDL and gastrocnemius muscles from 
QNRLisPred were significantly decreased 18-29% compared to treated and untreated D2-
mdx (p<0.05). Lastly, EDLs from Q-treated D2-mdx mice were 7-11% greater than 
untreated D2-mdx and NR-treated D2-mdx (p<0.05). When tissues masses were 
normalized to body mass, gastrocnemius and TA masses were decreased by 45-53% and 
22-35%, respectively, in all D2-mdx groups compared to DBA (p<0.05). Similarly, D2-
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mdx EDL relative mass was decreased by 26% compared to DBA (p<0.05), and 
treatment with Q or QNRLis increased muscle mass by 23-29% compared to EDLs from 
untreated D2-mdx mice (p<0.05). Additionally, Q-treated D2-mdx EDL relative mass 
was increased 10-16% compared to NR, QNR, Lis and QLis (p<0.05),. Lastly, soleus 
relative mass was increased by 16-32% in treated and untreated D2-mdx mice compared 
to DBA (p<0.05) and were similar to each other.  
 In vitro muscle function. Muscle function was assessed in the soleus and EDL 
following 7 months of treatment (Figures 1 and 2).  Soleus tetanic force and specific 
tension were decreased by 25% in D2-mdx compared to DBA (p<0.05) with no effect of 
treatments (Figure 1A).  Following 10 sec of a fatigue protocol, force production was 
similar between groups, however, following 120 sec QNRLisPred produced 25% greater 
force than DBA (p<0.05) mice while DBA and D2-mdx were similar.  Additionally, 
QNRLisPred produced 32% more force than D2-mdx and DBA following 300 sec of 
fatigue protocol that was maintained through 600 sec of 1 contraction/sec fatigue protocol 
(p<0.05; Figure 1C).   
In the EDL, tetanic and specific tension were significantly decreased by 50% and 
20%, respectively, in D2-mdx groups compared to DBA (Figure 2A&B; p<0.05).  
Additionally, EDL tetanic tension was further decreased by 25% in QNRLisPred treated 
mice compared to remaining D2-mdx groups (p<0.05). Resistance to contraction-induced 
injury was assessed by measuring peak force during five eccentric contractions, in which 
the muscles were stretched 10% past Lo. Following contractions 3, 4 and 5, D2-mdx 
produced 18%, 27% and 36% less force compared to DBA (p<0.05), respectively.  
Following contraction 4, Q, NR, QNR and Lis produced 17-19% less force than DBA 
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(p<0.05).  Similarly, after contraction 5, Q, NR, Lis, QLis and QNRLis-treated groups 
produced 20-29% less for than DBA (p<0.05).  QNRLisPred-treated mice produced 32% 
more force during the 5th contraction than D2-mdx and was statistically similar to DBA, 
suggesting protection from contraction induced injury (Figure 2B).   
Histology. Given that muscle function was largely similar between untreated and 
treated D2-mdx mice, we performed histopathological examination on groups that 
showed therapeutic promise (numerical changes suggestive of therapeutic potential) 
(Figure 3). Hence, we assessed histological muscle damage in the DBA, D2-mdx, QLis, 
QNRLis, and QNRLisPred groups.  Soleus contractile area decreased from 95% in DBA 
mice to approximately 65-73% in D2-mdx, QNRLis, and QNRLisPred (p<0.05).   
Surprisingly, contractile area was only 41% in QLis. In the EDL, contractile area was 
decreased by 41-64% in D2-mdx groups compared to DBA mice (Figure 3; p<0.05).  
Treatment with QNRLis further decreased contractile area compared to QLis and 
QNRLisPred.  
Given the above findings, secondary analyses were performed on the soleus in 
order to gain further insights. Fibrotic area increased from less than 5% in DBA to 11-
18% in D2-mdx groups (p<0.05). Treatments did not significantly decrease fibrotic area 
compared to D2-mdx, but treatment with QNRLisPred significantly increased fibrotic 
area compared to QLis, (Figure 4; p<0.05).   
Distribution of fiber cross-sectional area was shifted toward an overabundance of 
smaller fibers and a corresponding underrepresentation of larger fibers in D2-mdx groups 
compared to DBA (Figure 5A).  The mean fiber area was similar between DBA, D2-mdx 
and QLis, but was decreased by 32% in QNRLis and QNRLisPred compared to DBA 
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(Figure 5B; p<0.05).  Median fiber cross-sectional area was decreased by 20-45% in all 
D2-mdx groups compared to DBA (Figure 5B; p<0.05).  Additionally, the variance 
coefficient was at least doubled in all D2-mdx groups compared to DBA and increased 
19% in QNRLis compared to D2-mdx and QLis (Figure 5B; p<0.05).    
Discussion 
 DMD is caused by a mutation in the dystrophin gene resulting in the absence of 
functional dystrophin protein and a complicated sequela due to DMD.  Researchers and 
clinicians continue to pursue a variety of strategies intended to counter these cellular 
dysfunctions and slow or prevent disease progression. While transformative therapies are 
currently in various phases of FDA approval to treat tomorrow’s patients, pragmatic 
solutions are urgently needed to treat today’s patients.  In this study, our purpose was to 
determine the extent to which treatment of D2-mdx mice with quercetin, nicotinamide 
riboside (NR), and/or Lisinopril (Lis) improved muscle function and decreased disease-
related muscle damage. Counter to our hypotheses, we failed to demonstrate that 
treatment with quercetin, NR, or Lisinopril independently or in combination 
meaningfully improved muscle function or decreased histopathological injury. Only a 
cocktail containing Pred (QNRLisPred) provided some protection to fatigue and 
contraction induced injury but did not decrease histological.   
Consistent with our earlier work using long-term quercetin treatment of mdx 
mice, a relatively less severe rodent model of DMD (27), application of quercetin over 7 
months to D2-mdx mice did not correspond to improved limb muscle function. 
Previously, we demonstrated that quercetin improved soleus specific force, but did not 
potentiate other parameters of muscle function. We then surmised that the transient 
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nature of quercetin-mediated protection (27) may be due to depleted NAD+ and 
successfully treated with NR (27). Early support for this rationale was established by 
prior observations that NAD+ depletion in mdx mice was corrected following 12 weeks 
of NR supplementation (24). This promising outcome was accompanied by an improved 
exercise capacity despite elevated energetic stress due to decreased mitochondrial 
oxidative phosphorylation rate and increased mitochondrial ATP production load (24). 
Despite dosing differences in this investigation, it is likely that the advanced disease 
progression in the present investigation (older mice, more severe model) and/or the long-
term use of NR limited its efficacy.  Given that 1) the D2-mdx model more accurately 
recapitulates injury in humans than the mdx mouse model and 2) long-term treatment 
should be expected with DMD patients, the applicability of NR to DMD seems tenuous 
based on the current findings.  
In the present investigation, Lisinopril did not improve measures of muscle 
function nor decrease histological damage. Similarly, short-term treatment with 
Lisinopril did not improve muscle function in an mdx/Utrn+/- model, though Lisinopril 
decreased histological injury (20).  When used in combination with spironolactone, an 
aldosterone receptor antagonist, Lisinopril increased EDL and diaphragm function and 
decreased histological injury in the quadriceps when treatment was started at 4 weeks but 
not at 8 weeks in mdx/Utrn+/- mice (22). Interestingly, in the mdx model, treatment with 
Lisinopril and spironolactone did not improve muscle function nor decrease histological 
damage (18). While differences in animal model, duration of study, dose (33 mg/L or 66 
mg/L) and use of drug in combination likely account for some differences between these 
investigations, collectively they provide underwhelming support for continued use of 
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Lisinopril, alone, as a skeletal muscle therapy for DMD.  Notably, the combination of 
Lisinopril and metoprolol (b-blocker) mitigate some aspects of disease severity in cardiac 
muscle in a clinical population (31).  
Within the context of preclinical murine experiments to date, DMD has been most 
commonly modeled by the C57BL/10-mdx (mdx) mouse. While this mouse model has 
been useful for studies related to disease mechanism, its mild phenotype may contribute 
to translational limitations of therapeutic findings to human populations. In this study we 
used an emerging model of DMD, the DBA/2J-mdx (D2-mdx) mouse, which has a 
relatively severe, progressive pathology and early-onset cardiac dysfunction (9). 
Consistent with our data from 48-week-old D2-mdx mice, EDL tetanic force and specific 
force were decreased at 7, 28 and 52 weeks (9). Moreover, similar to our current findings 
in soleus, increased fibrosis was previously reported in tibialis anterior, gastrocnemius, 
and quadriceps in 6- and 8-month-old D2-mdx mice compared to control (14). 
Interestingly, fat accumulation was significantly increased at 6 months in the 
gastrocnemius and at 6 and 8 months in the quadriceps (14), but in this investigation fatty 
infiltration was not visually apparent in the 11-month-old soleus or EDL. Ostensibly, 
increased fatty infiltration decreased contractile cross-sectional area is this prior work 
(14), and support functional observations in the current investigation. Moreover, as in this 
investigation, Coley et al. (9) discovered that the distribution of fiber area was shifted 
toward a greater frequency of small fibers. These data in combination with current 
findings, when paired with decreased muscle mass and findings from H&E and trichrome 
analyses, support a reduction in fiber size as well as functional cross section area of the 
whole muscle, which translate to dramatic reductions in muscle function. 
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In summary, and counter to our study hypotheses, quercetin, nicotinamide 
riboside, and Lisinopril (alone and in combination), were not associated with resistance to 
dystrophic disease progression in limb muscle. Treatment with QNRLisPred provided 
partial improvements in muscle function but did not mitigate other indices of disease 
progression. Collectively, these data indicate that quercetin and these quercetin-based 
cocktails have limited value in the treatment of dystrophin-deficient limb muscles and 
alternative approaches should be considered.   
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Figures and Tables 
Table 1. Animal and muscle masses. Body mass was decreased in dystrophic (D2-mdx) 
compared to healthy (DBA) mice, and treatment with QNRLisPred further decreased 
body mass.  Absolute muscle masses were reduced in dystrophic mice compared to 
healthy, except the soleus was similar between groups. Treatment with QNRLisPred 
further decreased absolute muscle masses. Similarly, relative muscle masses were 
decreased in dystrophic mice, regardless of tissue or treatment,  DBA (n=10), D2-mdx 
(n=8), Q (n=9), NR (n=8), QNR (n=8), Lis (n=7), QLis (n=10), QNRLis (n=8), and 
QNRLisPred (n=9).  Values are reported as mean ± SEM.
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 DBA D2-mdx Q NR QNR Lis QLis QNRLis QNRLisPred 
Body Mass (g) 39.53 ± 1.81 34.36 ± 1.13* 28.36 ± 1.25*# 29.63 ± 1.14*† 31.18 ± 1.49*† 32.28 ± 1.71*† 31.38 ± 0.76*† 28.92 ± 0.84* 24.57 ± 0.98*# 
Soleus (mg) 7.5 ± 0.2 7.6 ± 0.2 7.1 ± 0.3† 6.9 ± 0.3† 7.1 ± 0.2† 7.2 ± 0.2† 7.5 ± 0.2† 6.9 ± 0.2† 6.0 ± 0.2*# 
Rel Soleus (mg/g) 0.19 ± 0.01 0.22 ± 0.01* 0.25 ± 0.01* 0.24 ± 0.01* 0.23 ± 0.01* 0.23 ± 0.01* 0.24 ± 0.01* 0.24 ± 0.01* 0.25 ± 0.01* 
EDL (mg) 8.9 ± 0.1 5.9 ± 0.1* 6.3 ± 0.2*#† 5.7 ± 0.2*†‡ 5.9 ± 0.1*† 6.0 ± 0.2*† 5.9 ± 0.1*† 5.9 ± 0.2*† 4.7 ± 0.1*# 
Rel EDL (mg/g) 0.23 ± 0.01 0.17 ± 0.00* 0.22 ± 0.01#† 0.19 ± 0.01*‡ 0.19 ± 0.01*‡ 0.19 ± 0.01*‡ 0.20 ± 0.00*‡ 0.21 ± 0.01# 0.20 ± 0.01* 
Gast (mg) 123.30 ± 2.2 51.30 ± 1.6* 49.43 ± 2.14*† 47.93 ± 1.49*† 46.99 ± 1.36*† 48.26 ± 1.12*† 48.85 ± 1.58*† 46.03 ± 2.03*† 36.29 ± 1.09*# 
Rel Gast (mg/g) 3.17 ± 0.09 1.50 ± 0.05* 1.74 ± 0.06* 1.63 ± 0.06* 1.52 ± 0.06* 1.52 ± 0.07* 1.56 ± 0.05* 1.60 ± 0.08* 1.49 ± 0.05* 
TA (mg) 50.00 ± 3.5 28.40 ± 0.9* 28.24 ± 0.73* 25.83 ± 0.75* 26.73 ± 0.86* 27.33 ± 0.82* 28.87 ± 0.74*† 28.03 ± 0.71* 22.01 ± 0.95* 
Rel TA (mg/g) 1.28 ± 0.08 0.83 ± 0.03* 1.00 ± 0.03* 0.88 ± 0.04* 0.87 ± 0.03* 0.85 ± 0.03* 0.92 ± 0.02* 0.97 ± 0.03* 0.91 ± 0.05* 
Masses and relative (rel) masses are represented as mean ± SEM. EDL – extensor digitorum longus; Gast – gastrocnemius; TA – tibialis anterior. 
*Indicates significantly different from DBA, # indicates significantly different from D2-mdx, ‡ - significantly different from Q and † = 
significantly different from QNRLisPred, P<0.05.
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Figure 1. Soleus muscle function. A) Tetanic force and specific force were decreased in 
D2-mdx mice, regardless of treatment, compared to DBA. B) Resistance to fatigue was 
measured over 10 min. C) Despite similar fatigue resistance between DBA and D2-mdx 
at these time points, QNRLisPred increased fatigue resistance at 120, 300 and 600 
seconds compared to D2-mdx. DBA (n=10), D2-mdx (n=7-8), Q (n=8), NR (n=8), QNR 
(n=8), Lis (n=7), QLis (n=9-10), QNRLis (n=7), and QNRLisPred (n=9).  Statistical 
significance was established at p<0.05, * = significantly different from DBA, # = 
significantly different from D2-mdx. 
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Figure 2. Extensor digitorum longus muscle function. A) Tetanic force and specific 
force were decreased in D2-mdx mice, regardless of treatment, compared to DBA. 
QNRLisPred further decreased tetanic force compared to all groups, but specific tension 
similar to D2-mdx groups. B) Resistance to contraction induce injury was decreased in 
D2-mdx mice. Treatment with QNRLisPred improved resistance to contraction induced 
injury following the 5th contraction. DBA (n=9), D2-mdx (n=7-8), Q (n=8-9), NR (n=8), 
QNR (n=8), Lis (n=7), QLis (n=9-10), QNRLis (n=7-8), and QNRLisPred (n=9).  
Statistical significance was established at p<0.05, * = significantly different from DBA, # 
= significantly different from D2-mdx. 
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Figure 3. H&E staining of soleus and EDL. A) Representative H&E images (40X) of 
soleus muscle and quantification of contractile area. B) Representative H&E images 
(40X) of EDL and quantification of contractile area. Contractile area was significantly 
decreased in D2-mdx mice, which was not corrected by these treatments. DBA (n=8-9), 
D2-mdx (n=8), QLis (n=10), QNRLis (n=7-9), and QNRLisPred (n=8).  Statistical 
significance was established at p<0.05, * = significantly different from DBA, # = 
significantly different from D2-mdx, † = significantly different from QLis, ‡ = 
significantly different from QNRLis. 
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Figure 4. Trichrome staining of the soleus. Representative trichrome images (40X) of 
soleus muscle and quantification of fibrotic area. Fibrotic area was increased in 
dystrophic muscle. DBA (n=9), D2-mdx (n=8), QLis (n=10), QNRLis (n=8), and 
QNRLisPred (n=8).  Statistical significance was established at p<0.05, * = significantly 
different from DBA, † = significantly different from QLis. 
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Figure 5. Fiber area distribution of the soleus. A) Dystrophic fiber area distribution 
was shifted towards an abundance of small fibers. B) Mean fiber area was similar 
between health and dystrophic muscle, but median was decreased in all D2-mdx groups. 
Additionally, the variance coefficient was elevated in dystrophic muscle, regardless of 
treatment.  C) Representative IHC images (10X) of laminin in soleus muscle. DBA 
(n=8), D2-mdx (n=7), QLis (n=7), QNRLis (n=4), and QNRLisPred (n=5).  Groups were 
compared within each fiber area bin using a one-way ANOVA.  Significance was 
established at p<0.05, * = significantly different from DBA, # = significantly different 
from D2-mdx, † = significantly different from QLis. 
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Abstract 
Duchenne muscular dystrophy (DMD) is characterized by the absence of 
dystrophin protein and causes muscle weakness and muscle injury culminating in 
respiratory failure and cardiomyopathy. Quercetin has been shown to transiently improve 
respiratory function but failed to maintain long-term therapeutic benefits in mdx mice. In 
this study we combined quercetin with nicotinamide riboside, Lisinopril and prednisolone 
to assess the efficacy of quercetin-based cocktails. Nicotinamide riboside (NR) alone has 
been shown to improve dystrophic muscle function, and when combined with quercetin 
may replenish the NAD+ pool depleted in dystrophic muscle that is necessary to main the 
SIRT1 activity, an NAD+-dependent deacetylase, and prolong benefits of quercetin. 
Additionally, Lisinopril, an ACE-inhibitor, has been shown to prevent injury in both 
dystrophic hearts and skeletal muscle. We hypothesized that quercetin, NR and Lisinopril 
independently would improve respiratory function and decrease diaphragm injury, and 
when administered in combination would have additive effects. To address this 
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hypothesis, in vivo respiratory function, in vitro diaphragm function, and histological 
injury were assessed in DBA (healthy), D2-mdx (dystrophic) and D2-mdx mice treated 
with combinations of quercetin, NR and Lisinopril from 4-11 months of age. Lastly, we 
included prednisolone in the most complete cocktail to mimic the pharmacology of many 
DMD patients.  Contrary to our expectations, treatments largely failed to improve 
respiratory and diaphragmatic function, or histological injury. Manifestations of disease 
were apparent as respiratory and diaphragm function were decreased and histological 
injury was increased in dystrophic mice compared to healthy mice in this emerging DMD 
mouse model. Together these data suggest that quercetin, NR and Lisinopril 
independently and in combination did not prevent diaphragm injury nor preserve 
respiratory function.  
Keywords: DMD, prednisolone, glucocorticoid, ACE inhibitor, quercetin  
Introduction 
 Duchenne muscular dystrophy (DMD) is caused by a mutation to the dystrophin 
gene resulting in the absence of functional dystrophin protein. Dystrophin is a structural 
protein and anchor of the dystroglycoprotein complex that protects the sarcolemma 
during muscle contraction (26). Patients experience progressive muscle wasting that 
causes muscle weakness, wheelchair confinement and ultimately respiratory or cardiac 
failure (14). The absence of dystrophin is accompanied by a multitude of cellular 
dysfunctions including increased oxidative stress, calcium mishandling, chronic 
inflammation and impaired autophagy (5, 22, 34). Development of therapeutics to restore 
dystrophin protein to dystrophic muscles are ongoing (32), but immediate interventions 
are needed in order to protect and preserve muscle function. We and others are pursuing 
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pharmaceutical and nutraceutical interventions to treat the secondary dysfunctions of 
DMD with the goal of using these agents to preserve muscle function, improve quality of 
life, and prolong life expectancy, e.g. Hollinger et al. (19), Lowe et al (23), Ryu et al. 
(29).   
Given these cellular dysfunctions, exercise-mediated adaptations would appear to 
offset many pathological hallmarks of disease, however, when considered in aggregate, 
the effects of exercise on DMD are equivocal (35). Activation of the transcriptional co-
activator PGC-1α may be a means by which to acquire exercise-mediated protection 
without the risk of contraction induced injury. Indeed, vector-mediated and transgenic 
overexpression of PGC-1a in dystrophic muscle reduced muscle damage and preserved 
muscle function (10, 16-18, 31). Given the success of PGC-1a overexpression, we began 
to investigate the effect of quercetin, a natural flavonoid that stimulates PGC-1α activity, 
on disease severity in dystrophic muscle (2-4, 19, 30, 33). Quercetin serves to increase 
PGC-1α activity through SIRT1, an NAD+-dependent deacetylase (13, 25). Quercetin 
also functions as an anti-oxidant and anti-inflammatory, which may assist in protecting 
dystrophic muscle from damage (1, 6, 12). 
In studies in which quercetin was administered for 6 months, quercetin decreased 
histological injury in dystrophic diaphragms and hearts (4, 19), however, following 12 
months of treatment, skeletal muscle function and histological damage were similar in 
quercetin-treated and untreated muscle (30, 33). We also found that quercetin improved 
respiratory function for the first 4-6 months of treatment, but by the conclusion of the 
study (14 months of age) respiratory function was similar between treated and untreated 
dystrophic mice (30). As NAD+ plays a role in SIRT1 function, and in dystrophic 
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skeletal muscle NAD+ abundance is decreased (8, 29), NAD+ depletion may limit 
quercetin-mediated PGC-1α activation. We hypothesized that treatment of dystrophic 
mice with quercetin in combination with the NAD+ donor, nicotinamide riboside (NR), 
would enhance the efficacy of quercetin, particularly during long-term treatment (33). 
Indeed, 10-12 weeks of NR supplementation improved dystrophic muscle function and 
enhanced satellite cell and mitochondrial function (29, 36).  
In this study, our objective was to determine the extent to which quercetin-based 
cocktails protect respiratory function, diaphragm function, and decrease histological 
damage in the diaphragm of dystrophin-deficient mice. We hypothesized that quercetin in 
combination with NR would prolong quercetin-mediated improvements in in vivo 
respiratory function and increase in vitro diaphragm function while reducing histological 
damage in 11-month-old dystrophic mice. Additionally, DMD disease pathology includes 
cardiomyopathy, therefore cardioprotective drugs may be used alongside skeletal muscle-
targeted therapies. Lisinopril, a cardioprotective drug, has been shown to protect the 
dystrophic myocardium and skeletal muscle (21, 28). Therefore, in this study, we 
evaluated the effect of Lisinopril, a cardioprotective drug, on respiratory function, 
diaphragm function and muscle damage both alone and in combination with quercetin-
based cocktails.  Lastly, prednisolone was combined with the most complete quercetin-
based cocktail to understand the effect of these agents within the context of the current 
pharmacological standard of care, glucocorticoids. 
Methods 
Animal Treatments. Animal protocols were approved by the Institutional Animal 
Care and Use Committees at University of Montana (047-16JQHHP-072616) and the 
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University of Florida (201508822). Male DBA2/J (DBA; control) mice and D2.B10-
Dmdmdx/J (D2-mdx; dystrophin-deficient) mice were obtained from Jackson Laboratory 
(Bar Harbor, ME). Mice were acclimated for at least one week, then at 4 months of age 
mice were separated into treatment groups (n=10/group): DBA, untreated D2-mdx, and 
D2-mdx treated with quercetin (Q, 0.2% by diet, 275 mg/kg/d), nicotinamide riboside 
(NR, 55 mg/kg/d by diet), Q and NR (QNR), Lisinopril (Lis, 33 mg/L in water), Q and 
Lis (QLis), QNRLis, or  QNRLis with prednisolone (QNRLisPred, 10 mg/L by water).  
Mice weighed approximately 26 g throughout the investigation, ate approximately 3.6 
g/day, and drank approximately 7.2 ml/day.  Given the use of glucocorticoids in the 
treatment of DMD patients, a QNRLisPred group was included to assess the QNRLis 
cocktail within a common pharmacological context. All animals had ad libitum access to 
food and water. Prior to the start of the treatments, groups were assigned numbers to 
preserve blinded conditions throughout data collection.  
Respiratory function. In vivo respiratory function was assessed using whole body 
plethysmograph as previously reported (27, 30). Briefly, beginning at 4 months of age, in 
vivo respiratory function was measured every 2 months until 10 months of age using a 
four-chamber whole body unrestrained plethysmography system (Buxco, now Data 
Sciences International, St. Paul, MN, USA), which has been shown to effectively identify 
differences between healthy and dystrophic mice (20, 30).  As previously described, mice 
were allowed a 20 min acclimation period, then data were collected over 8 minutes (27).  
Muscle function. In vitro muscle function of the diaphragm was assessed at the 
University of Florida Myology Institute Physiological Assessment Core as previously 
described (24, 31). Briefly, costal diaphragms were removed following sedation with 
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ketamine and xylazine and then separated into two hemi-diaphragms: one for in vitro 
function measures and the other for histology. The hemi-diaphragm for histology was 
coated in OCT, rolled to create a tube, then frozen in liquid nitrogen-chilled isopentane. 
Specific tension and resistance to fatigue were measured in the second hemi-diaphragm. 
The hemi-diaphragm strip was placed in oxygenated Ringer’s solution (NaCl, 4.7mM 
KCl, 2.5mM CaCl2, 1.2mM KH2PO4, 1.2mM MgSO4, 25mM HEPES and 5.5mM 
glucose), then attached at one end to a force transducer and the other end to an anchor.  
Muscles were simulated at 100 Hz for 500ms to established optimum length (Lo) during 
tetanic contractions. To measure tetanic force, tetanic contractions were performed once 
every 10 minutes for 30 minutes.  Specific force and cross-sectional area were calculated 
using standard equations (7). Data were collected with an Aurora dual mode lever system 
(Ontario, Canada) using DMC software (version 3.2).  Fatigue resistance was measured 
at 1 contraction/sec at 100 Hz for 330 msec with 200 µsec pulses for 10 min. Fatigue 
resistance was reported as percentage of remaining initial force.  
Histology. Hematoxylin & eosin (H&E) and Masson’s Trichrome (KTMTRPT, 
American MasterTech, Lodi, CA) staining were used to assess muscle damage and 
fibrosis as previously described (30, 33). Ten-micron sections were stained with H&E or 
Masson’s Trichrome, and 3-5 sections/muscle were imaged at 40x magnification on an 
inverted Lecia DMI3000 B microscope and QICAM MicroPublisher 5.0 (MP5.0-RTV-
CLR-10, QIMAGING) camera with QCapture software (Surrey, BC, Canada) by a 
blinded, trained technician. H&E-stained muscle sections were used to quantify 
contractile area using the Open Lab Software (Improvision) density slice function, which 
identifies regions based on prescribed pixel parameters. Areas of necrosis, connective 
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tissue, and hypercontracted cells were quantified using the density slice function were 
subtracted from the total area to calculate area of healthy contractile tissue. The healthy 
tissue area was expressed relative to the total image cross sectional area. Similarly, the 
density slice function was used to selectively identify the fibrotic area (blue area) in 
trichrome images.  Fibrotic area was divided by the total area to determine the percent of 
fibrosis in each muscle section.  
Statistics. To analyze single time point measurements such as specific force, 
necrotic area and fibrotic area ANOVAs were preformed using GraphPad Prism with a 
Newman-Keuls post-hoc test. In vivo respiratory function data were analyzed using a 
repeated measures model that assumes the variance-covariance structure was auto-
regressive. Fatigue resistance data were analyzed using repeated measures where the 
model incorporated a spatial power variance-covariance structure. In both respiratory 
function and fatigue resistance the repeated effect was time relative to age of the animal. 
Using mixed model methods (Proc Mixed, SAS V9.0, SAS Inst. Inc., Cary, NC) where 
the model included group, time, and group×time interaction as fixed effects and pre-
treatment value (20min baseline measurement at 4 months of age) was used as a linear 
covariate.  The experimental unit was individual mouse (n=7-10 per group) and model 
fixed effects were considered significant when their p ≤  0.05. When model fixed effects 
were significant sources of variation, the fixed effect level of LS means were separated 
using the PDIFF statement of SAS to determine pairwise differences. 
Results 
  To determine the extent to which quercetin, nicotinamide riboside, Lisinopril and 
prednisolone protect respiratory function, diaphragm function and muscle damage, D2-
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mdx mice were treated with a 0.2% quercetin enriched diet, a 55 mg/kg per day 
nicotinamide riboside enriched diet, 33 mg/L Lisinopril enriched water, and 10 mg/L 
prednisolone enriched water. Body mass was decreased 13-38% in all D2-mdx mice 
compared to DBA (please refer to Chapter 3). Additionally, the QNRLisPred group was 
further decreased by over 25% compared to untreated D2-mdx and DBA mice. Similarly, 
absolute and relative EDL, gastrocnemius and TA masses were decreased in D2-mdx 
groups compared to DBA. Consistent with body weight, gastrocnemius and EDL 
absolute muscle masses in the QNRLisPred group were further decreased compared to 
DBA and untreated D2-mdx. Interestingly, soleus mass was similar between all groups, 
though it was decreased with QNRLisPred treatment.  
In vivo respiratory function. Respiratory function was assessed using whole body 
plethysmography in alternating months starting at 4 months (mo) of age through the 
conclusion of the study. For clarity, all statistically significant differences are discussed 
below, but only comparisons that were significantly different from DBA or D2-mdx mice 
were noted in Figure 1.  Peak inspiratory flow (PIF) was similar between healthy (DBA) 
and diseased (D2-mdx) mice at each time point, regardless of treatment. At 6 mo of age, 
PIF of D2-mdx mice treated with QLis was increased 16% compared to DBA (p<0.05).  
Additionally, QLis was increased as a main effect of treatment compared to DBA (Figure 
1A; p<0.05). Peak expiratory flow (PEF) was similar between all groups, but PEF was 
decreased in QNRLisPred-treated mice compared to QLis and QNRLis as a main effect 
of treatment (Figure 1B; p<0.05). Similarly, tidal volume was decreased in QNRLisPred 
as a main effect of treatment compared to all groups but was specifically decreased by 
approximately 15% compared to QLis at 6 mo and 8 mo (p<0.05), 10% compared to 
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QNR at 6 mo (p<0.05), and 9% compared to Q at 8 mo (p<0.05). Additionally, QLis tidal 
volume increased 12% compared to DBA at 6 mo. QNRLisPred tidal volume was 
decreased 16% compared to DBA at 10 mo (p<0.05) and 13% compared to untreated D2-
mdx at 8 mo (p<0.05) and 10 mo (Figure 1C; p=0.076).  
Frequency of breaths was elevated 12-14% in QNRLisPred compared to DBA 
and untreated D2-mdx at 8 mo (p<0.05) and 10 mo of age (p<0.05). Similarly, breath 
frequency of mice treated with Lis was decreased 12-14% to DBA and D2-mdx at 8 mo 
and QLis and QNRLis frequency of breaths were increased 10-16% at 10 mo of age 
compared to DBA (p<0.05) and 13-18% compared to untreated D2-mdx (p<0.05). 
Additionally, QNRLisPred was increased 12-19% at 6 mo compared to Q, Lis, and QLis, 
11-30% at 8 mo compared to NR, Lis and QLis, and 16% compared to Lis at 10 mo. Lis 
breath frequency was decreased 14-16% compared to Q, NR and QNR at 8 mo, while 
QLis increased 14% at 10 mo compared to Lis alone. Lastly, Lis was decreased as a main 
effect of treatment compared to DBA, D2-mdx, Q, NR, and QNR, while QNRLisPred 
was increased as a main effect of treatment compared to all other groups, except for 
QNRLis.  QLis and QNRLis frequency of breaths were increased as a main effect of time 
compared to Lis alone (Figure 1D). Minute ventilation was similar between all groups 
regardless of treatment (Figure 1E). Collectively these data suggest that respiratory 
function was similar between DBA and D2-mdx. When treatments were compared to 
either DBA or D2-mdx, occasional comparisons deviated from DBA or D2-mdx, but as a 
whole these quercetin-based cocktails did not improve respiratory function.   
 In vitro diaphragm function. Specific force and fatigue resistance were assessed in 
diaphragms. Specific force decreased 48-65% in all D2-mdx groups compared to DBA 
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(p<0.05; Figure 2A). NR-treated D2-mdx diaphragm specific force was further decreased 
by 25% compared to Q and QNRLisPred (p<0.05).  QNR, Lis, QLis and QNRLis 
specific force was decreased 20-32% relative to QNRLisPred (p<0.05).  Fatigue 
resistance was similar between all groups regardless of treatment at 10s, 120s, 300s and 
600s during the fatigue protocol (Figure 2B&C).            
 Histology. Given that in vivo and in vitro function data were largely similar 
between treatment groups, we narrowed our investigation to evaluate histological injury 
in treatment groups with the most therapeutic potential (Figure 3). We quantified 
diaphragm contractile area and fibrotic area in DBA, D2-mdx, QNR, QLis, QNRLis, 
QNRLisPred groups (Figures 3 and Figure 4). Contractile area was decreased over 10% 
in all D2-mdx groups compared to DBA (p<0.05). Contractile area was further decreased 
by 7% in QNRLis compared to QLis (p<0.05) (Figure 3). Fibrotic area was increased 5-
12 fold in all D2-mdx groups compared to DBA (p<0.05; Figure 4). QNR was further 
increased 1.5-2 fold compared to untreated D2-mdx, QLis and QNRLisPred (p<0.05). 
Additionally, QNRLis fibrotic area was increased 2-fold compared to QLis (p<0.05).  
Discussion 
 Duchenne muscular dystrophy is caused by the absence of functional dystrophin 
protein due to a mutation to the dystrophin gene. Dystrophin deficiency results in 
progressive muscle wasting culminating in respiratory or cardiac failure (14). While some 
researchers are developing approaches to restore dystrophin protein (32), we and others 
are working to identify pharmaceutical and nutraceutical interventions with potential for 
immediate application to mitigate disease pathology. In these experiments we 
investigated the extent to which quercetin-based cocktails preserved respiratory and 
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diaphragm function and prevented histological damage in the D2-mdx mouse model of 
DMD.  Specifically, we treated dystrophic mice with quercetin, nicotinamide riboside, or 
Lisinopril alone and in various combinations including one complete combination with 
prednisolone. We hypothesized that in vivo respiratory function and in vitro diaphragm 
function would be reduced and histological damage would be increased in D2-mdx mice 
compared to DBA and that treatment with quercetin-based cocktails would mitigate these 
disease-related changes. We found that dystrophin deficiency increased some parameters 
of disease, however, counter to our hypothesis, quercetin-based cocktails failed to 
attenuate disease severity.  
Previously, we found that 6 months of treatment with quercetin preserved in vivo 
respiratory function, but by 12 months of age respiratory function was similar between 
quercetin-treated and untreated mdx mice (30). In the present investigation, which used 
the D2-mdx model, we did not detect a functional improvement in any quercetin-treated 
group, regardless of duration of treatment. Interestingly, D2-mdx mice treated with the 
complete cocktail, QNRLisPred, decreased tidal volume and increased frequency of 
respiration suggesting decreased alveolar ventilation compared to D2-mdx at 8 months 
and DBA at 10 months of age. Similar to findings using aged mdx mice (30), diaphragm 
specific force was reduced in D2-mdx at the conclusion of the study, and was not 
improved following long-term treatment with quercetin. Given the reduction of NAD+ in 
dystrophic muscle (8, 29), and recent evidence of improved muscle and mitochondrial 
function in mdx mice following 11-12 weeks of nicotinamide riboside administration (29, 
36), we postulated that supplementation with nicotinamide riboside would independently 
improve respiratory function in dystrophic mice. Furthermore, nicotinamide riboside 
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could also boost quercetin effectiveness via increased NAD+-mediated SIRT1 activity, 
which is necessary for quercetin-mediated activation of the PGC-1α pathway. Though 
long-term quercetin treatment did not decrease histological damage in this study or a 
previous study (30), despite successfully reducing histological injury following 6 months 
of quercetin treatment in 8-month-old in mdx mice (19), the use of quercetin in 
combination with NR may result in an additive or even synergistic therapeutic effect. 
Contrary to our hypothesis, nicotinamide riboside alone and in combination with 
quercetin did not improve measures of respiratory function. These data suggest that long-
term administration of quercetin does not protect dystrophic diaphragms from damage 
and muscle weakness even when given in combination with nicotinamide riboside. We 
cannot rule out the possibility that age of animals at initiation of treatment, duration of 
treatment, and our selected animal model may have limited the efficacy of nicotinamide 
riboside (or other drugs/combinations).  Indeed, the combination of the severe D2-mdx 
model coupled with the deliberate selection of a four-month-old start date to allow 
advanced disease may have made the muscle unresponsive to this intervention.  Our 
rationale was that such a rescue paradigm is necessary to convincingly establish efficacy 
as onset of treatment begins in DMD patients following diagnosis that is ultimately 
caused by muscle injury sufficient to impair locomotion.  Hence, studies of therapeutics 
in a model that more closely recapitulates disease severity is important.  Further, as 
patients may be taking drugs for years establishment of long-term efficacy is essential.    
Guided by the necessity to treat multiple aspects of DMD disease pathology, 
Lisinopril was added to the quercetin-based cocktails. While primarily used as a 
cardioprotective agent, Lisinopril has been shown to reduce histological damage in 
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skeletal muscle in the mdx/Utrn+/- model (23). In the present investigation, we found that 
Lisinopril did not decrease fibrosis nor preserve contractile area independently or when 
given in combination with quercetin, or quercetin, nicotinamide riboside and/or 
prednisolone. Similarly, respiratory function and diaphragm function were not improved 
with these interventions. Counter to our findings, Lisinopril administered with 
aldosterone receptor antagonist, spironolactone, improved function and reduced damage 
in the mdx/Utrn+/- mouse (28), though not in the mdx model (21). The stage of disease in 
which treatments were initiated may impact efficacy of treatments such that initiation at 4 
weeks of age improved skeletal muscle function and decreased injury, while the same 
treatment started at 8 weeks failed to improve these parameters (28). Similarly, animal 
model may also play a role in study outcomes, as demonstrated by the benefits of 
Lisinopril in mdx/Utrn+/- mice that were not recapitulated in the mdx model (21).   
Though C57BL/10-mdx (mdx) mice are conventionally used to model DMD in 
mice, in this study we employed the DBA/2J-mdx (D2-mdx) mouse model. The mdx 
mouse generally has a mild phenotype compared to human patients (9), which has 
hindered translational research. The emerging D2-mdx model has an early onset of 
disease, a more severe phenotype, and a latent TGF-b-binding protein gene 4 (Ltbp4) 
genetic modifier contributing to increased fibrosis and inflammation, which has been 
linked to earlier loss of ambulation in DMD patients (15). Our data demonstrate that 
fibrotic area was notably increased in D2-mdx mice, which coincided with decreased 
contractile area. Similarly, in a previous study comparing mdx and D2-mdx mice, muscle 
fiber damage, evaluated by Evan’s blue dye uptake, was increased by approximately 2-
fold compared to DBA and also increased over 30% compared to mdx at 8 weeks of age 
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(11) supporting increased disease severity in the D2-mdx model compared to the mdx 
model.  
Despite decreased diaphragm specific force and advanced histological injury in 
dystrophic diaphragms compared to healthy, in vivo respiratory function was surprisingly 
similar between D2-mdx and DBA mice. While beyond the scope and capacity of this 
investigation, it is reasonable to suggest that accessory muscles are likely compensating 
for the failing diaphragm in D2-mdx. The assistance of accessory muscle results in 
similar respiratory function, assessed via whole body plethysmography, despite increased 
diaphragm injury and dysfunction. As DMD is a progressive disease we hypothesized 
that, despite potential contributions by accessory muscles, respiratory failure may be 
detected by careful scrutiny of changes occurring during the final phase of our 
investigation.  Indeed, we discovered that in D2-mdx mice parameters of respiratory 
function declined between 8-10 months of age compared to DBA mice, which suggests 
that respiratory function is compromised in dystrophin-deficient mice even if the 
modality of respiration differs dramatically between healthy and dystrophic mice.  
Specifically, peak expiratory flow, which is ostensibly dependent on the elasticity of the 
respiratory system, significantly declined while in healthy mice this continued to increase 
(p<0.05). Similarly, tidal volume and minute ventilation also declined between 8-10 
months of age in the D2-mdx model compared to DBA (p<0.05), while peak inspiratory 
flow and breath frequency were similar between groups.   
In summary, counter to our hypothesis, our data suggest that these quercetin-
based cocktails did not protect dystrophic diaphragms from injury nor preserve 
respiratory function. Based on our collective body of work investigating quercetin, we 
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suggest that other therapeutic avenues be considered. Importantly, this investigation 
provides novel data regarding diaphragm and respiratory function in the D2-mdx model, 
an emerging model of DMD.  
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Figures 
 
Figure 1: In vivo respiratory function. Only statistical differences between all groups 
compared to DBA and treatment groups compared to D2-mdx are indicated in the figures. 
Statistically significant difference between treatment groups are included in the results 
section.  A) The main effect of QLis increased peak inspiratory flow compared to DBA 
and specifically increased peak inspiratory flow at 6 mo of age, but all treatment groups 
were similar to D2-mdx. B) Peak expiratory flow was not altered at any time point 
compared to DBA or D2-mdx, regardless of disease or treatment C) QNRLisPred tidal 
volume was decreased compared to DBA at 10 months and decreased as a main effect of 
QNRLisPred treatment compared to DBA and D2-mdx. Additionally, tidal volume of 
QLis treated animals was increased compared to DBA. D) Respiratory rate was increased 
in QNRLisPred as a main effect of treatment compared to DBA and D2-mdx. Also, at 8 
mo, respiratory rate was increased in QNRLisPred compared to DBA and D2-mdx but 
decreased in Lis treated mice compared to DBA and D2-mdx. Lastly, at 10 mo 
QNRLisPred breath frequency was still increased compared to DBA and D2-mdx. 
QNRLis was increased compared to DBA and D2-mdx, and QLis was increased 
compared to DBA.  E) Minute Ventilation was similar between all groups regardless of 
disease or treatment. DBA (n=10), D2-mdx (n=10), Q (n=9), NR (n=9-10), QNR (n=9-
10), Lis (n=7-10), QLis (n=10), QNRLis (n=8-9), and QNRLisPred (n=8).  Statistical 
significance was established at p<0.05. * = significantly different from DBA, # = 
significantly different from D2-mdx.  
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Figure 2: In vitro diaphragm function. A) Specific force was decreased in all D2-mdx 
groups compared to DBA. NR, QNR, Lis, QLis and QNRLis-treated mice were reduced 
compared to QNRLisPred. B & C) Fatigue resistance was similar between groups at 
selected time points corresponding to the immediate energy system (10 s), glycolytic 
system (120 s), and aerobic system (300 s and 600 s).  DBA (n=9-10), D2-mdx (n=6-8), 
Q (n=7-8), NR (n=7-8), QNR (n=8), Lis (n=7), QLis (n=9-10), QNRLis (n=8), and 
QNRLisPred (n=7-8).  Statistical significance was established at p<0.05, * = significantly 
different from DBA, † = significantly different from Q, ‡ = significantly different from 
QNRLisPred.
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Figure 3: H&E contractile area. Representative H&E images (40x) of diaphragm 
muscle. Contractile area was decreased in D2-mdx mice, which was not corrected by 
treatments. DBA (n=6), D2-mdx (n=5), QNR (n=8), QLis (n=10), QNRLis (n=6), and 
QNRLisPred (n=7).  Statistical significance was established at p<0.05, * = significantly 
different from DBA, † = significantly different from QLis. 
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Figure 4: Trichrome fibrotic area. Representative trichrome images (40x) of 
diaphragm muscle. Fibrotic area was increased in dystrophic muscle, and not attenuated 
by any treatment. DBA (n=9), D2-mdx (n=8), QLis (n=10), QNRLis (n=8), and 
QNRLisPred (n=8).  Statistical significance was established at p<0.05, * = significantly 
different from DBA, # = significantly different from D2-mdx, † = significantly different 
from QNR, ‡ = significantly different from QLis.  
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Abstract 
Aim 
Duchenne muscular dystrophy is caused by the absence of functional dystrophin protein 
and results in a host of secondary effects.  Emerging evidence suggests that dystrophic 
pathology includes decreased pro-autophagic signaling and suppressed autophagic flux in 
skeletal muscle, but the relationship between autophagy and disease progression is 
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unknown.  The purpose of this investigation was to determine the extent to which basal 
autophagy changes with disease progression.  We hypothesized that autophagy 
impairment would increase with advanced disease.   
Methods  
To test this hypothesis, seven week old and 17 month old dystrophic diaphragms were 
compared to each other and age-matched controls.   
Results  
Changes in protein markers of autophagy indicate impaired autophagic stimulation 
through AMPK, however, robust pathway activation in dystrophic muscle, independent 
of disease severity.  Relative protein abundance of p62, an inverse correlate of autophagic 
degradation, was dramatically elevated with disease regardless of age.  Likewise, relative 
protein abundance of Lamp2, a lysosome marker, was decreased 2-fold at 17 months of 
age in dystrophic muscle and was confirmed, along with mislocalization, in histological 
samples, implicating lysosomal dysregulation in this process.  In dystrophic muscle 
autophagosome-sized p62 positive foci were observed in the extracellular space.  
Moreover, we found that autophagosomes were released from both healthy and 
dystrophic diaphragms into the extracellular environment, and the occurrence of 
autophagosome escape was more frequent in dystrophic muscle.   
Conclusion 
These findings suggest autophagic dysfunction proceeds independent of disease 
progression, blunted degradation of autophagosomes is due in part to decreased lysosome 
abundance, and contributes to autophagosomal escape to the extracellular space. 
Key words: Autophagy, DMD, dystrophin, extracellular vesicle, lysosome 
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Introduction 
 Duchenne muscular dystrophy (DMD) is an X-linked muscle wasting disease in 
which muscle dysfunction, degeneration, and progressive muscle weakness result from 
the absence of functional dystrophin protein.  Underlying this progression of muscle 
weakness and injury is mitochondrial dysfunction, oxidative stress, membrane instability, 
proteolysis, and decreased calcium homeostasis, among other pathologic changes.1-4  
Autophagy has become recognized as a critical process to remove damaged and 
dysfunctional organelles, proteins aggregates and cellular components promoting cell 
survival.5, 6  Further, maintenance of basal autophagy appears to play a vital role in 
healthful muscle maintenance.7 
Recent evidence demonstrates increased autophagy in dystrophic muscle could 
provide therapeutic benefit to patients suffering from DMD.  For example, 
pharmacological activation of AMPK resulted in increased autophagy in mdx mice 
concomitant with decreased disease-related injury and improved muscle function in 
dystrophic diaphragms.8  Interestingly, improved function was due, at least in part, to 
improved mitochondrial integrity via selective autophagic removal of damaged 
mitochondria.8  Further evidence of impaired autophagy is observed by the activation of 
AKT and mTOR in dystrophic flexor digitorum brevis and diaphragm muscle,9 as 
pathway activation of these two molecules inhibit autophagy.10, 11    
During autophagy, cellular components and organelles are engulfed by 
autophagosomes, which fuse with lysosomes culminating in degradation.  Organelle 
movement through the autophagic process ultimately results in constituent degradation 
commonly referred to as ‘autophagic flux’.  While evidence of autophagic impairment in 
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dystrophic muscle exists,9, 12, 13 the mechanisms and signaling that link this biological 
process with diminished outcomes are not well understood.  Accordingly, the purpose of 
the present study was to investigate signaling involved in impaired autophagy in 
dystrophic muscle and determine the relationship between the degree of impairment and 
disease progression.  We hypothesized that increased disease progression would further 
decrease basal autophagic signaling and suppress autophagic degradation.  
Results 
Activation of autophagy in dystrophic skeletal muscle.   
Damaged organelles and protein aggregates are cleared from cells by 
autophagosomal packaging and transport to the lysosomes for degradation and is 
inhibited by mTOR activity, which is increased in dystrophic muscle. In contrast, 
autophagy is stimulated by AMPK activity, which is equivocally altered in dystrophic 
muscle.  Given these mixed reports8, 14-16 it was important to clarify the role of AMPK 
activation in dystrophic skeletal muscle to appreciate its influence on autophagic 
regulation with disease progression.  To address this aim, AMPK protein abundance was 
measured by Western blot from diaphragms of 7 week and 17 month old dystrophic 
(mdx) and age-matched control (C57) mice.  We found that dystrophin deficiency 
increased total AMPK 3-5-fold (p<0.05), however phosphorylated AMPK at threonine 
172 was similar between groups (Figure 1).  Alternatively, the pAMPK threonine 
172/AMPK ratio was decreased by 3.8-fold in dystrophic muscle (p<0.05).  In addition, 
AMPK activation was suppressed 1.4-fold (p<0.05) by aging in healthy diaphragms.   
Phosphorylation of ACC  serine 79, another indicator of AMPK activation, was similar 
between dystrophic and control mice in both young and old mouse diaphragms.  
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Phosphorylation of ULK1 at serine 555, required for phosphorylation of Beclin-1 at 
serine 14,17 was similar between 7 week control and dystrophic diaphragms. In contrast, 
ULK1 phosphorylation was decreased by 65% in 17 month old diaphragms with 
advanced disease progression.   
Autophagic machinery is increased in dystrophic muscle. 
To evaluate the abundances of autophagic machinery, markers of phagosome 
formation and maturation were evaluated by Western blot.  Despite similar pAMPK 
protein abundance autophagy appeared to be initiated by increased Beclin-1. This latter 
conclusion is supported by the observation that phosphorylated Beclin-1 and PI3K class 
III were increased more than 3.5-fold (p<0.05) in dystrophic muscle, a finding that was 
independent of disease severity (Figure 2).  Further, Atg12-5 complex formation, 
indicative of autophagosome formation, was increased over 30-fold (p<0.05) in 
dystrophic diaphragms regardless of age.  Protein abundance of Atg7, an E1 activating 
enzyme that binds Atg5 and 12, was similar between groups.  LC3I was increased 3-4-
fold in dystrophic diaphragms compared to healthy diaphragms and reached statistical 
significance in tissues from 7 week old animals (p<0.05).  The lipidation product, LC3II, 
which binds to the autophagosome membrane indicating maturation, was significantly 
increased 2.9-fold (p<0.05) in 7 week dystrophic diaphragms, but abundance of LC3II 
was similar between 17 month dystrophic and control diaphragms.  
Autophagic flux markers indicate dysfunction in dystrophic skeletal muscle 
Markers of autophagic flux and degradation, including LC3II/LC3I and p62 
protein abundance, indicate downstream autophagy is impaired in both 7 week and 17 
month dystrophic diaphragms (Figure 3).  Specifically, the LC3II/LCI ratio was 
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numerically decreased 1.4-fold in 7 week and significantly decreased 2.7-fold (p<0.05) in 
17 month old dystrophic diaphragms compared to respective controls.   Similarly, p62, a 
protein found in autophagosomes trafficked for lysosomal degradation, increased over 5-
fold (p<0.05) in dystrophic diaphragms from both 7 week and 17 month old animals. 
Collectively, these findings indicate a substantial impairment in autophagic degradation 
of autophagosomes.  Additionally, the abundance of ubiquitinated proteins was increased 
3-fold in dystrophic diaphragms, further supporting decreased autophagic degradation.18 
Decreased lysosomal content in dystrophic muscle.   
Increased autophagic signaling and pathway activation coupled with decreased 
markers of autophagic degradation suggested a role of lysosomes in this process.  During 
functional autophagy, autophagosomes fuse to lysosomes to form autophagolysosomes, 
which results in the degradation of autophagosome cargo.  Thus, decreased cellular 
lysosomal content could impair autophagic flux.  In 17 month dystrophic diaphragms 
lysosomal content was decreased 2-fold (Figure 3), as indicated by lysosome-associated 
membrane protein 2 (Lamp2) protein abundance.   
To better understand the role of lysosomes and autophagosomes in dystrophic 
muscle we next investigated archived diaphragm samples from 14 month old dystrophic 
and healthy mice by immunohistochemistry, and observed lysosomal content was also 
decreased in these dystrophic diaphragms (Figure 4). Consistent with hypothesized 
outcomes, lysosome content, as measured by Lamp2, were localized to muscle cells in 
healthy muscle.  However, in dystrophic diaphragms not only was total Lamp2 decreased 
but appeared to have localized to the extracellular space around non-fiber nuclei (Figure 
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4).  In addition, we confirmed that p62-positive puncta were largely contained within the 
presumptive autophagosomal range of 0.5-1.5 microns.19   
Given that both our Western blot and immunohistochemistry data supported 
decreased Lamp2 and suggested insufficient intracellular lysosome abundance, we next 
assessed transcription factor EB (TFEB) localization.  Dephosphorylation and 
translocation of TFEB into the nucleus results in expression of transcripts involved in 
autophagy and lysosomal biogenesis.20  We assessed TFEB localization by 
immunohistochemistry in diaphragm samples from 17 months old dystrophic and healthy 
mice.  In dystrophic muscle, TFEB was notably excluded from centralized nuclei, while it 
was apparent in peripheral nuclei of healthy muscle (Figure 5A and B).  TFEB also 
appears to be excluded from some extra-muscular nuclei in healthy and dystrophic 
muscle and likely represents a common sub-population of resident cells.  
Skeletal muscle releases autophagosomes into the extracellular environment. 
We also noted that p62 positive puncta were apparent outside dystrophic muscle 
cells but not healthy muscle cells (Figure 4).  In most cases p62 was located within 
Lamp2 positive areas, and ostensibly within immune cells, but we also noted 
unaccompanied foci.  Merged images show p62 puncta within Lamp2 as well as p62 
outside the intramuscular space and independent of Lamp2 (Figure 4 and 7A).  This 
finding raised the possibility of autophagosomal migration from the intramuscular space 
to the extracellular space and escaping lysosomal degradation.    
To address this intriguing possibility we first investigated if skeletal muscle cells 
release vesicles morphologically similar to autophagosomes.  We have previously 
demonstrated that muscles release small lipid vesicles in the 40-150 nm size range 
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(termed exosomes) into the extracellular space by incubating differentiated myotubes in 
serum free media and then isolating exosomes from the media via high-speed 
centrifugation (100,000g).21, 22  Using the same approach but with a lower centrifugation 
speed (12,000g) to pellet larger vesicles followed by scanning electron microscopy we 
identified that skeletal muscle cells release a variety of vesicles including vesicles 
morphologically similar to autophagosomes (Figure 6).   
To determine if dystrophic muscle releases an extracellular vesicle population 
containing autophagosomes we incubated costal diaphragms from healthy and mdx mice 
at approximately Lo in an oxygenated Krebs bath and isolated large vesicles using the 
same centrifugation protocol.  Interestingly, flow cytometry analysis revealed that both 
healthy and dystrophic diaphragms release autophagosomes, but dystrophic diaphragms 
release nearly 4-fold more autophagosomes (Figure 7B).        
Discussion 
Duchenne muscular dystrophy is a muscle wasting disease characterized by the 
absence of functional dystrophin protein that leads to eventual death due to respiratory or 
cardiac failure.  Autophagy functions as a mechanism by which dysfunctional protein, 
organelles, and cellular components are consumed within the cell.  With or without 
physiologic stress, autophagy is activated by a variety of stimuli including mitochondrial 
dysfunction and accumulation of dysfunctional organelles or proteins.  Indeed, given the 
potential for these to accumulate in dystrophic muscle we reasoned that autophagy was 
suppressed in dystrophic muscle. We further reasoned that autophagic signaling would be 
repressed with advancing disease.     
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Several investigations have demonstrated decreased AMPK phosphorylation 14, 16 
and increased mTOR phosphorylation,9 both anti-autophagic signals, in dystrophic 
muscle suggesting impaired autophagic signaling.  In recent years autophagic trafficking 
has been assessed by LC3II/I ratios and p62 accumulation as an indirect metric of 
suppressed flux.9, 12, 13 Consistent with previous findings our data indicate AMPK 
activation was decreased in dystrophic muscle compared to healthy muscle.  Further, we 
report decreased phosphorylation of ULK at serine 555 at 17 months of age, which also 
suggests suppression of autophagic signaling.  Despite this, we found autophagy was 
strongly induced in dystrophic muscle suggesting that a non-canonical mechanism may 
initiate this process.  Specifically, we noted that Beclin-1 and PI3K class III were 
markedly increased in dystrophic muscle as was formation of the Atg12-5 complex.  This 
latter point is of high importance because Atg12-5 complex formation results from 
several protein/protein interactions and is a marker of pathway activation.23  Despite this 
activation, and consistent with the findings of others,9, 12, 13, 24 autophagic degradation 
appeared to be blunted by dystrophin deficiency as the LC3II/I ratio was decreased and 
p62 was increased compared to healthy muscle.   
Given these data, it is unlikely that autophagy is regulated by upstream AMPK or 
mTOR signaling in dystrophic muscle.  From a therapeutic perspective these data 
indicate that direct stimulation of autophagy is unlikely to be a successful long-term 
approach as autophagic machinery is already in place.  It is interesting to note that the 
marked increase in p62 protein abundance promotes mTOR stability 25 and liberates 
Beclin-1 from Bcl-2 26 resulting in simultaneous inhibition and stimulation of autophagy.  
Moreover, mTOR not only inhibits autophagy but also may inhibit degradation of 
 
 
 
152 
autophagosomal content by interfering with lysosomal function.27  These results appeared 
to be independent of disease severity as autophagic dysfunction was independent of a 
number of secondary pathologies that may be exacerbated by disease progression 
(oxidative stress, inflammation, etc.) and instead depend upon lysosomal dysfunction or 
cytoskeletal derangement.  Indeed De Palma et al.12 also observed stalling of autophagy 
and suggested that it may be due to signaling but could not exclude other potential 
mechanisms.   
Lysosomal protein abundance was decreased at 17 months of age in dystrophic 
muscle compared to age matched controls.  This finding raised the possibility that stalling 
of autophagosome degradation in dystrophic muscle is due, at least in part, to a lysosomal 
insufficiency.  If correct, this postulate is likely compounded by a shift in lysosome 
localization from fibers to the extracellular space, ostensibly to immune cells.  Hence, the 
intrafibrillar lysosomal population is smaller than would be anticipated by Western blot, 
alone.  Moreover, selective exclusion of TFEB, a master regulator of the autophagy-
lysosomal pathway,20 from dystrophic centralized nuclei plays a significant role in this 
process.  Consistent with this rational, TFEB exclusion from nuclei can be driven by 
increased mTOR activity as is commonly reported in dystrophic muscle.9, 28, 29 Consistent 
with our findings a previous report demonstrated decreased lysosome abundance in 
dystrophic limb muscle compared to controls, as measured by Lamp1 mRNA and protein 
abundance.9  
Interestingly, we observed poor colocalization of lysosomes (Lamp2) and 
autophagosomes (p62) in dystrophic muscle, further supporting impaired 
autophagosome/lysosome fusion.  Similarly, blunted lysosome and autophagosome 
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colocalization were observed previously in dystrophic limb muscle 9 suggestive of 
autophagic stalling via impaired autophagolysosome formation.   
As a collective response, autophagy appears to be robustly activated in dystrophic 
muscle, but degradation simultaneously blunted.  Accumulation of autophagosomes 
would be the natural consequence of a ‘dystrophic program’, however, despite significant 
prior work in the area, there is no precedent for this outcome occurring in dystrophic 
muscle.  After careful scrutiny of our p62 immunohistochemical images we noted p62 
positive foci clustering outside of muscle cells in the extracellular environment as well as 
in infiltrating immune cells.  This led us to consider whether autophagic stalling results in 
the escape of autophagosomes into the extracellular environment.   To address this 
hypothesis we first imaged vesicles released from healthy myotubes via scanning electron 
microscopy to determine the feasibility of muscles releasing autophagosome-sized 
vesicles.  Interestingly, in addition to the small exosomes and microvesicles produced by 
muscle,21, 22 large vesicles similar in size and morphology to autophagosomes are among 
the vesicles released from muscle (Figure 6).  Remarkably, we observed that healthy 
diaphragm muscle releases a significant number of autophagosomes into the extracellular 
environment while dystrophic muscle releases significantly more.  Indeed, careful 
inspection of p62/LC3 images by Pal et al.9 (Figure 1L, bottom series) supports this novel 
postulate that dystrophic muscle produce extracellular autophagosomes.  While, the 
physiological mechanisms and biological purpose of muscle released autophagosomes to 
the extracellular environment are unknown it may occur as a means of removing 
damaged cellular components in an attempt to maintain intracellular homeostasis.  Thus, 
autophagosome escape in dystrophic muscle may serve as means of cell survival.  
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Related to this concept, cancer researchers recently found evidence of autophagosome 
release as Zhou et al 30 identified tumor cell-released autophagosomes (TRAPs), which 
function in suppression of anti-tumor immunity.  Similarly, healthy neurons and neurons 
affected by stroke conditions release mitochondria in a disease-specific pattern.31, 32  
In total, these data support previous findings of upstream inhibition of autophagic 
signaling and impaired flux in dystrophic muscle.  However, we found that despite the 
decreased pro-autophagic signaling and apparent reduction in autophagic degradation, 
protein abundance of autophagic machinery was increased at both 7 weeks and 17 
months of age.  Hence, counter to our hypothesis, autophagic dysfunction was 
independent of disease progression.  Moreover, our evidence implicates lysosomal 
insufficiency as critical to this process.  Finally, we discovered compelling new evidence 
that healthy and dystrophic muscle release autophagosomes to the extracellular 
environment raising the possibility of a novel paracrine and, given the mass of skeletal 
muscle, endocrine function of skeletal muscle.  Importantly, it seems likely that 
suppressed autophagic degradation led to increased autophagosome escape in dystrophic 
muscle.  We think it likely that this phenomenon is occurring in other pathologic states 
that limits autophagy and may contribute to chronic inflammation that accompanies a 
host of muscle injuries and pathologies.   
Methods 
Animal Treatment.  All animal procedures were approved by the Institutional 
Animal Care and Use Committee at Iowa State University, Auburn University, or Temple 
University.  Seven week old C57 (n=5) and mdx (n=8) mice along with 17 month old 
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C57 (n=4) and mdx (n=10) mice were sedated and sacrificed by cervical dislocation.  
Diaphragms were removed and snap frozen for biochemical analyses.   
Immunochemistry.  Snap frozen diaphragm tissue was powdered with a steel 
mortar and pestle then homogenized in 200 μL of whole muscle buffer (10mM Sodium 
Phosphate buffer, pH 7.0, 2% SDS) using a hand held homogenizer.  After 
homogenization, cellular debris was separated from protein by 15 minutes of 
centrifugation at 20,000 x g and the supernatant retained.  Protein concentration was 
measured using the Pierce BCA Protein Assay Kit (23225, ThermoScientific, Waltham, 
MA, USA) and diluted to 2 μg/μL with 2x Laemmli buffer.  Following dilution, samples 
were heated for 5 minutes at 95°C; then 24 μg of protein were separated for 20 minutes at 
60 volts followed by 60 minutes at 120 volts using 4-20% gradient gels (Lonza, Basel, 
Switzerland).  Once separated by mass, proteins were transferred to a nitrocellulose 
membrane (BioRad, Hercules, CA, USA) at 100 volts for 60 minutes.  Membranes were 
blocked for 1 hour in 5% milk, then probed overnight using the following antibodies 
from Cell Signaling (Danvers, MA, USA), unless otherwise noted:  AMPK (Primary (P) 
1:1000 5% milk, Secondary (S) 1:1000 1X TBST), phospho (p)AMPK (T172) (P 1:500 
5% milk, S 1:1000 5% milk), pACCS79 (Millipore, P 1: 1000 5 % milk, S 1: 2000 5 % 
milk), pULK (serine 555) (P1:500 1% milk, S 1:500 2.5% milk), PI3K Class III (P 
1:1000 5% milk, S 1:2000 5 % milk), Beclin-1 (P 1:500 5% milk, S 1:1000 5% milk), 
pBeclin-1 (P 1:500 1X TBST, S 1:500 1% milk),  ATG12-5 (P 1:750 5% milk, S 1:1500 
5% milk), ATG7 (P 1:500 5% milk S 1:1000 5% milk), LC3AB (P 1:500 5% milk, S 
1:2000 5% milk), p62 (Abcam, Cambridge, UK, P 1:500 5% milk, S 1:1000 5% milk), 
Ubiquitin (P 1:1000 1X TBST, S 1:2000 5% milk), and Lamp2 (P 1:2000 5 % milk, S 
 
 
 
156 
1:1500 1X TBST).  Following primary antibody, membranes were washed in 1X TBST 
for 10 minutes three times then incubated in anti-rabbit secondary for 1 hour.  After 
antibody incubation, membranes were washed three times for 30 minutes in 1X TBST, 
then Clarity™ western enhanced chemiluminescence (ECL) blotting substrate (BioRad, 
Hercules, CA, USA) was applied to the membranes for 7 minutes.  Once exposed to 
ECL, membranes were developed and films were imaged and quantified using 
Carestream (Carestream Health, Inc. New Haven, CT).  All membranes were stained with 
Ponceau S to verify equal loading.  
Immunohistochemistry.  To complement protein measures, we performed 
immunohistochemical measures on archived diaphragm samples from 14 and 17 month 
old healthy and dystrophic diaphragm muscles.  Additional information about these 
tissues has been previously published.14, 15  Diaphragm sections were blocked for 1 hour 
with 5% BSA (Bovine serum albumin).  Anti-p62 (1:100, Abcam, rabbit) and anti-Lamp2 
(1:100, Abcam, rat) primary antibodies were applied to the 14 month old diaphragm 
samples at 4°C overnight.  At room temperature, sections were washed three times for 10 
minutes in 1X PBS (phosphate-buffered saline) then exposed to anti-rabbit AlexaFluor 
488 (1:100, Cell Signaling) and goat anti-rat rhodamine secondary antibody (1:200, 
Thermo) for 1 hour.  Sections were washed three times for 10 minutes, then c and 
confocal images were taken at 63x on a similar Leica microscope.  Similarly, diaphragm 
sections from 17 month old mice were blocked for 45 minutes at room temperature in 5% 
BSA; then washed as described above.  Anti-Transcription Factor EB (TFEB) (1:50, 
Bethyl) and anti-laminin (1:100, Thermo) primary antibodies and anti-rabbit AlexaFluor 
488 (1:500, Cell Signaling) and anti-rat (1:200, Thermo) secondaries were applied to 
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diaphragm sections as previously described.  Total fluorescence of TFEB within the 
nucleus was measured using ImageJ and normalized to the area of the nucleus and the 
cellular TFEB intensity.   
Cell Culture, Ex Vivo Muscle Preparations, and Extracellular Vesicle Isolation.  
C2C12 myotubes were grown to full confluence as we have previously described.21, 22  
Briefly, mouse C2C12 myoblasts were cultured in growth medium [DMEM + 10% fetal 
bovine serum (Atlanta Biologicals, Lawrenceville, GA)] with 1% penicillin-streptomycin 
(Invitrogen, Carlsbad, CA); all experiments were conducted using cells from passages 3–
7.  Myoblasts were grown to ∼95% confluence and then induced to differentiate into 
myotubes by replacement of growth medium with differentiation medium (DMEM 
supplemented with 2% horse serum + 1% penicillin-streptomycin) for 3 days.  After 3 
days in differentiation medium, cells were washed with serum-free medium and then 
incubated in serum-free medium.  After 6 hours, the medium was collected to isolate 
large extracellular vesicles.  Large extracellular vesicles were isolated from cell culture 
medium (or tissue bath buffer, described below) via centrifugation.  First, medium or 
buffer was centrifuged at 500 x g for 10 minutes to pellet intact cells and debris, and then 
supernatant was centrifuged at 12,000 x g to pellet larger vesicles and resuspended in 
sterile PBS.   
A suspension of the large extracellular vesicles taken from myotubes was fixed 
with an equal volume of 4% paraformaldehyde in 0.08 M phosphate buffer.  After 1 hour, 
20 µl aliquots were placed on copper tape, which had been attached to standard SEM 
stubs, and the liquid gradually replaced with graded Ethanol solutions, followed by 
HMDS (Hexamethyl disilazane), and allowed to air dry.  The samples were then sputter 
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coated with gold, and examined in an Agilent FESEM at 1 kv accelerating voltage, using 
secondary emission detection. 
To follow up cell culture experiments 7 week old C57 and mdx mice were 
anesthetized with isoflurane before muscle isolation.  Whole diaphragms were rapidly 
excised and prepared in Krebs Ringer solution containing (in mM): 121 NaCl, 5.9 KCl, 
2.0 CaCl2, 1.0 MgCl2, 0.6 Na2HPO4, 21 NaHCO3, 0.45 Na2SO4, 11.5 glucose and 10 
μM D-tubocurarine.  Costal diaphragms were pinned at approximate muscle Lo, and 
baths were continuously bubbled with 95% O2/5% CO2.   After 2 hours, buffer was 
collected for extracellular vesicle isolation.   
Flow Cytometry.  Large, muscle-released extracellular vesicles were isolated as 
described above.  Autophagosomes were quantified using the CYTO-ID Autophagy 
Detection Kit (ENZ-51031; ENZO Life Sciences) that is well established to identify 
autophagosomes.34, 35  The kit’s instructions were followed with slight modifications in 
centrifugation speed (all washing/collection steps were performed at 12,000 x g).  
Samples were analyzed using a MoFlo AstriosEQ (Beckman-Coulter, Inc., Miami, FL), 
utilizing logarithmic forward scatter (FSC) photomultipliers and various masks to 
optimize small particle detection and gate of interest and analyzed via a dotplot of Green 
Fluorescence (513/26 nM) vs. Orange Fluorescence (576/21 nM). 
Statistics.  Relative protein abundance was compared using two-way ANOVA 
with a Newman-Keuls post-hoc test where appropriate.  Immunohistochemical 
experiments were analyzed with a Student’s T-test and flow cytometry experiments were 
analyzed with a one-way ANOVA with Newman-Keuls post-hoc test.   Significance was 
established as p<0.05, a priori.  Data are presented as mean ± SEM. 
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Figures 
 
Figure 1. Autophagic regulation.  Protein abundance measured by Western blot in 7 
week and 17 month old dystrophic (mdx) and control (C57) diaphragms.  Significance 
was established at p<0.05. White bars – C57 7 weeks (n=5), blue bars – mdx 7 weeks 
(n=8), gray bars – C57 17 months (n=4), red bars – mdx 17 months (n=10).  * indicates 
significantly different from age-matched C57 controls, # indicates significant main effect 
of disease. 
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Figure 2. Autophagy initiation and maturation.  Protein abundance measured by 
Western blot in 7 week and 17 month old dystrophic (mdx) and control (C57) 
diaphragms.  Significance was established at p<0.05. White bars – C57 7 weeks (n=5), 
blue bars – mdx 7 weeks (n=8), gray bars – C57 17 months (n=4), red bars – mdx 17 
months (n=10).  All measures were made relative to C57 7 weeks old controls except 
pBeclin-1 which was made relative to mdx 7 week old mice. * indicates significantly 
different from age-matched C57 controls, # indicates significant main effect of disease † 
= indicates significant main effect of age. 
 
 
 
165 
 
Figure 3. Autophagic degradation.  Protein abundance measured by Western blot in 7 
week and 17 month old dystrophic (mdx) and control (C57) diaphragms.  Significance 
was established at p<0.05. White bars – C57 7 weeks (n=5), blue bars – mdx 7 weeks 
(n=8), gray bars – C57 17 months (n=4), red bars – mdx 17 months (n=10).  * indicates 
significantly different from age-matched C57 controls, # indicates significant main effect 
of disease. 
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Figure 4. Autophagosome and lysosome colocalization.  Confocal images at 63X 
magnification of DAPI (blue), p62 (green) and Lamp2 (red) from 14 mo old dystrophic 
and control mice diaphragms.   
 
 
Figure 5. Confocal images of TFEB localization.  A) 2X zoomed confocal images (63X 
images) of immunohistochemistry fluorescence of DAPI (blue), TFEB (green) and 
laminin (red) from 17 month old dystrophic (mdx) and control (C57) diaphragms.  
Arrows indicate centralized nuclei in which TFEB is excluded.  * indicates peripheral 
nuclei, + indicates extra-muscular nuclei. B) Quantification of decreased TFEB 
fluorescent intensity within centralized nuclei of mdx mice compared to nuclei of C57 
mice. 
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Figure 6. Scanning electron microscopy images of media from C2C12 myotubes 
demonstrating muscle cells release vesicles of differing size and morphology including 
round vesicles between 500-2000 nm, consistent with morphology and size of 
autophagosomes.   
 
 
Figure 7. Autophagosome escape from dystrophic and healthy diaphragms. A) 5X 
zoomed confocal images (63X) of immunohistochemistry fluorescence of DAPI (blue), 
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p62 (green) and Lamp2 (red) from 14 months old dystrophic diaphragms. Arrows 
indicate p62 foci independent of Lamp2, which indicates autophagosomes are present in 
the extracellular space outside muscle cells.  B) Autophagosomes were isolated from a 
bath of intact diaphragms, ex vivo, and quantified by flow cytometry.  These data verify 
autophagosomes are released from both healthy and dystrophic diaphragms, with a 
greater amount of autophagosomes released from dystrophic muscle. 
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Abstract 
Duchenne muscular dystrophy (DMD) is caused by the absence of functional 
dystrophin protein and results in progressive muscle wasting. Dystrophin deficiency leads 
to a host of dysfunctional cellular processes including impaired autophagy. Autophagic 
dysfunction appears to be due, at least in part, to decreased lysosomal abundance 
mediated by decreased nuclear localization of transcription factor EB (TFEB), a 
transcription factor responsible for lysosomal biogenesis, among other functions. PGC-1α 
overexpression decreased disease severity in dystrophin-deficient skeletal muscle and 
increased PGC-1α has been linked to TFEB activation in healthy muscle. The purpose of 
this study was to determine the extent to which PGC-1α overexpression increased nuclear 
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TFEB localization, increased lysosome abundance, and increased autophagosome 
degradation. We hypothesized that overexpression of PGC-1α would drive TFEB nuclear 
translocation, increase lysosome biogenesis, and improve autophagosome degradation. 
To address this hypothesis, we delivered PGC-1α via adeno-associated virus (AAV) 
vector injected into the right limb of 3-week-old mdx mice and the contralateral limbs 
received a sham injection. We demonstrated that at 6 weeks of age our approach 
increased PGC-1α gene expression by 60-fold. This increased TFEB nuclear localization 
in gastrocnemii from PGC-1a treated limbs by 2-fold compared to contralateral controls. 
Furthermore, lamp2, a marker of lysosome abundance, was significantly elevated in the 
muscles from limbs overexpressing PGC-1α. Lastly, increased LC3II and similar p62 in 
PGC-1α overexpressing-limbs compared to contralateral limbs is supportive of increased 
degradation of autophagosomes. These data provide mechanistic insight into PGC-1α-
mediated benefits to dystrophin-deficient muscle, such that increased TFEB nuclear 
localization in dystrophin-deficient muscle leads to increased lysosome biogenesis and 
autophagy.  
Introduction 
Duchenne muscular dystrophy (DMD) is a devastating muscle wasting disease 
affecting 1:3,500-5,000 boys (12). This progressive disease is typically diagnosed from 3-
5 years of age due to muscle weakness and locomotor dysfunction, advances to 
wheelchair dependence for mobility by their early teens and culminates in death by 
cardiac or respiratory failure in their mid to late twenties. DMD is caused by the absence 
of functional dystrophin protein and results in various cellular dysfunctions such as 
membrane instability, mitochondrial dysfunction, oxidative stress, calcium mishandling, 
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and dysregulation of autophagy (1, 2, 5, 8, 18, 28). Autophagy is a process by which 
cellular components tagged for degradation are collected within autophagosomes, then 
fused with lysosomes to degrade the autophagosome cargo (16, 22). In dystrophin-
deficient skeletal muscle, autophagosome degradation is blunted, resulting in 
autophagosome accumulation and subsequent escape of autophagosomes into the 
extracellular space (28). In this same study, lysosome abundance was decreased in 
dystrophin-deficient skeletal muscle (28), therefore, it seems likely that reduced 
lysosomal abundance, at least in part, contributes to blunted degradation of 
autophagosomes.   
Lysosome biogenesis is regulated by transcription factor EB (TFEB) (23, 26), 
which is translocated to the nucleus to promote transcription of lysosomal and autophagy 
related genes. Nuclear TFEB localization is regulated by phosphorylation in which 
dephosphorylation of TFEB by calcineurin at Ser142 (15) promotes nuclear translocation. 
Conversely, phosphorylation by mammalian target of rapamycin (mTOR), protein kinase 
B (AKT), or extracellular signal-regulated protein kinase (ERK1/2) sequesters TFEB in 
the cytosol (14, 19, 26). We have previously demonstrated that TFEB nuclear localization 
is decreased in dystrophin-deficient muscle compared to healthy muscle (28). In healthy 
muscle TFEB abundance was decreased in peroxisome proliferator-activated receptor-
gamma coactivator 1-alpha (PGC-1α) knockout mice (6, 29); conversely, TFEB nuclear 
localization and transcription were increased with exercise suggesting a PGC-1α-
dependent mechanism and indicative of a relationship between PGC-1a and TFEB (6). 
We and others have previously found that PGC-1α overexpression decreased disease-
related injury though protection was largely attributed to increased utrophin expression 
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associated with a type I fiber shift.  The extent to which PGC-1α may also increase TFEB 
nuclear localization, lysosomal content, and degradation of autophagosomes has not been 
previously considered in this context.  Given that PGC-1α plays a role in TFEB 
regulation and localization, we hypothesized that overexpression of PGC-1α would 
increase TFEB nuclear localization and ultimately increase lysosome abundance and 
restore autophagosome degradation in dystrophin-deficient skeletal muscle.   
Methods 
Animal Treatment. The Institutional Animal Care and Use Committee at Iowa 
State University approved all procedures.  A detailed description of animal treatments 
and a demonstration of PGC-1α-mediated rescue of dystrophic soleus muscles has been 
previously published (10).  Briefly, at three-weeks of age, 1x1011 genome copies of an 
adeno-associated viral (AAV; serotype 6) vector driving expression of PGC-1α were 
injected into the right triceps surae group of male and female mdx mice in a single 50 μl 
dose, while the contralateral limb was injected with an empty capsid (sham) (n=8 
mice/group). We have previously used this vector to demonstrate disease prevention and 
rescue (10, 11, 25). At 6 weeks of age, we sacrificed mice by cervical dislocation and the 
gastrocnemii were harvested. Gastrocnemii designated for western blotting and qPCR 
were flash frozen in liquid nitrogen, and gastrocnemii for immunofluorescence were 
frozen in isopentane and embedded in optimal cutting temperature compound (OCT). 
Data from these mice have been previously published establishing PGC-1α-mediated 
histological rescue of treated muscle (10).             
qPCR. Quantitative PCR was used to confirm PGC-1α overexpression and was 
done as previously described (24). Briefly, gastrocnemii were powdered on dry ice and 
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RNA was extracted using TriZol (15596018, ThermoScientific) and RNeasy purification 
kit (Qiagen) according to manufacturer instructions. cDNA was reverse transcribed using 
QuantiTect Reverse Transcriptase Kit (205310, Qiagen), as described by the 
manufactures except random hexamers (51-0118-01, IDT Premade Primers) were used 
instead of the RT primer mix provided (Qiagen). The Ppargc1a (Pgc-1α) primer set was 
as follows: Forward – 5’atgtgtcgccttcttgctct-3’ Reverse – 5’-atctactgcctggggacctt-3’.  
Ppargc1a was normalized to 18s (Forward – 5’-ctctagataacctcgggccg-3’ Reverse – 5’-
gtcgggagtgggtaatttgc-3’). Delta (Δ) CT values were calculated by subtracting the 18s CT 
value from Ppargc1a CT value. These values were used for statistical comparisons. 
ΔΔCT was calculated by subtraction of the ΔCT of each sample from the average ΔCT of 
the mdx-control samples. Data are presented as a fold-change as calculated from ΔΔCT. 
Western Blot. Western blotting was performed as previously described (27). 
Briefly, whole homogenate, nuclear protein fractions and cytoplasmic protein fractions 
were extracted from powdered gastrocnemius muscles. Total protein was extracted using 
lysis buffer (1% Triton-x-100, 50mM HEPESS, 150mM NaCl, 10% Glycerol, 50mM 
NaF, 2mM EDTA, 0.1% SDS, pH 7.5). Additionally, the nuclear protein fraction was 
separated from the cytoplasmic fraction using a NE-PER™ Nuclear and Cytoplasmic 
Extraction Reagents (78833, ThermoScientific). Total, nuclear and cytoplasmic protein 
abundances were measured by Pierce BCA Protein Assay Kit (23225, ThermoScientific) 
and diluted in 2X Laemmli buffer (161-0737, Bio-Rad). Protein was loaded into 4-20% 
gels (58545, Lonza), separated by gel electrophoresis and transferred to a nitrocellulose 
membrane (1620112, Bio-Rad). Membranes were treated with ponceau S (PS) solution to 
verify equal loading. Membranes were washed in 1X tris buffered saline with 0.2% 
 
 
 
174 
Tween20 (1X TBST) and blocked with 5% milk in 1X TBST for 1 hour. Primary 
antibody was applied to the membrane and rocked overnight at 4ºC. Once primary 
antibody was removed, the membrane was washed in 1X TBST for 10 minutes, three 
times. Following washes, anti-rabbit IgG HRP-linked secondary antibody (7074, Cell 
Signaling) or anti-rat IgG HRP-linked secondary antibody (7077, Cell Signaling) were 
applied to the membrane for 1 hour at room temperature. After 1 hour the membrane was 
washed again for 10 minutes, three times. Lastly, Clarity™ Western enhanced 
chemiluminescence (1705060S, Bio-Rad) was applied to the membrane for 7 minutes, 
then developed in a dark room. Films were imaged, and protein bands were quantified 
using densitometry software (Carestream). The primary antibodies used in this study are 
listed in Table 1.   
Immunofluorescence. We performed immunofluorescence as previously 
described (28). Briefly, muscle sections were blocked for 45 minutes in blocking solution 
(5% goat serum, 5% bovine serum albumin, 1% DMSO in 2X PBS).  We applied primary 
antibody to the slides and placed the slides at 4ºC overnight, then washed the slides for 10 
minutes in 1X phosphate buffered saline (PBS) three times. Corresponding secondary 
antibody was applied to sections for 1 hour at room temperature in the dark (anti-rabbit 
IgG AlexaFluor 488 [Cell Signaling, 4412] or goat anti-rat IgG rhodamine conjugated 
[Thermo Scientific, 31680]) and then slides were washed in 1X PBS for 10 minutes, three 
times. Finally, sections were treated with SlowFade™ Gold Antifade Mountant with 
DAPI (S36938, ThermoScientific) and sealed with nail polish. Primary and secondary 
dilutions can be found in Table 1. Sections were imaged on a QICAM 12-bit Mono Fast 
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1394 Cooled (QIC-F-M-12-C, QIMAGING) camera attached to a Leica microscope at 
40x, and confocal images were taken at 63x on a similar Leica microscope.   
Statistics. Data were statistically assessed by paired t-test (PRISM). Data are 
reported as mean ± SEM.  We consider p-values less than or equal to 0.05 to be 
significant. 
Results 
PGC-1α overexpression increased nuclear TFEB abundance.  Overexpression of 
Ppargc1a, the gene encoding PGC-1α, was confirmed using qPCR (Figure 1). Consistent 
with our previous experiments (10, 11, 25), Ppargc1a was increased approximate 60-
fold. Of note, the 60-fold elevation observed in this investigation was greater than the 10-
fold elevation observed in soleus muscles obtained from the same mice.  It is likely that 
the differing fiber types of the muscles or that the gastrocnemius likely received a greater 
content of the injected volume (and hence, viral particles) likely contributed to this 
difference.  PGC-1α gene transfer resulted in an approximate 6 mg reduction (p<0.05) in 
muscle mass compared to control (Control - ~103 ± 4; PGC-1α – 97 ± 4 mg), which we 
previously reported (10).  To assess the effect of PGC-1α overexpression on TFEB 
abundance, TFEB protein abundance was measured in whole homogenate by Western 
blot. Total TFEB abundance was similar between groups (Figure 2A). To determine the 
effect of PGC-1α gene transfer on TFEB nuclear localization, TFEB protein abundance 
was assessed in nuclear protein fractions. PGC-1α overexpression increased nuclear 
TFEB abundance 2.2-fold compared to untreated limbs (Figure 2A). In confirmatory 
experiments using an immunofluorescent approach it was visually apparent that total 
TFEB was similar between groups, which was further supported by objective 
 
 
 
176 
quantification of total fluorescence (Figure 2B&C). Subjective evaluation of confocal 
images were supportive of nuclear translocation of TFEB in PGC-1α overexpressing 
limbs compared to contralateral controls (Figure 2D).   
PGC-1α overexpression increased lysosome abundance and markers of 
autophagosome degradation. Given that nuclear TFEB was elevated following PGC-1α 
overexpression and that TFEB is a transcription factor that promotes lysosomal 
biogenesis, we next evaluated the effect of PGC-1α gene transfer on lysosome 
abundance. Using an immunofluorescent approach we discovered that lamp2, a 
lysosomal marker, was increased by 30% (Figure 3A&B) in PGC-1α overexpressing 
limbs compared to control limbs. These findings were confirmed by Western blot from 
whole homogenate (Figure 3C). As our working model is that degradation of 
autophagosomes in dystrophin-deficient muscle is blunted, as least in part, due to a 
lysosomal insufficiency we further investigated the effect of increased lysosome 
abundance on markers of autophagy (Figure 4). Markers of autophagic activation, ULK 
and pULK (S555), and beclin-1, a marker of autophagosome nucleation, were similar 
between mdx-PGC-1α and mdx-control muscles. Despite similar total beclin-1 protein 
abundance in mdx-control compared to mdx-PGC-1α, p-beclin-1 (S93) was numerically 
increased compared to mdx-control (p=0.18). Interestingly, PI3K CIII, a protein involved 
in autophagosome initiation, was similar between mdx-control and mdx-PGC-1α. 
Conversely, Atg5/12 was increased numerically (p=0.16) but failed to reach significance 
due to high variability. A marker of autophagosome formation, LC3II, was elevated with 
PGC-1α overexpression, while p62, a marker of autophagosome degradation was similar 
between groups. Hence, elevated autophagosome formation paired with similar p62 
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abundance suggests increased degradation of autophagosomes following PGC-1α 
overexpression.       
Discussion 
Duchenne muscular dystrophy is a severe muscle wasting disease in which a host 
of cellular pathways are altered secondary to a dystrophin protein deficiency. We and 
others have recently established that autophagic dysfunction is included in the disease 
sequelae (2, 5, 18, 28).  More specifically, our data indicate lysosome abundance is 
decreased and autophagosome degradation is impaired in dystrophin-deficient skeletal 
muscle (28). Previous evidence demonstrates that PGC-1α overexpression decreased 
disease-related injury and preserved muscle function using both prevention and rescue 
strategies (4, 9, 10, 25). Emerging evidence points to a PGC-1α-mediated activation of 
TFEB (6) while others have demonstrated a relationship between TFEB and lysosome 
biogenesis and autophagy (23, 26). We previously established that TFEB nuclear 
localization is decreased in dystrophin-deficient skeletal muscle as was lysosomal 
abundance suggesting that decreased lysosomal content is due, at least in part, to 
dysregulation of TFEB (28). Further, as we and others have demonstrated decreased 
degradation of autophagosomes in dystrophin-deficient muscle, this dysregulation of 
TFEB and subsequent blunting of lysosomal content may contribute to impaired 
degradation of autophagosomes in dystrophin-deficient muscle  Given this, we 
hypothesized that PGC-1α overexpression in dystrophic muscle would drive TFEB 
nuclear translocation leading to increased lysosome abundance and increased degradation 
of autophagosomes (28). 
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While the underlying mechanism governing the relationship between PGC-1a and 
TFEB is currently unknown, PGC-1α appears to regulate expression of TFEB. For 
example, PGC-1α overexpression or PGC-1α knockout in healthy muscle results in a 
parallel effect on TFEB, such that PGC-1α overexpression increased TFEB protein 
abundance (29) and knockout decreased TFEB transcript and protein abundance (6, 13, 
29). Given the relationship between PGC-1α and TFEB and that our previous work 
hinted of a PGC-1α-mediated change in autophagy (10), continued study of tissues from 
3 week old mdx mice treated with PGC-1α provided an opportunity for a probative study 
regarding TFEB and autophagy in dystrophin-deficient muscle. Contrary to our 
expectations, in this investigation following 3 weeks of PGC-1α overexpression total 
TFEB abundance was similar between groups, however, nuclear TFEB was increased by 
PGC-1α gene transfer. These data indicate regulation of TFEB abundance and/or activity 
by PGC-1α is more complex than simple transcriptional regulation and likely includes 
indirect regulation via post-translational modification via a yet-to-be appreciated 
mechanism(s).  Speculatively, as mTOR activity is known to be increased in dystrophin-
deficient muscle (18) and that phosphorylation of TFEB by mTOR, AKT or ERK1/2 
leads to nuclear exclusion (17, 20, 26), mTOR-mediated inhibition of TFEB and 
subsequently decreased lysosomal content seems likely. In support of this notion, PGC-
1α-mediated inhibition of mTOR signaling has recently been demonstrated (3) providing 
a plausible and testable mechanism for PGC-1α-mediated regulation of TFEB 
localization.    
PGC-1α overexpression has been known for some time to preserve muscle 
function and decrease histopathological injury in dystrophin-deficient muscle using 
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prevention and rescue paradigms (9-11, 25). In addition to histological and functional 
protection in the dystrophin-deficient soleus, PGC-1α overexpression also altered gene 
expression suggestive of increased autophagy in the same animals used herein (10). In the 
present investigation evaluating the gastrocnemius, our data suggest increased 
autophagosome formation following PGC-1α overexpression (increased LC3II) and 
increased degradation (similar p62). It seems likely this increased degradation was 
facilitated by increased lysosomal abundance. Further, given the relationship between 
PGC-1a and TFEB as well as the role of TFEB in autophagy that mitophagy would also 
be improved following PGC-1a overexpression. While mitophagy and mitochondrial 
biogenesis/content was beyond the scope of this investigation, in a previous study using 
these animals, PGC-1a overexpression numerically increased transcript abundance of 
BNIP3, a protein which promotes mitophagy, by 50% (10). Similarly, mice treated with 
AICAR, which stimulates AMPK and ultimately PGC-1a, also increased BNIP3 protein 
abundance in dystrophin deficient skeletal muscle (21) supporting the notion that PGC-
1a overexpression may stimulate mitophagy.   
Perspectives and Significance 
These data indicate that PGC-1α increased nuclear TFEB localization, lysosomal 
abundance, and degradation of autophagosomes. We speculate that increased PGC-1α 
caused, directly or indirectly, increased nuclear TFEB translocation, which in turn, 
increased lysosome abundance, which allowed for greater degradation of 
autophagosomes. We temper our conclusions within the limitations of a probative study 
employing archived samples and encourage future investigations specifically intended to 
address questions raised herein. In addition to the role of TFEB-mediated elevations in 
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lysosome abundance, it is important to note that degradation of autophagosomes may be 
impacted by lysosome function (7) and/or capacity for colocalization due to cytoskeletal 
derangement or impaired fusion. How these factors may interact and be altered by 
dystrophin deficiency remains largely unknown.  
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Figures and Tables 
Table 1. Western blot and immunofluorescence antibody details including protein name, 
primary and secondary dilations, and product number. Secondary antibodies used were 
specific to the primary antibody host species, which is also indicated in this table 
alongside the product number. Secondary antibody details can be found in the methods 
section. 
 
Western blot antibodies 
Protein Primary dilution Secondary dilution Company & Product 
number (host) 
autophagy related 
(ATG) 5/12 
1:1000 1X TBST 1:2000 1X TBST Cell Signaling 4180 
(rabbit) 
beclin-1 1:500 5% milk 1:2000 5% milk Cell Signaling 3495 
(rabbit) 
phospho (p) beclin-1 
(Ser93) 
1:1000 5% milk 1:1000 1X TBST Cell Signaling 14717 
(rabbit) 
light chain 3 (LC3) 1:500 5% milk 1:2000 5% milk Cell Signaling 12741 
(rabbit) 
lysosomal associated 
membrane protein 2 
(lamp2) 
1:1000 1X TBST 1:2000 5% milk Abcam ab13524 (rat) 
phosphoinositide 3 
kinases (PI3K) class III 
1:1000 5% milk 1:2000 5% milk Cell Signaling 3358 
(rabbit) 
 
 
 
184 
Western blot antibodies 
Protein Primary dilution Secondary dilution Company & Product 
number (host) 
sequestosome 1 
(SQSTM1, p62) 
1:500 5% milk 1:1000 5% milk Abcam ab109012 
(rabbit) 
transcription factor EB 
(TFEB) 
1:1000 1% milk 1:1000 1X TBST Bethyl Laboratories 
A303-673A-M 
(rabbit) 
Unc-51 like autophagy 
activating kinase 1 
(ULK) 
1:1000 1X TBST 1:2000 1X TBST Cell Signaling 8054 
(rabbit) 
p-ULK (Ser555) 1:500 1X TBST 1:1000 1X TBST Cell Signaling 5869 
(rabbit) 
Immunofluorescence antibodies 
Protein Primary dilution Secondary dilution Company & Product 
number (host) 
laminin beta-1 1:100 5% BSA 1:200 5% BSA ThermoFisher MA5-
14657 (rat) 
lysosomal associated 
membrane protein 2 
(lamp2) 
1:100 5% BSA 1:100 5% BSA Abcam ab13524 (rat) 
transcription factor EB 
(TFEB) 
1:50 5% BSA 1:500 5% BSA Bethyl Laboratories 
A303-673A-M 
(rabbit) 
 
 
 
 
 
Figure 1. PPARGC1A gene expression increased following AAV injection. PPARGC1A 
transcript abundance was normalized to 18S and confirmed overexpression of 
PPARGC1A, which encodes for PGC-1α, in AAV treated gastrocnemii (n=8/group), * = 
significantly different from mdx-control by paired sample t-test, p < 0.05. 
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Figure 2. PGC-1α overexpression increased nuclear TFEB. A) Total TFEB protein 
abundance was similar between groups regardless of treatment, (n=6/group).  Nuclear 
TFEB abundance significantly increased with PGC-1α overexpression, (n=6/group). 
Ponceau stain (PS) was used as a total protein loading control. B) mdx-control and mdx-
PGC-1a overexpressing gastrocnemii were probed for TFEB (green), membrane marker, 
Laminin (red), and nuclei (dapi, blue) using immunofluorescence.  C)  Immuno-
fluorescence quantification confirms that total TFEB abundance was similar between 
mdx-control and mdx-PGC-1α, (n=5/group) E) Representative confocal images from C at 
63X with 5x zoomed insets showing the increased nuclear localization of TFEB with 
PGC-1α overexpression.  * = significantly different from mdx-control by paired sample t-
test, p<0.05. 
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Figure 3. PGC-1α overexpression increased lysosome abundance. A) Mdx-control and 
mdx-PGC-1α gastrocnemii were probed for lysosome marker, lamp2 (red), using 
immunofluorescence and nuclei (dapi, blue). B) Quantification of lamp2 (red) fluorescent 
intensity, (n=5/group). C) Increased lamp2 was confirmed by Western blot, (n=6/group). 
Ponceau stain (PS) was used as a total protein loading control. * = significantly different 
from mdx-control by paired sample t-test, p<0.05. 
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Figure 4. PGC-1α overexpression increased autophagosome degradation.  
Markers of autophagy related proteins were largely unchanged with PGC-1α 
overexpression.  However, these data suggest increased autophagosome degradation due 
to increased LC3II with PGC-1α overexpression and similar p62, an inverse correlate of 
autophagosome degradation. (n=6/group). Ponceau stain (PS) was used as a total protein 
loading control. * = significantly different from mdx-control by paired sample t-test, 
p<0.05. 
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CHAPTER 8: GENERAL CONCLUSION 
 Duchenne muscular dystrophy is a progressive muscle wasting disease for which 
there is no cure and for which few pharmacological interventions are available. While 
development of therapeutics to replace dystrophin is ongoing, patients are in need of 
immediate interventions. In healthy populations, exercise has been shown to alleviate a 
variety of dystrophin-associated symptoms (2), but the use of traditional exercise is 
controversial for DMD patients (14). Therefore, exercise mimetics may be a safer means 
by which to acquire exercise benefits without the detrimental effects of traditional 
exercise in those with DMD. Previously it has been demonstrated that transcriptional 
coactivator, PGC-1a, can induce these positive exercise effects in dystrophic muscle (3, 
8, 12). In a preliminary study, quercetin, a natural flavonoid which can drive PGC-1a 
through SIRT1, attenuated disease severity. This suggested that quercetin and quercetin 
base-cocktails may be therapeutic for DMD patients (10). Our research investigated the 
extent to which FDA-approved pharmaceuticals and nutraceuticals mitigate disease 
pathology. Additionally, we probed autophagy to determine the extent to which the 
autophagy pathway might be manipulated as a therapeutic target for DMD and 
subsequently the effect of PGC-1a overexpression on autophagy in dystrophic muscle.  
 In chapter 2, we evaluated the extent to which quercetin attenuated loss of muscle 
function and reduced muscle damage after 12 months of treatment. Due to the longevity 
of the disease and need for long-term treatment, our goal was to determine the efficacy of 
quercetin treatment on dystrophin-deficient skeletal muscle over time. Contrary to our 
hypothesis, we found that 12 months of quercetin treatment did not preserve muscle 
function or prevent muscle damage (13). In a companion study from these same animals, 
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quercetin failed to improve diaphragm function or mitigate muscle damage, but 
transiently protected respiratory function for 6 months (11). In this same study, SIRT1 
deacetylation activity, as measured by abundance of acetylated histone 3 lysine 9, was 
similar between treated and untreated.  Given that SIRT1 is a NAD+ dependent 
deacetylase and that NAD+ abundance is reduced in dystrophin-deficient skeletal muscle, 
we hypothesized that supplementation with nicotinamide riboside (NR), an NAD+ 
precursor, would enhance long-term efficacy of quercetin. Therefore, in chapters 3 and 4, 
we determined the extent to which quercetin, NR, Lisinopril and prednisolone alone and 
in combination protected dystrophic muscle. Once again, quercetin did not preserve 
respiratory function, muscle function, or prevent injury. Similarly, these quercetin-based 
cocktails did not improve these parameters, suggesting that quercetin is not a suitable 
therapy for DMD. 
 When evaluating these quercetin-based cocktails, we utilized an emerging model 
of DMD, the D2-mdx mice, instead of conventional mdx mice. D2-mdx mice present a 
more severe phenotype of DMD with increased inflammation and more muscle damage 
than mdx mice (4). Though a more severe model of DMD is necessary to properly assess 
potential therapeutics, the D2-mdx mouse may be too severe. For example, at 8 weeks of 
age, Evan’s blue dye uptake was increased in D2-mdx mice compared to both DBA and 
mdx mice, suggestive of increased muscle fiber damage at 8 weeks.  Grip strength was 
also reduced in D2-mdx mice compared to mdx mice at 9-11 weeks and 22-24 weeks of 
age (6), likely due to increased muscle damage and subsequent decreased abundance of 
muscle fibers (6). Furthermore, the self-renewal efficiency of DBA mice was decreased 
compared to C57, likely contributing to the severity of the D2-mdx model (6). Together, 
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these data suggest that the D2-mdx model has increased muscle injury, decreased muscle 
fiber abundance and decreased regenerative efficiency, reducing the viable fibers in 
which therapeutics can be successful and decreasing regenerative capacity.  
 Despite the inability of quercetin and these quercetin-cocktails to reduce disease 
severity, we established in chapter 6 that PGC-1a can improve autophagosome 
degradation in dystrophic muscle by increasing myonuclear localization of TFEB and the 
subsequent elevation in lysosome abundance. Before overexpressing PGC-1a in 
dystrophic muscle, we established that autophagy was impaired in dystrophic skeletal 
muscle prior to degradation of the autophagosome (chapter 5). This impaired 
autophagosome degradation could be due to decreased lysosome abundance, an inability 
of lysosomes and autophagosomes to fuse properly, decreased lysosome function, or a 
combination of these things.  As demonstrated in chapter 6 and its companion study (8), 
PGC-1a can preserve muscle function, increase TFEB myonuclear localization and 
ultimately increase autophagosome degradation, improving the impaired pathway.  
The precise relationship between PGC-1a and TFEB is unclear. Using PGC-1a 
knockout and TFEB overexpression models, Erlich et al. (5) identified that TFEB 
overexpression increased PGC-1a abundance and PGC-1 knockout reduced TFEB 
abundance. Further exploration of this relationship would be beneficial to the 
understanding these potential therapeutic targets but given what is currently known about 
PGC-1a and TFEB, it possible that stimulation of TFEB would result in increased 
lysosome biogenesis, increased autophagosome degradation and also increased PGC-1a 
activity. This resulting PGC-1a activity would provide additional therapeutic benefits for 
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dystrophic muscle, such as increased mitochondrial biogenesis and increased utrophin 
abundance to protect the sarcolemma (7-9, 12). 
Independent of PGC-1a, we discovered that healthy and dystrophic skeletal 
muscle release autophagosome into the extracellular space, albeit more abundantly in 
dystrophic muscle. Given the discrepancy between abundance of autophagosomes 
released from dystrophic and healthy skeletal muscle, the mechanism and purpose of 
autophagosome release may be of interest. The release of autophagosomes may be a 
means by which cells can remove excess autophagosomes. Alternatively, the release of 
autophagosomes may allow autophagosomes, like exosomes (1), to play a role in cell-to-
cell communication or endocrine signaling.  
In summary, DMD patients are still in need of immediate therapeutic 
interventions. Quercetin and quercetin-based cocktails failed to attenuate disease 
pathology in long-term studies, suggesting that these quercetin-based therapies should not 
be further investigated for DMD. However, increased abundance and activity of PGC-1a 
continues to show therapeutic promise. In this investigation, we demonstrated that PGC-
1α overexpression increased autophagosomes degradation, which was impaired in 
dystrophic muscle. Additionally, PGC-1a overexpression increased TFEB myonuclear 
localization, likely contributing to increased lysosome biogenesis and autophagosome 
degradation. Together, these data suggest that PGC-1a is still a promising therapeutic 
target and TFEB should be further investigated within the context of DMD.  
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